News
Celebrate 35 years of Technoclone and a Special Ceveron® s100 price
It’s Not Just Support. It’s Solutions.
JOIN DIAPHARMA AS WE CELEBRATE
35 YEARS OF TECHNOCLONE
BY SAVING ON CEVERON® s100
35 years of our partner, Technoclone 🎈
35 days of celebration 🎉
From now through Sunday December 18th, 2022, get a special Ceveron® s100 celebration price – this very unique special offer is valid during the 35 days celebration promotion time.
Contact your territory manager today for details.
Why Ceveron®?
- Ceveron® s100 all-in-one coagulation analyzer
- Automated ADAMTS13 Activity, Thrombin Generation, FXIII Activity, C1-Inhibitor Activity, and more
- The latest Lupus Anticoagulant information
- You name it, Ceveron® s100 can do it!
Research use only in U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00994Rev01
Thank you for visiting us at The Liver Meeting®
It’s Not Just Support. It’s Solutions.
DIAPHARMA AND VLVbio THANK YOU!
We enjoyed meeting so many of you in-person at the AASLD The Liver Meeting®, and sharing new studies using CK18/K18-M30® and CK18/K18-M65® as blood-based biomarkers in the world of NASH, acute alcohol-associated hepatitis, and DILI.
DiaPharma has also added new and unique assay kits to assess liver injury and fibrosis. If you missed us, reach out to us today to discuss with one of our scientists.
For research use only in U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00991Rev01
Because matrix matters! The path to liver disease is paved with MMPs and collagen
It’s Not Just Support. It’s Solutions.
DiaPharma and QuickZyme Know Matrix Matters!
Matrix Metalloproteases (MMPs) degrade collagen and elastin. As indicators of inflammation and disease, they are key targets for drug development.
- Biliary Atresia – MMP-7 has garnished much research support for its role in mediating biliary injury in the disease.
- NAFLD/NASH – Serum MMP-7 can further research of advanced fibrosis. MMP-9 is useful when researching NAFLD.
- ALD – Publications show that MMP-2, MMP-8 and MMP-9 may be markers of alcohol-associated liver cirrhosis. Also, pre-clinical rat models show that MMP-9 is elevated when exposed to chronic alcohol consumption.
QuickZyme specializes in collagen-related assays and MMP activity assays (MMP-2, MMP-7, MMP-8, MMP-9, MMP-14). These assays were developed by scientists to fill an unmet need in their studies. They give a more granular insight to the role that fabrication and degradation of the extracellular matrix can play in fibrosis, inflammation, and metastatic tumors.
Finally, a test to accurately and specifically quantify MMP activity in relevant biological samples (blood, sputum, urine, cell cultures, etc.). These kits make testing more efficient, with a dual readout option: Measure endogenous active MMP-7 (naturally occurring) or total (active + pro) MMP-7 for each plate.
Available QuickZyme MMP Activity Assays:
- QuickZyme Human MMP-2 Activity Assay Kit
- QuickZyme Human MMP-7 Activity Assay Kit
- QuickZyme Human MMP-8 Activity Assay Kit
- QuickZyme Human MMP-9 Activity Assay Kit
- QuickZyme Mouse MMP-9 Activity Assay Kit
- QuickZyme Human MMP-14 Activity Assay Kit
Make your life easier with these QuickZyme kits.
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
More to Explore
DiaPharma offers an extensive portfolio of liver biomarkers, including Cytokeratin 18 (CK18, K18) ELISAs – M30® and M65®, Liver-FABP (FABP1), TSP-2, GDF-15, Adiponectin, FGF-21, Neutrophil Elastase, Adipocyte-FABP (FABP4), Osteopontin, Quickzyme Total Collagen.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00989Rev01
What’s New at DiaPharma?
It’s Not Just Support. It’s Solutions.
DiaPharma in the Community
DiaPharma staff supports many impactful causes.
DiaPharma and our staff proudly sponsor events close to our hearts and our community. Most recently, DiaPharma sponsored Ross’s Race in the Alzheimer’s Association Walk to End Alzheimer’s®, and the Circle Tail Golf Classic for Circle Tail assistance dogs and facility dogs, and Han’s White Tiger Break-a-Thon for Cincinnati Children’s Hospital. We are grateful to be able to contribute to so many worthy causes.
Celebrating 25 Years
DiaPharma delivers solutions by providing strong personal support with technical competence and experience. Our strength is grounded in both science and staff. For 25 years, DiaPharma has been proud to give each of our customers a truly personalized experience — a focused, dedicated resource that understands our customers’ needs, and has the scientific and technical expertise to help customers make the best product choices.
Meet us in person this year at the following events:
- Obesity & NASH Drug Development Summit: November 29 – December 1 in Boston, MA
- 64th ASH Annual Meeting and Exposition: December 10 – 13 in New Orleans, LA
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00990Rev01
DiaPharma has a lot to share at The Liver Meeting® – come see us!
It’s Not Just Support. It’s Solutions.
VISIT DIAPHARMA AND VLVbio
AT THE LIVER MEETING®!
A LOT has happened since the last in-person AASLD The Liver Meeting® and DiaPharma has a lot to share about new studies using CK18/K18-M30® and CK18/K18-M65® as blood-based biomarkers in the world of NASH, acute alcohol-associated hepatitis, and DILI.
Booth # 712 is where Team DiaPharma will be. We will host representatives from VLVbio, the Swedish manufacturers of the M30® and M65 ELISA kits. All are open to good conversation.
DiaPharma has also added new and unique product offerings that measure MMPs, collagen, TSP2, GDF-15, L-FABP, Noggin, Wnt3a, sCD163, Intact Proinsulin, etc. Interested in NETosis? We are, too! Let’s talk.
For research use only in U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00988Rev01
Thank you for connecting with DiaPharma at Midwest Platelet!
It’s Not Just Support. It’s Solutions.
THANK YOU TO THOSE WHO CONNECTED WITH US AT THE MIDWEST PLATELET CONFERENCE
DiaPharma is proud to celebrate 25 years in the hemostasis and coagulation business. Thank you to those who stopped by our booth at the Midwest Platelet Conference. We welcomed the opportunity to talk all things bleeding & clotting, and demo new technology for measuring platelet function.
Interested in learning more? Please reach out for instrument details or to set up a Ceveron® s100 or T-TAS® 01 demo.
Contact us or visit diapharma.com to learn more about our extensive portfolio of products, including Thrombin Generation automated and manual methods with different triggers to suit your specific needs, flow cytometry antibodies, immunothrombosis biomarkers, von Willebrand Factor assays, and ADAMTS13 activity.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00983Rev01
Overworked staff? The T-TAS® 01 platelet function analyzer can lighten the burden
It’s Not Just Support. It’s Solutions.
T-TAS® 01 PL Assay: One test, one result, one total answer for platelet function
Help address staffing and budgetary challenges with a frontline test for overall total platelet function
- Single assay with easy-to-interpret test result provides simple and comprehensive platelet reactivity status
- Consolidate testing from multiple platforms, for better assessment of platelet function at a lower cost
- Get a better clinical picture using true physiological flow/shear rates
- T-TAS® 01 analyzer is low-cost, takes up modest space in the lab, and is uncomplicated to learn and operate
T-TAS® 01 PL Assay allows a single assay to be used for direct comparison of the effects of various antiplatelet therapy regimens. Soluble agonist-based agonist assays isolate a single activation pathway and ignore others, and do not reflect total activity.
Our team is eager to talk all things bleeding & clotting, and demo new technology in platelet function measurement. Connect with us to learn more.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-08-00042Rev01
Special Pricing on Non-Invasive, Non-Destructive Ecotoxicology Assays
It’s Not Just Support. It’s Solutions.
Environmental Impact Matters.
PERFORM ENDOCRINE DISRUPTOR STUDIES
WITHOUT KILLING THE FISH
NON-INVASIVE, EASY TO USE, ACCURATE ECOTOXICOLOGY ELISAs
Contact your territory manager for
special 4th quarter pricing on Vitellogenin ELISAs!
Use TECO® Mucus Collection Swabs and test kits to test fish:
- follow individuals and populations over time
- endocrine disruption – vitellogenin ELISA
- liver damage – hyaluraonic acid ELISA
- stress – cortisol ELISA
- applicable to over 35 different fish species
- save cost and time
- standards and controls included
Visit diapharma.com to learn about our new Vitellogenin kits, fish Cortisol Assays, and fish Hyaluronic Acid Assays for general ecotoxicology assessments.
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating twenty five years of scientific expertise,
with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00982Rev01
Go further than FEV1 and FVC – Mechanistic Biomarkers for Lung Disease
It’s Not Just Support. It’s Solutions.
A Case for Letting Endotype Lead the Way in Drug Development…

Neutrophilic VS Eosinophilic
The molecular mechanisms that drive chronic lung disease are heterogenetic. To evolve past a “one drug fits all approach”, toward a more individualized and precision approach, pharmaceutical companies are focusing on drugs that can address each etiology within a disease. These subtypes of mechanistic drivers or pathobiology, endotypes, have come to the forefront in drug design. An endotype approach is therefore important for selecting targets for drug development and deployment.
- COPD, bronchiectasis, and asthma are typically endotyped as eosinophilic or neutrophilic
- Neutrophilic driven disease is indicated by high activity of neutrophil proteases, neutrophil elastase (NE), or proteinase 3 (PR3)
- Neutrophil elastase activity measurement offers a way to better select targets for drug development aimed at neutrophil-specific pathways
DiaPharma offers assays from ProAxsis using ProteaseTag™ technology:
- Neutrophil Elastase (NE) Activity Immunoassay – quantitative 96-well kit
- Proteinase 3 (PR3) Immunoassay – quantitative 96-well kit
- NEATstik Neutrophil Elastase – semi-quantitative lateral flow kit
For research use only. Not for use in diagnostic procedures.
Learn more about DiaPharma’s complimentary portfolio of products for pulmonary research
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise,
with support just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00970Rev01
Factor XIII Assays to Fit Your Needs
t’s Not Just Support. It’s Solutions.
Factor XIII Activity Assays – The Right Fit for your Needs
Manual and automated solutions for measuring FXIII Activity
Technofluor® Factor XIII
Fully automated on the Ceveron s100 for the determination of FXIII activity levels.
- Minimal hands-on time
- Data in under 30 minutes
- Single calibration per lot
- No need for blank samples
- Sensitive at low range
Technochrom® FXIII
Manual ammonia release assay for FXIII activity
- Fast results (10 minutes)
- Limited interferences due to use of NADPH instead of NADH
- Sensitivity down to ~ 0.6% depending on reader
Technoclone products are for research use only in the U.S. and Canada
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise,
with support just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00971Rev01
Endotyping for Clinical Trial Success with COPD, bronchiectasis, asthma
It’s Not Just Support. It’s Solutions.
Endpoints for clinical trials in lung disease could be better…
- FEV1 and FVC are relatively blunt tools for getting a complete picture of a disease state – they do not provide information on the pulmonary microenvironment.
- Inflammation is a hallmark of chronic lung diseases and an important piece of the bigger picture to understand when evaluating effectiveness of a drug
- Decreasing lung-specific inflammation is a key strategy for pharmaceutical targets
- Mechanistic markers of inflammation, such as these, can be detected earlier and indicate sub-clinical improvements in outcomes which help drive decision making during the drug design and clinical trial process
ADD DETAIL to a drug’s storyline with accurate and lung-specific measurements of inflammation by measuring neutrophil elastase (NE) and proteinase 3 (PR3) in sputum.
ProAxsis offers products that are proven to be valuable in enrolling participants, stratifying results, and measuring effectiveness of respiratory drugs in development. The ready- to -use kits offer sensitive, reliable, and accurate read-outs of NE and PR3 activity in sputum or broncheoalveolarlavage (BAL) fluid. NE and PR3 activity levels have been shown to correlate with disease severity, time to next exacerbation, and bacterial load. They can be more globally seen as mechanistic markers of a neutrophilic-driven inflammatory state.
DiaPharma offers assays from ProAxsis using ProteaseTag™ technology:
- Neutrophil Elastase Activity Immunoassay – quantitative 96-well kit
- Proteinase 3 Immunoassay (PR3) – quantitative 96-well kit
- NEATstik Neutrophil Elastase – semi-quantitative lateral flow kit
For research use only. Not for use in diagnostic procedures.
Learn more about DiaPharma’s complimentary portfolio of products for pulmonary research
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise,
with support just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00969Rev01
Measure fibrosis in a more meaningful way using TOTAL collagen assays
It’s Not Just Support. It’s Solutions.
Let DiaPharma introduce you to a new partner in fibrosis research, QuickZyme Biosciences
DiaPharma is excited to announce that we now offer QuickZyme products. QuickZyme knows, “Matrix Matters”.
Collagens are a main component of the extracellular matrix and are the most abundant proteins in the body. Collagens play important roles in cell growth, wound healing, and cartilage. Collagens also provide important readouts on fibrotic disease states of the skin, liver, lung, kidney, and more. Collagen analysis is an important tool to use while investigating and understanding fibrosis, however there is a major hurdle to overcome…
Problem: Collagen is an insoluble protein, how can it be accurately measured?
- ELISA – what exactly is being measured? Only soluble collagen? What about insoluble, mature collagen?
- Histology – Is this quantitative enough? What about tissue heterogeneity?
- PRO-collagen tests – specific for new collagen production, what about existing collagen?
Solution: Total Collagen measurement – chromogenic hydroxyproline detection method
- All types and all forms of collagen are detected
- Compatible with established tissue hydrolysis protocols
- Quantitative measurements with a wide detection range
- Easy 2-hour protocol with no drying step
- Colorimetric read-out, no special equipment required
- Available for low collagen organs and paraffin embedded tissues
- Detects total collagen from all species
Which test is right for your needs?
Collagen assays available from QuickZyme Biosciences:
- QuickZyme Soluble collagen assay
- QuickZyme Total collagen assay
- QuickZyme Sensitive Tissue Collagen Assay
- QuickZyme Hydroxyproline assay
- QuickZyme Sensitive Tissue Hydroxyproline Assay
Collagen is tough (pun intended), make your life easier with these QuickZyme kits.
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Visit DiaPharma at AASLD The Liver Meeting® to discuss our entire offering for blood based liver biomarkers to study Non-alcoholic Steatohepatitis (NASH), Alcoholic Hepatitis (AH) and Drug Induced Liver Injury (DILI).
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00974Rev01
AASLD The Liver Meeting™ 2022
DiaPharma offers non-invasive biomarker tests for researching NASH, AH, DILI, and metabolic syndrome. Visit us and our VLVbio colleagues at booth 712 to discuss M30® and M65® Cytokeratin/Keratin 18 ELISAs for assessing hepatocyte apoptosis/necrosis, and explore our full portfolio of liver injury biomarkers. Research use only in U.S. and Canada.
Tools for Sickle Cell Disease Research
It’s Not Just Support. It’s Solutions.
Tools for Sickle Cell Disease Research
September is National Sickle Cell Awareness Month. From Anti-Hemoglobin S antibodies, coagulation kits, and biomarker assays, to exciting new instrumentation for clotting analysis, DiaPharma has what matters covered for impactful Sickle Cell research.
Research projects like gene therapy require many decisions, including investigating what products will fit and be most effective. You need a partner who can support your work at every stage and help you find solutions, from the start. That’s DiaPharma.
Connect with a DiaPharma scientist to learn more about our portfolio of products to help with your cutting edge research.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00968Rev01
Time to include Human TSP2 in your next NASH study?
It’s Not Just Support. It’s Solutions.
Time to include Thrombospondin-2 in your next NASH study…
- Thrombospondin-2 has been identified by transcriptomics as an emerging NASH biomarker.
- Protein analysis shows that it has promise for use in studying NAFLD, NASH, metabolic disease, and diabetes.
- This Human TSP2 ELISA kit, from ImmunoDiagnostics, is proven reliable for clinical research samples related to NASH and diabetes.
Connect with a DiaPharma scientist to learn more about ImmunoDiagnostics Human Thrombospondin-2 (TSP2) ELISA Kit.
Visit DiaPharma at AASLD The Liver Meeting® to discuss our entire offering for blood based liver biomarkers to study Non-alcoholic Steatohepatitis (NASH), Alcoholic Hepatitis (AH) and Drug Induced Liver Injury (DILI).
About ImmunoDiagnostics: ImmunoDiagnostics Limited (IMD) is a spin-off biotech company from Immunoassay Services (AIS) from the University of Hong Kong (HKU), and has R&D activities in both Toronto and Hong Kong. IMD’s Mission is to be the worldwide pioneer in the production and manufacture of research products regarding immuno-metabolism. READ MORE
Further Reading:
- Wu X, Cheung CKY, Ye D, et al. Serum Thrombospondin-2 Levels Are Closely Associated With the Severity of Metabolic Syndrome and Metabolic Associated Fatty Liver Disease. J Clin Endocrinol Metab. 2022;107(8):e3230-e3240. doi:10.1210/clinem/dgac292
- Kozumi K, Kodama T, Murai H, et al. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology. 2021;74(5):2452-2466. doi:10.1002/hep.31995
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00967Rev01
Thank you for celebrating with DiaPharma!
It’s Not Just Support. It’s Solutions.
THANK YOU TO THOSE WHO CELEBRATED WITH US AT THSNA 2022
DiaPharma is proud to celebrate 25 years in the hemostasis and coagulation business. Thank you to those who stopped by our booth at the Thrombosis and Hemostasis Summit of North America (THSNA) this year in Chicago, IL. We welcomed the opportunity to talk all things bleeding & clotting, and demo new technology for measuring platelet function.
Now that we are all packed up from THNSA and back to the normal grind, please reach out to set up a Ceveron® s100 or T-TAS® 01 demo. These jolly gents could be visiting your lab next.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00960Rev01
What’s New at DiaPharma?
It’s Not Just Support. It’s Solutions.
Meet Genesis Cautivar
West Territory Manager
Genesis Cautivar joined DiaPharma in July 2022. He is a native of Vancouver, British Columbia, Canada and currently resides in the Dallas-Fort Worth, Texas Metroplex. He received his B.S. in Medical Technology from Walla Walla University (WA). He has many years of experience in clinical labs, technical support, management, sales training, and specialty sales in biotech, medical, and pharmaceutical industries. He keeps an active lifestyle with hobbies such as road and gravel bike riding, soccer, rucking, music, and cooking. He is married and has 3 children and 2 dogs.
Celebrating 25 Years
DiaPharma delivers solutions by providing strong personal support with technical competence and experience. Our strength is grounded in both science and staff. For 25 years, DiaPharma has been proud to give each of our customers a truly personalized experience — a focused, dedicated resource that understands our customers’ needs, and has the scientific and technical expertise to help customers make the best product choices.
Meet us in person this year at the following events:
- Foundation for Women and Girls with Bleeding Disorders (FWGBD) 2022 Conference: September 24 – 25 in Arlington, VA
- Association for the Advancement of Blood and Biotherapies (AABB): October 1 – 4 in Orlando, FL
- Midwest Platelet Meeting: October 6 – 8 in Ann Arbor, MI
- The Liver Meeting (AASLD): November 4 – 8 in Washington, DC
- 64th ASH Annual Meeting and Exposition: December 10 – 13 in New Orleans, LA
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00959Rev01
Celebrate with us at THSNA and Learn about T-TAS® 01
It’s Not Just Support. It’s Solutions.
STOP BY BOOTH 416 TO CELEBRATE WITH US AT THSNA 2022
DiaPharma is proud to celebrate 25 years in the hemostasis and coagulation business at the Thrombosis and Hemostasis Summit of North America (THSNA) this year in Chicago, IL. We would love to see old friends and meet new acquaintances August 16th – 18th at the Sheraton Grand Chicago in Booth #416.
Our team is eager to talk all things bleeding & clotting, and demo new technology in platelet function measurement.
We will have Open House hours to demonstrate the T-TAS® 01 in a private suite at the Sheraton Grand Chicago.
- Tuesday August 16: 11:45 am – 1:15 pm
- Wednesday August 17: 12:20 pm – 1:50 pm
Stop by our booth #416 any time during exhibit hours, or email us for details.
Stop by booth 416 to learn about T-TAS® 01 PL Assay for total platelet function assessment.
- Single easy-to-interpret test result provides simple and comprehensive platelet reactivity status, making T-TAS® 01 PL Assay a good frontline test for overall total platelet function
- Get a better clinical picture using physiological conditions under flow/shear
- T-TAS® 01 analyzer is low-cost, takes up modest space in the lab, and is uncomplicated to learn and operate.
- One test, one result, one total answer for platelet function.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00956Rev01
Celebrate with DiaPharma at THSNA 2022 and learn about Ceveron® s100
It’s Not Just Support. It’s Solutions.
STOP BY BOOTH 416 TO CELEBRATE WITH US AT THSNA 2022
DiaPharma is proud to celebrate 25 years in the hemostasis and coagulation business at the Thrombosis and Hemostasis Summit of North America (THSNA) this year in Chicago, IL. We would love to see old friends and meet new acquaintances August 16th – 18th at the Sheraton Grand Chicago in Booth #416.
Our team is eager to talk all things bleeding & clotting, and demo new technology in platelet function measurement.
We will have Open House hours to demonstrate the Ceveron® s100 in a private suite at the Sheraton Grand Chicago.
- Tuesday August 16: 11:45 am – 1:15 pm
- Wednesday August 17: 12:20 pm – 1:50 pm
Stop by our booth #416 any time during exhibit hours, or email us for details.
Stop by booth 416 to discuss:
- Ceveron® s100 all-in-one coagulation analyzer
- Automated ADAMTS13, Thrombin Generation, FXIII Activity, C1-Inhibitor Activity, and more
- The latest Lupus Anticoagulant information
- You name it, Ceveron® s100 can do it!
Research use only in U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00957Rev01
Celebrate with DiaPharma at THSNA in Chicago
It’s Not Just Support. It’s Solutions.
STOP BY BOOTH 416 TO CELEBRATE WITH US AT THSNA 2022
DiaPharma is proud to celebrate 25 years in the hemostasis and coagulation business at the Thrombosis and Hemostasis Summit of North America (THSNA) this year in Chicago, IL. We would love to see old friends and meet new acquaintances August 16th – 18th at the Sheraton Grand Chicago in Booth #416.
Our team is eager to talk all things bleeding & clotting, and demo new technology in platelet function measurement.
*Research use only in U.S. and Canada. Not for use in diagnostic procedures.
Talk with us about:
- Coagulation + Fibrinolysis Markers
- Thrombo-inflammation Markers
- Anticoagulation Measurement Kits and Reagents
- Hemostasis Analyzers
- Hepatotoxicity biomarkers for early detection of liver injury
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00955Rev01
Exploratory Biomarkers for Acute and Chronic Kidney Injury Studies
It’s Not Just Support. It’s Solutions.
Spotlight on Acute and Chronic Kidney Injury
Enhanced assays with improved sensitivity and specificity to assist in kidney disease studies
L-FABP ● NGAL ● Osteopontin ●
alpha-GST ● Cystatin C ● RBP4 ●
Anti-EHEC
There are large gaps in the information that standard kidney markers, like serum creatinine, can provide in the context of kidney injury. Indication of risk level, etiology of damage or disease, treatment response, and outcomes are all areas that can be greatly improved upon. DiaPharma is proud to offer a unique and well characterized panel of kidney biomarkers that can be used to overcome these gaps. Our biomarkers include stress or damage markers that provide mechanistic information of sub-clinical levels of damage associated with chronic and acute kidney injury. From cardio-renal to diabetes studies, these biomarkers can provide earlier and more descriptive insight than the standard kidney markers.
Learn about our extensive line of mechanistic biomarker assays for drug development and drug safety studies. Our knowledgeable scientists are happy to discuss our portfolio of biomarker assays. |
![]() |
Biomarker | Sample Type | Description | Available Assays | Product # |
Liver Fatty Acid Binding Protein (L-FABP) | Urine | Biomarker for proximal tubule damage | Urinary L-FABP | 006 |
Alpha Glutathione S-Transferase (α-GST) | Urine | Biomarker for acute proximal tubule injury | TECO® alpha-GST | TE1056 |
Neutrophil Gelatinase-Associated Lipocalin (NGAL) | Urine | Biomarker for acute global tubular injury | Diapharma NGAL (96) Diapharma NGAL (2 x 96) IMD Lipocalin-2 |
DPG-NGAL DPG-2NGAL 31050 |
Cystatin C (CysC) | Serum plasma, or Urine | Biomarker of glomerular filtration (serum CysC) and tubular dysfunction (urinary CysC) | IMD Rapid Cystatin C | 31241 |
Osteopontin (OPN) | Urine | Biomarker for global tubular injury | Osteopontin Osteopontin N-Half |
DPG27158 DPG27258 |
Retinol Binding Protein 4 (RBP4) | Urine | Biomarker of proximal tubule function | Retinol Binding Protein 4 (RBP4) | 31060 |
Anti-EHEC O157:H7 IgM | Serum, plasma | Biomarker for the investigation of STEC-HUS and associated acute kidney injury | Hycult EcHECk | HK508 |
Sample Collection Tubes | Urine | Preserves urinary proteins. The 5 ml tubes are filled with 0.8 ml of buffer | TECO® Urine Stabilizing Tubes | TE1050 |
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00940Rev01
Clot Club #32
CHROMOGENIC FACTOR X ASSAYS vs the PT/INR TO MONITOR SUBJECTS ON COUMADIN THERAPY WHEN AN INDIVIDUAL APPROACH IS NECESSARY
Visit DiaPharma at ISTH and Register to Win!
It’s Not Just Support. It’s Solutions.
CONNECT WITH US AT ISTH 2022
Visit us at the ISTH 2022 Congress July 9-13 to learn about our full line of hemostasis clinical and research products.
Stop by booth 1125 to discuss:
- Ceveron® s100 all-in-one coagulation analyzer
- Automated ADAMTS13, Thrombin Generation, FXIII Activity, C1-Inhibitor Activity, and more
- You name it, Ceveron® s100 can do it!
- The latest Lupus Anticoagulant information
Research use only in U.S. and Canada. Not for use in diagnostic procedures.
REGISTER TO WIN an Oculus Quest 2 All-In-One VR Headset!
U.S. and Canada only. See diapharma.com for details.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00944Rev01
Supporting International NASH Day
DiaPharma Supports International NASH Day
Heppy the Liver Man with his Finishers Medal
June 9, 2022 is International NASH Day (IND). IND is an initiative started by the Global Liver Institute to raise awareness of the growing worldwide epidemic of non-alcoholic fatty liver disease (NAFLD) and its more advanced form, non-alcoholic steatohepatitis (NASH).
There are currently no approved drugs to treat NAFLD or NASH, and following a lifestyle that includes a healthy diet and regular exercise – like going for a run – is still the best way to prevent and treat these diseases.
DiaPharma supports the development of pharmacological therapies for NASH by offering noninvasive tests (NITs) for biomarkers like CK18 that provide early, biologically plausible indications of changes in disease activity.
Visit us with VLVbio™ in the Biotech Village at the EASL International Liver Congress™ 2022
June 22 – 26 in London
DiaPharma offers additional non-invasive biomarker assays for NAFLD/NASH, AH, and DILI research. Incorporating these biomarkers into your research adds valuable information about changes in disease activity, which could decrease time and costs of studies. M30® and M65® Cytokeratin 18 (CK18) ELISAs, Intact Proinsulin, Osteopontin, Mac-2 Binding Protein, sCD163, L-FABP, FGF-19, and FGF-21 are just a few of the biomarker assays offered by DiaPharma to help your drug candidate move forward.
If you’d like to speak with an expert about which biomarker would be most useful for your project, call 800.447.3846 or email us today.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00930Rev01
International NASH Day (IND)
June 9, 2022, is International NASH Day (IND). IND is an initiative started by the Global Liver Institute to raise awareness of the growing worldwide epidemic of non-alcoholic fatty liver disease (NAFLD) and its more advanced form, non-alcoholic steatohepatitis (NASH).
There are currently no approved drugs to treat NAFLD or NASH, and following a lifestyle that includes a healthy diet and regular exercise – like going for a run – is still the best way to prevent and treat these diseases.
DiaPharma supports the development of pharmacological therapies for NASH by offering noninvasive tests (NITs) for biomarkers like CK18 that provide early, biologically plausible indications of changes in disease activity in drug development research.
#NASHDay
#StopNASHNow
#NAFLD
#NASH
#Loveyourliver
#RunHeppyrun
News from the front lines at SOT 2022: Checkpoint Inhibitor Liver Toxicity
It’s Not Just Support. It’s Solutions.
Spotlight on Liver Toxicity:
Immune-mediated Liver Injury
Caused by Checkpoint Inhibitors (ILICI)
One thing that jumped out at the Society of Toxicology (SOT) meeting this past March was a new phase of liver toxicology research focused on therapies that have a direct effect on immune function, specifically, hepatotoxicity related to the use of immune checkpoint inhibitors for treating cancer.
DiaPharma considers the complexities and outstanding research questions around Immune-mediated Liver Injury caused by Checkpoint Inhibitors (ILICI) in our blog post.
- Checkpoint inhibitor use is a successful new generation of cancer therapy, but can cause liver toxicity – as high as 10% in some cases
- The mechanism of liver toxicity is under investigation, but is not thought to be a result of toxic metabolites or direct hepatocyte toxicity
- There is a need for in-depth research into ILICI pathophysiology, and better liver injury biomarkers for liver toxicity.
Keratin 18 (K18) has potential to be a useful tool in understanding the role hepatocyte cell death plays in Immune-Mediated Liver Injury caused by Checkpoint Inhibitors (ILICI). For the drug development process, it can provide more liver-specific and earlier signals than ALT or AST. DiaPharma offers K18 and ccK18 assays, highly specific biomarkers for hepatocyte cell death.
M65® ELISA ● M65® EpiDeath ELISA ● M65® EpiRat ELISA ●
Learn about our extensive line of mechanistic biomarker assays for drug development and drug safety studies.
Our knowledgeable scientists are happy to discuss liver and kidney injury biomarker assays, featuring Keratin 18 (K18/CK18), L-FABP, α-GST, NGAL, Osteopontin, and Cystatin C.
For research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00926Rev01
Measure True Beta Cell Dysfunction with TECO Intact Proinsulin
It’s Not Just Support. It’s Solutions.
When it comes to measuring pancreatic Beta cell function, go with the Pro!
TECO® Intact Proinsulin ELISA
Save time and guess work by selectively measuring only intact proinsulin.
Proinsulin is synthesized in pancreatic β-cells and secreted as insulin. Insulin resistance (IR) or hyperglycemia causes increased secretion and finally secretion disorder. Intact proinsulin levels in plasma then increase while insulin levels decrease. Elevated fasting intact proinsulin is a specific biomarker for β-cell dysfunction and insulin resistance.
The TECO® Intact Proinsulin ELISA measures intact proinsulin, providing a direct measure of pancreatic β-cell function.
Benefits of the TECO® Intact Proinsulin ELISA:
- Reliable tool for Diabetes and Metabolic Syndrome research and drug development studies
- Measures intact Proinsulin only
- Intact Proinsulin is a direct measure of pancreatic Beta-cell function
- Avoid the noise – Total Proinsulin also measures intact and stable cleavage fragments
- Standardized against WHO reference 09/296
- Assay time less than 2.5 hours means fast results – no need for overnight incubation
- Sensitive and specific antibodies
- Available exclusively in North America from DiaPharma
Explore our additional diabetes research markers to assist in drug development, including:
- Anti- GAD
- Anti-ZnT8
- Anti- IA2
Visit diapharma.com for our comprehensive portfolio.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise,
with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00925Rev01
T-TAS®01 – The Leading Edge in Platelet Thrombus Formation Assessment
It’s Not Just Support. It’s Solutions.
Innovative Total Platelet Function Analysis using Whole Blood
Global evaluation of overall hemostatic ability using physiologic, flow conditions
Exclusively from DiaPharma.
Advantages of T-TAS® 01 PL Assay
Ease of Interpretation
A numeric cut-off easily identifies those with primary hemostasis disorders, assisting with more timely determination of appropriate treatment strategy
Reduced Costs
May need fewer blood draws, as extra tests may be eliminated, improving the patient’s experience as well as eliminating the associated costs
Simple Pre-Analytics
Fewer blood draws without required fasting improves the patient’s (and phlebotomist’s) experience
Direct use of whole blood minimizes pre-analytical errors
Rapid
Results in 10 minutes
Physiologically Relevant
T-TAS® 01 reconstructs in vivo blood flow conditions
For in vitro diagnostic use
Explore our full portfolio of hemostasis instruments and assays from DiaPharma
*Research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise,
with support just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00923Rev01
Respiratory Research Solutions from DiaPharma
It’s Not Just Support. It’s Solutions.
DiaPharma is Your Exclusive Source for ProAxsis products
Reach out to DiaPharma’s Olivia Stricker, who will be at
American Thoracic Society (ATS) 2022 in San Francisco, May 13 – 16.
Elevate your clinical research data by measuring active proteases
Targets:
Drug development evaluating new protease inhibitors or anti-inflammatory therapies for Cystic Fibrosis, Bronchiectasis, COPD and alpha 1 antitrypsin (AAT) deficiency.
Active Neutrophil Elastase (NE) and Proteinase 3 (PR3) are serine proteases that have been shown to correlate with the severity of disease, bacterial exacerbations, and inflammation.
Benefits:
ProteaseTag™ Technology enables you to target only the active form of the protease, thus providing a stronger correlation with disease status and pathogenic activity than assays that measure total protease levels. Ultimately, this provides an accurate quantitative assessment of changes in the inflammatory state of the lung over time as an endpoint.
ProteaseTag™ Active NE Immunoassay meets the need for a robust assay to measure the active biomarker – it’s the only assay that can detect active proteases with a standard microplate reader, without utilizing chromogenic or fluorogenic substrates.
Learn more about the assays ProAxsis offers and the ProteaseTag™ technology at diapharma.com.
ProteaseTag® Technology
|
|
Learn more about DiaPharma’s complimentary portfolio of products for pulmonary research
Biomarker | Significance in Lung Studies | Product | Packaging | Use | Catalog # |
Cytokeratin 18 |
Expressed in epithelial cells of the lung. Increases detected in lung damage or infection. Apoptosis assay-caspase readout. |
M30 Apoptosense® CK18 ELISA Kit | Kit/96 tests | RUO | P10011 |
M65® ELISA CK18 ELISA Kit | Kit/96 tests | RUO | P10020 | ||
M65 EpiDeath® CK18 ELISA Kit | Kit/96 tests | RUO | P10040 | ||
M30 CytoDeath™ CK18 ELISA Kit | Kit/96 tests | RUO | P10900 | ||
Periostin |
Secreted by activated fibroblasts and promotes fibrosis. Correlates with pulmonary function decline and disease progression in IPF. |
FluoBolt™ Periostin Immunoassay Kit | Kit/96 tests | RUO | FIA-1703 |
Soluble CD163 |
Soluble macrophage marker. Increases in inflammatory conditions. |
IQ Macro163™ ELISA Kit | Kit/96 tests | RUO | IQP-383 |
Neutrophil Elastase (NE) |
Degradative enzyme released by activated neutrophils. Increases reported as indication of inflammation and tissue damage. |
ProAxsis ProteaseTag® NE Activity Kit | Kit/96 tests | RUO | PA001US |
ProAxsis NEATstik® Rapid NE Activity Test | Box is 10 tests | RUO | PA004-10US | ||
ImmunoDiagnostics NE ELISA kit | Kit/96 tests | RUO | 31330 | ||
Proteinase 3 (PR3) |
Degradative enzyme released by activated neutrophils. Increases reported as indication of inflammation and tissue damage. |
ProAxsis ProteaseTag® PR3 Activity Kit | Kit/96 tests | RUO | PA008US |
ImmunoDiagnostics PR3 ELISA Kit | Kit/96 tests | RUO | 31300 | ||
Alpha 1 Antitrypsin (AAT) |
Inhibitor of neutrophil elastase enzyme. Decreases in AAT protein cause disease of the lung and liver. (Alpha-1 Antitrypsin Deficiency) |
ImmunoDiagnostics A1AT ELISA Kit | Kit/96 tests | RUO | 31420 |
Urokinase-type plasminogen activator (uPA) | Inflammatory and fibrinolysis marker, specific to lung tissue | Technozym® uPA Combi Actibind® ELISA Kit | Kit/96 tests | RUO | TC16010 |
All products are for research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Twenty five years of scientific expertise,
with support just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00923Rev01
Comprehensive Solutions for Anticoagulation Research
It’s Not Just Support. It’s Solutions.
Explore Assays from DiaPharma to Enhance Your Anticoagulation Research
Whether you’re researching vitamin K antagonists, thrombin inhibitors, FXa inhibitors, or contact pathway inhibitors, you need reliable, relevant tests. DiaPharma can help you select the right assays.
Thrombin Generation Testing
- Manual or automated options for studying potential new anticoagulants
Technothrombin® TGA*
- Applications for most fluorescent readers
- Choose optimized reagents with varying tissue factor and phospholipid concentrations based on your experimental needs
Ceveron® TGA*
- Automated for walk-away TGA
- Normalized TGA values
- Convenient kit options – choose reagents with varying tissue factor and phospholipid concentrations based on your experimental needs
DOAC-STOP™ Tablets*
The original DOAC neutralizer
- Effectively remove DOACs from plasma to get accurate results
- Perform clotting assays on plasma containing DOACs in anticoagulant research
Chromogenic substrate assays*
- From the leaders in chromogenic substrate technology
DOAC Calibrators & Controls*
- High quality calibrators and controls for the reliable measurement of Apixaban ● Rivaroxaban ● Edoxaban ● Arixtra ● Dabigatran
Plus, reliable tools for heparin & warfarin measurement
Coamatic® Heparin and Coatest® Heparin
- Chromogenic anti-Xa kit for accurate heparin measurement
- Well published, well established kits for clinical or industrial use
- Measure Low Molecular Weight Heparin (LMWH) and Unfractionated Heparin (UFH)
DiaPharma Factor X
- Chromogenic Factor X for warfarin patients with unreliable INRs
*For research use only. Not for use in diagnostic procedures.
Coagulation, Anticoagulation, Fibrinolysis, Thromboinflammation. DiaPharma is your resource for all things bleeding and clotting.
Not sure which assays best fit your needs? Give us a call or email to discuss.
It’s Not Just Support. It’s Solutions.
25 years of scientific expertise is just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00916Rev01
What’s New at DiaPharma?
It’s Not Just Support. It’s Solutions.
Meet Ryan McCaw
Midwest Territory Manager
Ryan joined DiaPharma in January of 2022. He obtained his BS in Medicine from the University of Iowa where he also completed the Medical Technology program. He was certified as a Medical Technologist with the ASCP and started his career in medical research and had various roles in the clinical lab, both hospitals and small clinics. He later moved into roles supporting and representing labs of various kinds such as molecular and toxicology. Born and raised in eastern Iowa where he currently lives with his wife and two daughters before they head off to college. He enjoys a variety of activities such as mountain biking, landscaping, traveling, fishing, hiking and kayaking.
DiaPharma delivers solutions by providing strong personal support with technical competence and experience. Our strength is grounded in both science and staff. For 25 years, DiaPharma has been proud to give each of our customers a truly personalized experience — a focused, dedicated resource that understands our customers’ needs, and has the scientific and technical expertise to help customers make the best product choices.
Meet us in person at the following events:
- UNC 10th Symposium on Hemostasis: April 28 – 30 in Chapel Hill, NC
- Vascular Discovery, from Genes to Medicine: May 12 – 14 in Seattle, WA
- American Thoracic Society (ATS) 2022: May 13 – 18 in San Francisco, CA
- ASGCT Annual Meeting: May 16 – 19 in Washington, DC
- EASL – THE INTERNATIONAL LIVER CONGRESS™: June 22 – 26 in London, UK
- International Society of Thrombosis and Hemostasis (ISTH) Congress: July 9 – 12 in London, UK
- AACC Annual Scientific Meeting & Clinical Lab Expo: July 24 – 28 in Chicago, IL
- Thrombosis and Hemostasis Societies of North America (THSNA) Summit: August 15 – 18 in Chicago, IL
- American Society of Clinical Pathologists (ASCP): September 7 – 9 Chicago, IL
- The Liver Meeting (AASLD): November 4 – 8 in Washington, DC
- 64th ASH Annual Meeting and Exposition: December 10 – 13 in New Orleans, LA
It’s Not Just Support. It’s Solutions.
Twenty five years of scientific expertise, with support just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00918Rev01
World Hemophilia Day
Did you know that the majority of people living with inherited bleeding disorders around the world still do not have access to diagnosis, treatment and care? DiaPharma supports World Hemophilia Day, to raise awareness and increase sustainable and equitable access to care.
#WHD2022
#DiaPharma
#WorldHemophiliaDay
#Hemophilia
#AccessForAll
#LightItUpRed
ML-00-00914Rev01
Emerging Biomarkers in Alcoholic Liver Disease
It’s Not Just Support. It’s Solutions.
Non-Invasive Biomarkers for Alcoholic Liver Disease Studies
Biomarkers of cell death and regeneration, inflammation, and immune response become useful tools as new potential Alcoholic Liver Disease (ALD) and Alcoholic Hepatitis (AH) treatment options are investigated. Serum biomarkers can provide valuable insights into:
- Disease severity and progression in ALD and AH research studies
- Mechanisms involved in ALD and AH pathogenesis
DiaPharma has the tools for ALD Research.
Measure hepatocyte apoptosis and/or necrosis with our Cytokeratin 18/Keratin 18 (CK18/K18) biomarkers:
- M30 Apoptosense® ccK18 ELISA
- Measures apoptosis
- M65® ELISA and M65® EpiDeath® K18 ELISA
- Measures total cell death
Additional Biomarkers of Interest:
- Osteopontin (OPN)
- Soluble CD163 (sCD163)
- Complement Factors 3a/5a/C5b-9
Visit diapharma.com for our comprehensive portfolio including biomarkers for Nonalcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH) and Drug Induced Liver Injury (DILI).
All products are for research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00894Rev01
Thrombin Generation Assay for Cancer Associated Thrombosis Research
It’s Not Just Support. It’s Solutions.
Technothrombin® and Ceveron® TGA
Thrombin Generation Testing for Cancer-Associated Thrombosis Research
Thrombosis is a common complication for individuals with cancer. Risk varies by malignancy type, treatment approaches, and individual risk factors. Thrombin generation assays (TGA) provide a global context of thrombosis.
When you want to measure thrombin generation in your cancer research studies, consider the options from DiaPharma to suit your needs.
Manual or automated options to suit your needs:
Technothrombin® TGA
- Give thrombotic potential a number
- Applications for most fluorescent readers
- Choose optimized reagents with varying tissue factor and phospholipid concentrations based on your experimental needs
Ceveron® TGA
- Automated for walk-away TGA
- Normalized TGA values
- Convenient kit options – choose reagents with varying tissue factor and phospholipid concentrations based on your experimental needs
- You name it, Ceveron® s100 can do it!
Visit diapharma.com for our comprehensive portfolio of hemostasis research products.
All Technoclone products are for research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00910Rev01
Visit DiaPharma IN PERSON at the SOT 61st Annual Meeting and ToxExpo
It’s Not Just Support. It’s Solutions.
Visit booth 1118 to learn about our extensive line of mechanistic biomarker assays for drug safety studies. Our knowledgeable scientists are happy to discuss liver and kidney injury biomarkers for early DILI/DIKI prediction, featuring Keratin 18 (K18/CK18).
K18 biomarkers have improved organ specificity over traditional biomarkers. Our K18 M30 Apoptosense® and M65® ELISAs detect apoptosis and/or necrosis whether caused by drugs, toxins, or disease.
Learn about our extensive line of biomarker assays for detecting safety signals in drug development, including osteopontin, L-FABP, α-GST, NGAL, and Cystatin C.
For research use only. Not for use in diagnostic procedures.
- Increased organ specific serum biomarker
- Quantifies hepatocyte cell death to assess liver toxicity
- Low day-to-day fluctuation and remarkably stable in serum
- Convenient ready-to-use ELISA format
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00890Rev01
Assays for your Gene Therapy Research in Rare Diseases
It’s Not Just Support. It’s Solutions.
Explore Assays for Gene Therapy and Cell Therapy Research in Rare Diseases
HEMOPHILIA A & B
- Chromogenic FVIII – Coamatic® FVIII, Coatest® SP/SP4 FVIII
- Sensitive and reproducible, featuring bovine factor reagents
- Chromogenic FIX – ROX FIX*
- Bringing chromogenic FIX testing into the next era with unsurpassed sensitivity
SICKLE CELL
DiaPharma offers a full panel of antibodies for detection of various types of hemoglobin.
- Anti-Hemoglobin S antibodies
- Anti-Hemoglobin F antibodies
- Analyte Specific Reagents (ASR). Analytical and performance characteristics are not established.
HEREDITARY ANGIOEDEMA (HAE)
- Technochrom® C1-INH*
- Chromogenic C1 Esterase Inhibitor (C1-INH) activity
- Easy, automatable, simple and fast assay for chromogenic determination of C1-INH activity in plasma or concentrates
- Technothrombin® TGA
- Ceveron®* for TGA and all-in-one coagulation analyzer
CYSTIC FIBROSIS
- ProAxsis ProteaseTag™ Active Neutrophil Elastase*
- ProAxsis NEATstik® Rapid NE Activity*
- Robust assay measures only active NE
- Available in 2 formats – standard and lateral flow, providing NE detection limits ranging from 7.2 – 1000 ng/ml.
HEPATOTOXICITY
- Cytokeratin 18 (CK18) M30® Apoptosense* and M65® ELISA*
- Serum biomarkers that measure hepatocyte death (apoptosis and necrosis)
- Increased organ specificity for early detection of liver injury
- M65® EpiRat ELISA*
- New tool for translational research
- Measure hepatocyte death in rat models
- Osteopontin, alpha-GST, N-GAL, L-FABP, Cystatin C* also available
*For research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00895Rev01
Non-Invasive, Non-Destructive Ecotoxicology Assays
It’s Not Just Support. It’s Solutions.
Environmental Impact Matters.
PERFORM ENDOCRINE DISRUPTOR STUDIES WITHOUT KILLING THE FISH
NON-INVASIVE, EASY TO USE, ACCURATE ECOTOXICOLOGY ELISAs
Use TECO® Mucus Collection Swabs and test kits to test fish:
- follow individuals and populations over time
- endocrine disruption – vitellogenin ELISA
- liver damage – hyaluraonic acid ELISA
- stress – cortisol ELISA
- applicable to over 35 different fish species
- save cost and time
- standards and controls included
Visit diapharma.com to learn about our new Vitellogenin kits, fish Cortisol Assays, and fish Hyaluronic Acid Assays for general ecotoxicology assessments.
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Twenty five years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00892Rev01
Go with the Pro – Intact Proinsulin for your Diabetes Research
It’s Not Just Support. It’s Solutions.
When it comes to measuring pancreatic Beta cell function, go with the Pro!
TECO® Intact Proinsulin ELISA
Save time and guess work by selectively measuring only active proinsulin.
Only 1% to 3% of proinsulin is secreted intact. However, because proinsulin has a longer half-life than insulin, circulating proinsulin concentrations are in the range of 5% to 30% of circulating insulin concentrations on a molar basis, with the higher relative proportions seen after meals and, in subjects with insulin resistance, metabolic syndrome, or early type 2 diabetes. Proinsulin can bind to the insulin receptor and exhibits 5% to 10% of the metabolic activity of insulin.
Benefits of the TECO® Intact Proinsulin ELISA:
- Measures intact active Proinsulin only
- Intact Proinsulin is a direct measure of pancreatic Beta-cell function
- Standardized against WHO reference 09/296
- Reliable tool for research studies and clinical trials involving risk for Type 1 or Type 2 Diabetes and for Metabolic Syndrome research and drug development studies
- Available exclusively in North America from DiaPharma
Explore our additional diabetes research markers, including:
- Anti- GAD
- Anti-ZnT8
- Anti- IA2
Visit diapharma.com for our comprehensive portfolio.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00891Rev01
You Name It, I’ll Do It – complete solutions for your hemostasis needs
It’s Not Just Support. It’s Solutions.
Ceveron® s100:
Your all-in-one coagulation research analyzer
Featuring automated ADAMTS13, Thrombin Generation Testing, FXIII Activity, and full menu of clotting and chromogenic tests
Introducing the do-it-all Ceveron® s100, for automated hemostasis research assays.
You name it, Ceveron® s100 can do it!
Featuring Technofluor® ADAMTS13 as your on-demand ADAMTS13 activity assay. This high-quality, quantitative, fully automated and cost-effective assay provides results in just 30 minutes.
Visit diapharma.com for our comprehensive ADAMTS13 research assays, including Technozym ADAMTS13 Activity ELISA.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
T-TAS® 01 – Explore the leading edge of assessment in impaired primary hemostasis
Get results quickly with whole blood. The T-TAS® 01 uses an automated microchip flow chamber system to asses thrombus formation process under physiologic flow conditions.
- Minimal pre-analytical handling.
- Small sample volume.
- Short assay run-time – results within 10 minutes.
- Simple to interpret numerical cut-off values allow for clear and reliable identification of patients with a primary hemostatic disorder, in ten minutes or less.
- Sensitive to aspirin and P2Y12 inhibition, as well as the various vWD subtypes and Glanzmann Thrombasthenia.
For your research needs:
- AR Chip for T-TAS® 01 for measurement of overall hemostatic function in whole blood the confluence of primary and secondary hemostasis.
- HD Chip for T-TAS® 01 for measurement of overall hemostatic function in whole blood with low platelet count (10,000 – 90,000/µL).
- For research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Celebrating 25 years of scientific expertise, with support just a call or click away.
Copyright © 2022 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00889Rev01
Tools for the puzzle of COVID-related coagulation
It’s Not Just Support. It’s Solutions.
Explore Assays from DiaPharma to enhance your COVID-19 Related Research
*For research use only. Not for use in diagnostic procedures.
Coagulation, Anticoagulation, Fibrinolysis, Thromboinflammation. DiaPharma is your resource for all things bleeding and clotting. Not sure which assays best fit your needs? Give us a call or email to discuss.
It’s Not Just Support. It’s Solutions.
25 years of scientific expertise is just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00885Rev01
A better way to measure functionally active prothrombin
It’s Not Just Support. It’s Solutions.
High Quality Assays for the Latest Hemostasis and Anticoagulation Research
Featuring ROX Prothrombin*
- Provides a prothrombinase based chromogenic method to measure biologically functional FII activity in plasma and FII containing concentrates
- Non-γ-carboxylated-FII is not activated in this method in contrast to snake venom based prothrombin methods
- High dilution means minimal interferences and detection limit of about 0.05 U/mL (5%)
- Precise method for detecting loss of functional activity that may occur during manufacturing of Prothrombin Complex Concentrate (PCC)
- The high quality you expect from Rossix
- Simplify your testing with the first product to effectively remove DOACs from plasma
- Perform clotting assays on plasma containing DOACs in anticoagulant research
DOAC Calibrators and Controls*
Plus, reliable tools for heparin & warfarin measurement
Coamatic® Heparin & Coatest® Heparin
- Well published, well established chromogenic anti-Xa kits for clinical or industrial use, from the leaders in chromogenic substrate technology
- Chromogenic Factor X assay kit for warfarin measurement in patients with unreliable INRs
Visit diapharma.com for our portfolio of hemostasis assays.
*Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Twenty five years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00879Rev01
Clot Club #28
THE NEW NOVEL ANTICOAGULANTS XI(a) and XII(a). THE CONTACT FACTOR INHIBITORS: Battling thromboembolism.
Go with the Pro – Intact Proinsulin for your Diabetes Research
When it comes to measuring pancreatic Beta cell function, go with the Pro!
TECO® Proinsulin ELISA
Why Measure Intact Proinsulin?
Proinsulin is the precursor of insulin and Connecting Peptide (C-Peptide). Following synthesis, proinsulin is packaged into secretory granules, where it is processed to C-Peptide and insulin by prohormone convertases (PC1/3 and PC2) and carboxypeptidase E.
Only 1% to 3% of proinsulin is secreted intact. However, because proinsulin has a longer half-life than insulin, circulating proinsulin concentrations are in the range of 5% to 30% of circulating insulin concentrations on a molar basis, with the higher relative proportions seen after meals and, in subjects with insulin resistance, MSY or early type 2 diabetes. Proinsulin can bind to the insulin receptor and exhibits 5% to 10% of the metabolic activity of insulin.
Save time by avoiding measuring Total Proinsulin with inactive insulin and breakdown products. Eliminate the guess work and be certain about what you are measuring!
Benefits of the TECO® Proinsulin ELISA:
-
- Measures intact active Proinsulin only
- Only intact Proinsulin is a direct measure of pancreatic Beta-cell function
- The only ELISA standardized against WHO reference.
- Measures intact active Proinsulin only
- Reliable tool for research studies and clinical trials involving risk for Type 1 or Type 2 Diabetes and for Metabolic Syndrome research and drug development studies
Explore our additional diabetes research markers, including:
- Anti-GAD
- Anti-ZnT8
- Anti-IA2
Visit diapharma.com for our comprehensive portfolio.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00871Rev01
Non-Invasive Solutions to Help Your Drug Candidate Move Forward
Non-Invasive Biomarker Assays for Liver Disease Drug Development Studies
The Need:
Non-Invasive, mechanistic biomarkers that add valuable information about your drug candidate’s efficacy
- Not all biomarkers provide information about the biological mechanism of drug candidates.
- Specific and comprehensive data are critical when deciding on a clinical trial strategy for a drug candidate.
M30®-Apoptosense, M65® ELISA, M65® EpiRat can help evaluate your drug candidate
- Serum CK18 (M65®) and ccK18 (M30®) measure hepatocyte apoptosis and necrosis.
- Apoptosis and necrosis are underlying mechanisms that are directly involved in the pathogenesis of NAFLD.
- Changes in CK18 and ccK18 levels may therefore be early indicators for changes in disease activity in response to drug treatment.
- CK18 biomarkers are beneficial to assess drug efficacy.
DiaPharma offers additional non-invasive biomarker assays for NAFLD/NASH, AH, and DILI research. M30® and M65® Cytokeratin 18 (CK18) ELISAs, Collagen IV, Osteopontin, Mac-2 Binding Protein, sCD163, L-FABP, FGF-19, and FGF-21 are just a few of the biomarker assays offered by DiaPharma to help your drug candidate move forward.
If you’d like to speak with an expert about which biomarker would be most useful for your project, call 800.447.3846 or email us today.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
ML-00-00869Rev01
Two Fields, One Company – Expertise in Liver Disease and Coagulation
It’s Not Just Support. It’s Solutions.
Markers for Bleeding and Thrombosis in Liver Disease
DiaPharma’s long-time expertise in the Hemostasis and Liver Disease fields means we’re uniquely positioned to deliver solutions.
Liver diseases – such as Non-alcoholic fatty liver disease (NAFLD), Alcoholic Hepatitis (AH), and cirrhosis – can be associated with imbalances in coagulation, whether due to abnormalities of platelet count/function, decreased synthesis or clearance of coagulation factors, or overactive fibrinolysis.
Research may focus on answering questions such as which subjects are bleeding risks? Which may have thrombotic complications? What is the severity of the liver disease? Do you need more information than the INR can give?
If you’re studying intrahepatic thrombosis, liver fibrogenesis, or developing new hemostasis-focused liver disease therapies, DiaPharma can help you select the assays that best suit your needs.
Thrombin Generation: Technothrombin® TGA*
- Give thrombotic potential a number. Research thrombin generation when studying disease and progression
- Fully automated on the Ceveron® s100 or t100
Fibrinolytic Markers*
- PAI-1 Activity and Antigen, Plasmin-Antiplasmin (PAP) Complex ELISAs
Bleeding Disorder Markers
- vWF activity, vWF antigen, vWF propeptide*, collagen binding* ELISAs
T-TAS 01® Platelet Function Analyzer
- Discover the leading edge in primary hemostasis assessment
- Global evaluation of overall hemostatic ability in whole blood, using physiologic, flow conditions
- Easy interpretation, reduced costs, simple pre-analytics
Non-Invasive Biomarkers for Fatty Liver Disease*
- CK18 and ccCK18 cell death biomarkers for liver disease
- Measure apoptosis (M30®) or total cell death (M65®)
Visit diapharma.com for our portfolio of biomarker assays for Complement, Bleeding Disorders, and Fibrinolysis
*Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00870Rev01
NASH Tsunami
“DiaPharma is proud to support the NASH Tsunami podcast and its efforts to raise awareness of the NASH epidemic and to make the latest developments easily accessible to everyone, from subject matter experts to laypeople.” – Michael Hambleton, Ph.D., Vice President
DiaPharma offers noninvasive, mechanistic biomarkers for early and biologically plausible indications of changes in disease activity in NASH drug development studies. Analyzing biomarkers like CK18 with the M30®-Apoptosense and M65® ELISAs can provide valuable information to help your drug candidate move forward.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
What’s New at DiaPharma?
It’s Not Just Support. It’s Solutions.
Staff Spotlight
Meet Nancy, Executive Assistant
We’re excited to welcome Nancy to the DiaPharma team. Nancy writes, “I was born in Farmington Hills Michigan. I have three children; my youngest daughter Brenna is still at home while attending University of Cincinnati. I have been with my husband Tim for 16 years now, and we’ve been married for two years. We have two dogs: Henry a Black Lab / Dachshund, and our newest addition is Zoe, a Beagle mix. My husband and I enjoy spending time together at home and with our grandchildren, Dean, 7 and Tala, 3.
I wasn’t looking for a job at the time, but a recruiter who I have worked with in the past called me about an opportunity with DiaPharma, and I was intrigued. After speaking with Amy and Madeleine via Zoom, I knew that I had found something amazing and was thrilled when I was offered the position. The best thing about DiaPharma is the attitude of the employees and the amount of time they have worked here! It says a lot of the management and the structure of the company!”
|
|
Product Spotlight
DiaPharma has the tools for your liver disease research: Nonalcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH), Alcoholic Hepatitis (AH), Drug Induced Liver Injury (DILI).
Measure apoptosis and total cell death with our cytokeratin 18/Keratin 18 (CK18/K18) biomarkers:
- M30 Apoptosense® ccK18 ELISA
- M65® ELISA K18 ELISA
- M65® EpiDeath® ELISA
Additional Biomarkers of Interest:
- Osteopontin (OPN)
- Soluble CD163 (sCD163)
- Complement Factors 3a/5a/C5b-9
Visit diapharma.com for our comprehensive portfolio.
All products are for research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Mechanistic Biomarkers in Drug Development | |||||
![]() FATTY LIVER DISEASE |
![]() DILI / TOXICOLOGY |
![]() CANCER RESEARCH |
![]() HEMOSTASIS |
||
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00863Rev01
Chromogenic Substrates – It’s in our Blood
It’s Not Just Support. It’s Solutions.
Chromogenic Substrates for your Coagulation, Anticoagulation, and Fibrinolysis Needs
Chromogenic substrate technology is in our blood.
Chromogenic Substrates for QC, Drug Development, R&D, for Anti-Xa Testing (S-2765), Contact Pathway Studies (S-2302), Thrombin Generation (S-2238), and more.
Chromogenic substrates are peptides that react with proteolytic enzymes with the formation of color. Most blood coagulation and fibrinolytic factors belong to the group of serine proteases (enzymes) and their zymogens (proenzymes), making chromogenic substrate technology a useful and routine tool in the hemostasis field.
Optimizing Your Assay: What are Enzyme Specificity and Substrate Selectivity?
SPECIFICITY is a property of the enzyme and describes how restrictive the enzyme is in its choice of substrate. A single serine protease may act on various substrates although at different rates. The most important factor governing the fit of a substrate for an enzyme is the amino acid sequence around the bond to be cleaved. SELECTIVITY indicates the degree to which the substrate is bound to and cleaved by different enzymes, given by the ratio kcat/Km.
Measurements made using chromogenic substrates reflect enzyme activity – one gains knowledge about the activity of an enzyme rather than the amount of protein present as found in an immunological assay.
Many factors go into optimizing a chromogenic substrate assay, such as proper selection of type of buffer, pH, relative concentrations of sample and reagents, addition of inhibitors, and/or choice of activator or incubation times. DiaPharma offers comprehensive overviews of our substrates to serve as a guide in selecting a proper substrate. The scientific team at DiaPharma is also here to assist.
For research use only. Not for use in diagnostic procedures.

Prothrombin, the natural substrate of Factor Xa, is cleaved by Factor Xa at two positions, each proceed by the same four amino acid sequence. Factor Xa activity can be determined by the chromogenic substrate S-2222*, which is composed of the same amino acids coupled to a chromophore.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00864Rev01
We’re hiring
DiaPharma is excited to announce we are expanding our team! We seek a West Territory Account Manager and a Midwest Territory Account Manager….
West Territory Account Manager
DiaPharma Group, Inc. – West Chester, Ohio
DiaPharma Group specializes in laboratory assays and biomarkers for hemostasis, liver disease, toxicology, ecotoxicology, and oncology. We deliver solutions and support to our customers!
Our clinical test kits and instruments are used in hospital laboratories, clinical reference laboratories, universities, and pharmaceutical companies. Our line of research products are used by researchers and medical corporations for product development, clinical research studies, and in quality control laboratories.
We are expanding our team!
We seek a seasoned sales professional with a strong scientific background to build collaborative relationships with our customers. A self-starter who can communicate effectively is required to drive sales and provide excellent support to our customers.
Key responsibilities include:
- Schedule, coordinate and implement sales activities in assigned territory in the US and Canada.
- Represent company at select conferences to promote products, expand scientific knowledge base, and develop customer relationships.
- Develop and execute strategies and tactics to sell our solutions within a diverse marketplace.
- Successfully prospect to find and close new opportunities in existing and new accounts.
- Engage current and prospective customers by email, phone, online and in person.
- Deliver sales presentations to key clients.
- Follow-up with customers to maintain customer contact, grow existing business, deliver support and product training, and resolve customer issues.
- Provide constructive feedback from customers to help effectively address customers’ needs
- Provide input on plans for advertising, promotional materials and trade shows.
- Provide sales forecasts and market developments within assigned territory.
- Communicate with home office by submitting written reports, updating Customer Relationship Management System, participating in regular meetings.
Requirements include:
- Five years’ experience plus diagnostic or research laboratory knowledge is highly desirable.
- Degree (B.S.) in Biochemistry, or related discipline, from a four-year college or university.
- Approximately 50% travel by various modes of transportation.
- Proficiency with Microsoft Office applications and SalesForce CRM.
- Ability to adapt and learn quickly.
- Residence within territory (continental United States) with convenient access to regional airports.
- Valid driver’s license.
- Must be legally authorized to work in the United States and permitted to travel to Canada.
- Meet DiaPharma approved customer/vendor credentialing requirements necessary to gain site access, unless prohibited by law. These requirements vary by customer/vendor and may include, but are not limited to: post-employment background checks, various forms of drug testing, vaccinations, fingerprinting, proof of valid identification, and/or adherence to customer-specific substance abuse programs. Your consent to participate in customer-requested screening is a requirement of this position.
We offer:
- A competitive base salary plus commission/bonus opportunity.
- Generous PTO and paid holiday schedule.
- Superior medical, dental, life, STD & LTD insurance.
- 401(k) participation with generous match.
- Supportive work environment.
- Continuing education and training opportunities.
* Benefits may be subject to eligibility requirements and waiting period.
Please forward your resume, cover letter and salary requirements to employment@diapharma.com
DiaPharma Group, Inc., provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.
This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
This employer participates in E-Verify.
Midwest Territory Account Manager
DiaPharma Group, Inc. – West Chester, Ohio
DiaPharma Group specializes in laboratory assays and biomarkers for hemostasis, liver disease, toxicology, ecotoxicology, and oncology. We deliver solutions and support to our customers!
Our clinical test kits and instruments are used in hospital laboratories, clinical reference laboratories, universities, and pharmaceutical companies. Our line of research products are used by researchers and medical corporations for product development, clinical research studies, and in quality control laboratories.
We are expanding our team!
We seek a seasoned sales professional with a strong scientific background to build collaborative relationships with our customers. A self-starter who can communicate effectively is required to drive sales and provide excellent support to our customers.
Key responsibilities include:
- Schedule, coordinate and implement sales activities in assigned territory in the US and Canada.
- Represent company at select conferences to promote products, expand scientific knowledge base, and develop customer relationships.
- Develop and execute strategies and tactics to sell our solutions within a diverse marketplace.
- Successfully prospect to find and close new opportunities in existing and new accounts.
- Engage current and prospective customers by email, phone, online and in person.
- Deliver sales presentations to key clients.
- Follow-up with customers to maintain customer contact, grow existing business, deliver support and product training, and resolve customer issues.
- Provide constructive feedback from customers to help effectively address customers’ needs
- Provide input on plans for advertising, promotional materials and trade shows.
- Provide sales forecasts and market developments within assigned territory.
- Communicate with home office by submitting written reports, updating Customer Relationship Management System, participating in regular meetings.
Requirements include:
- Five years’ experience plus diagnostic or research laboratory knowledge is highly desirable.
- Degree (B.S.) in Biochemistry, or related discipline, from a four-year college or university.
- Approximately 50% travel by various modes of transportation.
- Proficiency with Microsoft Office applications and SalesForce CRM.
- Ability to adapt and learn quickly.
- Residence within territory (continental United States) with convenient access to regional airports.
- Valid driver’s license.
- Must be legally authorized to work in the United States and permitted to travel to Canada.
- Meet DiaPharma approved customer/vendor credentialing requirements necessary to gain site access, unless prohibited by law. These requirements vary by customer/vendor and may include, but are not limited to: post-employment background checks, various forms of drug testing, vaccinations, fingerprinting, proof of valid identification, and/or adherence to customer-specific substance abuse programs. Your consent to participate in customer-requested screening is a requirement of this position.
We offer:
- A competitive base salary plus commission/bonus opportunity.
- Generous PTO and paid holiday schedule.
- Superior medical, dental, life, STD & LTD insurance.
- 401(k) participation with generous match.
- Supportive work environment.
- Continuing education and training opportunities.
* Benefits may be subject to eligibility requirements and waiting period.
Please forward your resume, cover letter and salary requirements to employment@diapharma.com
DiaPharma Group, Inc., provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.
This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
This employer participates in E-Verify.
DiaPharma is excited to bring you the latest at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
DiaPharma is excited to bring you the latest at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, including the Ceveron® s100*, from our partner, Technoclone. The Ceveron® s100* is the most versatile coagulation analyzer, allowing for automated hemostasis research assays, including ADAMTS-13, thrombin generation testing, and FXIII. Ceveron® s100* – You name it, I’ll do it!
*For Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Visit us at booth 317 to learn about our full line of assays for COVID-19-associated coagulopathy, specialty hemostasis, organ injury, and SARS-CoV-2 serology.
ML-00-00862Rev01
#aacc2021
#diapharma
#technoclone
2 in 1. One test, two COVID antibodies.
It’s Not Just Support. It’s Solutions.
Cov19 FluoBolt™-DAT Immunoassay
Quantitative Duplex Antibody Test (DAT) for antibodies to SARS-CoV-2 from Fianostics
The newest test for simultaneous, quantitative determination of anti- Spike Protein S1 Receptor-Binding Domain (anti-S1RBD) and anti-nucleocapsid (anti-NC) antibodies against SARS-CoV-2.
MEF-FIA for SARS-CoV-2 S1RBD and NC Antibodies
Assay Benefits:
- One measurement simultaneously determines anti-S1RBD and anti-NC Antibodies to SARS-CoV-2
- True quantitative test (µg/ml IgG) with calibrators and controls included
- Differentiate antibodies derived from native infection and/or vaccination
- Patented and proven FluoBolt™ microtiter plate technology
- Tested against NIBSC/WHO standards
- Correlates with surrogate virus neutralization test
- 10 µL of serum or plasma
- Fast- 60 minute incubation
The Cov19 FluoBolt™-DAT allows the simultaneous and quantitative measurement of antibodies against the S1RBD and nucleocapsid antigen of SARS-CoV-2 within one single measurement by using only 10 µl of sample and generates results within 60 minutes.
In contrast to other antibody assays, which detect all antibodies generated against the S1- or NC-protein, the Cov19 FluoBolt™-DAT is epitope specific and detects immune-dominant antibodies species, i.e. the most important ones generated by either vaccination or infection. This is also nicely demonstrated by the fact that it detects anti-S1RBD against all dominant virus variants identified so far (see chart).
The calibrators of this assay allow for a concentration calculation of antibodies in a sample (µg/mL). Therefore, the Cov19 FluoBolt™-DAT assay may be a valuable tool for researching antibody based “protective correlate”, i.e. what amount and type of antibody gives protection for a certain period of time. The assay is also a valuable tool to differentiate unvaccinated vs. only vaccinated vs. infected samples in any SARS-CoV-2 research study.
For research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00859Rev01
Non-Invasive Solutions for Your NASH Clinical Trials
It’s Not Just Support. It’s Solutions.
Biomarker Assays for NASH Clinical Trials
Non-Invasive Biomarkers for Fatty Liver Disease Research
The Problem:
In early phase NASH trials, performing liver biopsies to evaluate the effect of a potential drug candidate is not always practical or feasible.
- These relatively short-duration early trials may not result in significant changes in liver histology.
- Traditional non-invasive serum biomarkers used in NASH clinical trials, such as serum ALT and AST, are notoriously insensitive and non-specific, and do not always accurately reflect the extent of liver injury.
- Recent NASH drug failures and setbacks highlight the need for collecting data on multiple biomarkers to provide mechanistic and biological information on drug candidates.
- Fibrosis biomarkers may not reflect ongoing active disease and and may not be adequate for determination of possible drug effects.
- Specific and comprehensive data are critical for decision making when deciding on future clinical trials.
The Solution:
Non-Invasive, mechanistic biomarkers that are reflective and predictive of changes in liver histology
- Serum CK18 (M65®) and ccK18 (M30®) measure hepatocyte apoptosis and necrosis.
- Apoptosis and necrosis are underlying mechanisms that are directly involved in the pathogenesis of NAFLD.
- NASH is a multifactorial disease and multiple biomarker readouts of disease pathogenesis can indicate changes in biological pathways of the disease.
- Ongoing cell death indicates ongoing pathogenesis in NASH.
- Changes in CK18 and ccK18 levels may therefore be early indicators for changes in disease activity in response to drug treatment.
- Changes in serum CK18 and ccK18 levels have been shown to correlate with histological changes/endpoints in the liver.
- CK18 biomarkers are used widely in NASH clinical trials as a secondary endpoint to assess drug efficacy
- CK18 can be used for prescreening subjects in clinical trials to help identify individuals with “at risk” NASH (NAS ≤ 4, and F2-3)
DiaPharma offers additional non-invasive biomarker assays for NAFLD/NASH, AH, and DILI research. Incorporating these biomarkers into your research adds valuable information about changes in disease activity, which could decrease time and costs of studies. M30® and M65® Cytokeratin 18 (CK18)ELISAs, Osteopontin, Mac-2 Binding Protein, sCD163, L-FABP, FGF-19, and FGF-21 are just a few of the biomarker assays offered by DiaPharma to help your drug candidate move forward.
If you’d like to speak with an expert about which biomarker would be most useful for your project, call 800.447.3846 or email us today.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00847Rev01
Explore Solutions from DiaPharma at AACC 2021
It’s Not Just Support. It’s Solutions.
Join DiaPharma virtually or in person at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
Explore assays for SARS-CoV-2 Antibodies, Thromboinflammation, Coagulation, Fibrinolysis, Complement, Platelet Function, and Organ Injury
Join us at the Georgia World Congress Center in Atlanta, September 26-30! DiaPharma is pleased to announce our lineup of featured products during AACC 2021. We specialize in assays and mechanistic biomarkers for bleeding and clotting disorders, hemostasis analyzers, liver disease (Nonalcoholic Steatohepatitis, Alcoholic Hepatitis), drug-induced liver and kidney injury, and anti-cancer drug development.
![]() |
Researchers will be excited to learn about the do-it-all Ceveron® s100, for automated hemostasis research assays including ADAMTS13, FXIII, and Thrombin Generation Testing. You name it, Ceveron® s100 can do it! For research use only in the U.S. and Canada. Not for use in diagnostic procedures. |
Explore the leading edge in impaired primary hemostasis assessment with T-TAS® 01 – get results quickly with whole blood using an automated microchip flow chamber system developed for the quantitative assessment of the thrombus formation process under physiologic flow conditions. The test requires few steps to run, minimal pre-analytical handling, small sample volume, and a simple to interpret numerical cut-off makes for a simple and reliable identification of patients with a primary hemostatic disorder or to measure the efficacy of any anti-platelet therapeutic in ten minutes or less from assay start. The T-TAS® 01 is for the global evaluation of overall hemostatic ability using physiologic flow conditions, and is sensitive to both aspirin and P2Y12 inhibition, as well as the various vWD subtypes and Glanzmann Thrombasthenia. Separate reagent kit or addition of exogenous agonists aren’t necessary.
DiaPharma delivers solutions by providing strong personal support with technical competence and experience to ensure customer expectations will be met or exceeded. Our strength is grounded in both science and staff. For more than 20 years, DiaPharma has been proud to give each of our customers a truly personalized experience—a focused, dedicated resource that understands our customers’ needs, and has the scientific and technical expertise to help customers make the best product choices.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00838Rev01
Sickle Cell Matters
It’s Not Just Support. It’s Solutions.
September is National Sickle Cell Awareness Month, a time to acknowledge and educate how this often-invisible and rare disease impacts over 100,000 people in the U.S., most of whom are of African descent. Treatment can include antibiotics, pain management, intravenous fluids, blood transfusion and surgery.
Sickle Cell Disease Association of America (SCDAA) theme for 2021 is Sickle Cell Matters. DiaPharma celebrates the Scientists and Medical Professionals helping to advance knowledge, awareness, and treatment options for Sickle Cell Disease.
Tools for Sickle Cell Disease Research
From HbS flow cytometry antibodies, coagulation kits and biomarker assays to exciting new instrumentation for clotting analysis, DiaPharma has what matters covered for impactful Sickle Cell Research.
Anti-Hemoglobin S antibodies from DiaPharma for flow cytometry applications
Item | Clone | Description | Product Code |
Anti-HbS FITC | 57-8 | Anti-Hemoglobin S antibody conjugated with fluorochrome FITC | IQP-574F |
Anti-HbF1 Dy-410 | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome Dy-410 | IQP-567D |
Anti-HbF1 FITC | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome FITC | IQP-567F |
Anti-HbF1 R-PE | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome R-PE | IQP-567R |
Anti-panHb APC | PHB1 | Anti-pan Hemoglobin antibody conjugated with fluorochrome APC | IAP-585A |
Regulatory Status: Analyte Specific Reagent (ASR). Analytical and performance characteristics are not established.
Coagulation Markers in Research
It is suggested that aberrant coagulation and platelet overactivation contribute to the pathogenesis of SCD. Further research and clinical trials are needed to explore the mechanisms driving abnormal coagulation in SCD and to identify effective therapies to treat it. DiaPharma offers a range of assays to further SCD research:
Coagulation Factors | Components | Function | Biomarkers and Methods of Evaluation | Activity in Sickle Cell Disease |
Extrinsic Pathway | Tissue factor (TF) FVII | Primary pathway to initiate coagulation following vascular endothelial injury | Prothrombin time (PT) | Increased TF expression |
Intrinsic Pathway | Prekallikrein HMWK, FXII, FXI | Activated by exposed collagen in the subendothelium and functions to initiate clot formation | Activated partial thromboplastin time (aPTT) | Decreased Prekallikrein, FXII, and HMWK plasma levels Increased levels of procoagulant microparticles |
Common Pathway | FV, FVIII, FIX, FX thrombin FXIII fibrin |
Catalysts in the final steps of coagulation to cleave fibrinogen and form blood clots | Thrombin Generation Assays (TGA), TAT, PAP, F1.2, D-dimers, fibrinogen | Increased thrombin levels |
Fibrinolysis | Plasmin | Enzymatic degradation of fibrin in blood clots | uPA, tPA, PAI-1, D-dimers | Increased fibrinolytic activity |
Platelet Activation | Collagen Fibrinogen, vWF ADAMTS-13 |
Platelets activate and aggregate to form a platelet plug | vWF, ADAMTS-13, Platelet Function Tests | Increased platelet numbers, platelet activation, and platelet aggregation |
Complement System | C3a C5a |
Activated by the coagulation system and contributes to thrombus formation | C3a and C5a | Increased C3a and C5a expression |
Anticoagulation Proteins | Protein C Protein S |
Negative feedback to regulate coagulation and inflammation | Protein C Protein S |
Decreased Protein C and Protein S levels |
Automated Measurement of Primary and Secondary Hemostasis Markers
Instrument | Fully Automated Coagulation Analyzer | Clot Growth & Fibrinolysis Dynamics | Primary Hemostasis and Platelet Function Testing | |
Ceveron® 100 Series | Thrombodynamics | T-TAS® 01 | Atlas PST |
Ceveron® series, Thrombodynamics®, and Atlas® PST are for research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00855Rev01
Clot Club #25
THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) CLINICAL TRIALS: TARGETING THE NEEDS LEFT BY CURRENT TREATMENT OPTIONS
Now available from DiaPharma – CMV Brite™ Turbo Kit for detecting active CMV infection
It’s Not Just Support. It’s Solutions.
Save Time with CMV Brite™ Turbo
Early and rapid diagnosis of active CMV infection is of great importance in avoiding overtreatment with immunosuppressive drugs and in guiding antiviral therapy.
The CMV Brite™ Turbo Kit is a rapid immunofluorescence antigenemia kit for in vitro CMV diagnosis. The CMV Brite™ Turbo kit is available in 110 test format, contains all the reagents, and sample analysis can be completed within 2 hours of sample collection.
A unique feature of this kit is the option for further susceptibility studies of the (positive) isolated PBMC fraction not possible with any other antigenemia kit. With the CMV Brite™ Turbo kit, the lysis of erythrocytes is directly performed on whole blood rather than only after a dextran sedimentation step.
Features
- Complete kit for the diagnosis of an active CMV infection
- A cocktail of antibodies specific for pp65
- Detection at the single cell level
- Rapid results (<2 hr) after sample collection
- Control slides are included
- FDA cleared for IVD use
Save time without sacrificing reliability.
Item | Description | Package size | Product code |
CMV Brite™ Turbo Kit ![]() ![]() |
Complete kit for the rapid diagnosis of an active CMV infection in 2 hours. | 110 tests | VIR-CMV 110 |
Additional Products
CMV C10/C11 cocktail ![]() ![]() |
Mix of 2 CMV pp65 monoclonal antibodies | 200 tests | VIR-CMV C10/C11 |
CMV FITC Conjugate ![]() ![]() |
Sheep anti-mouse-FITC | 200 tests | VIR-FITC |
CMV Control slides ![]() ![]() |
CMV pp65 positive and negative cytospots | set of 5 | VIR-CMW CS05 |
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00849Rev01
Distribution Matters: Anti-Human HbS for flow cytometry
It’s Not Just Support. It’s Solutions.
Anti-Hemoglobin S antibodies from DiaPharma
Introducing a new monoclonal antibody for detection of HbS in flow cytometry applications. Now, researchers can accurately measure HbS distribution within a sample, giving additional information on distribution of hemoglobins. This unique antibody offering can be used in conjunction with additional flow cytometry antibodies that target HbA, HbF and pan Hb, for sickle cell research projects or new therapy development.
Flow cytometry analysis of whole blood stained with anti-HbS. Histograms: uninterrupted line represents HbS high sample, interrupted line represents blank sample.
Plus, a full panel of antibodies allows for detection of various types of hemoglobin. This is especially useful for measuring the distribution of hemoglobin types within the total number of cells in a sample.
Regulatory Status: Analyte Specific Reagent (ASR). Analytical and performance characteristics are not established.
Ordering information: Package size: 1.0mL (50µg/mL)
Item | Clone | Description | Product Code |
Anti-HbS FITC | 57-8 | Anti-Hemoglobin S antibody conjugated with fluorochrome FITC | IQP-574F |
Anti-HbF1 Dy-410 | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome Dy-410 | IQP-567D |
Anti-HbF1 FITC | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome FITC | IQP-567F |
Anti-HbF1 R-PE | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome R-PE | IQP-567R |
Anti-panHb APC | PHB1 | Anti-pan Hemoglobin antibody conjugated with fluorochrome APC | IQP-585A |
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00844Rev01
You Name It, I’ll Do It – The Ceveron® s100
It’s Not Just Support. It’s Solutions.
Ceveron® s100: Your all-in-one coagulation research analyzer
Featuring automated ADAMTS13, Thrombin Generation Testing, FXIII, and full menu of clotting and chromogenic tests
![]() |
Scientists will be excited to learn about the do-it-all Ceveron® s100, for automated hemostasis research assays. You name it, Ceveron® s100 can do it! Featuring Technofluor® ADAMTS13 as your on-demand ADAMTS13 activity assay using an optimized FRET method. This high-quality, quantitative, fully automated and cost-effective assay provides results in just 30 minutes. For research use only in the U.S. and Canada. Not for use in diagnostic procedures. |
T-TAS® 01 – Explore the leading edge in impaired primary hemostasis assessment
Get results quickly with whole blood. The T-TAS® 01 uses an automated microchip flow chamber system developed for the quantitative assessment of the thrombus formation process under physiologic flow conditions. The test requires few steps to run, minimal pre-analytical handling, and a small sample volume. A simple to interpret numerical cut-off allows for clear and reliable identification of patients with a primary hemostatic disorder or assessing the efficacy of any anti-platelet therapeutic in ten minutes or less.
The T-TAS® 01 is for the global evaluation of overall hemostatic ability using physiologic flow conditions, and is sensitive to both aspirin and P2Y12 inhibition, as well as the various vWD subtypes and Glanzmann Thrombasthenia. Separate reagent kit or addition of exogenous agonists aren’t necessary.
DiaPharma delivers solutions by providing strong personal support with technical competence and experience to ensure customer expectations will be met or exceeded. Our strength is grounded in both science and staff. For more than 20 years, DiaPharma has been proud to give each of our customers a truly personalized experience—a focused, dedicated resource that understands our customers’ needs, and has the scientific and technical expertise to help customers make the best product choices.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00841Rev01
AACC 2021 Press Release
September 2021, West Chester, OH – DiaPharma Group is pleased to announce our lineup of featured products during AACC 2021. Explore assays for COVID-19-associated coagulopathy, specialty hemostasis, organ injury, and SARS-CoV-2 serology. DiaPharma specializes in assays and mechanistic biomarkers for bleeding and clotting disorders, hemostasis analyzers, liver disease (Nonalcoholic Steatohepatitis, Alcoholic Hepatitis), drug-induced liver and kidney injury, and anti-cancer drug development.
Researchers will be excited to learn about the do-it-all Ceveron® s100, for automated hemostasis research assays including ADAMTS13, FXIII, and Thrombin Generation Testing. You name it, Ceveron® s100 can do it! For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Explore the leading edge in impaired primary hemostasis assessment with T-TAS® 01 – get results quickly with whole blood using an automated microchip flow chamber system developed for the quantitative assessment of the thrombus formation process under physiologic flow conditions. The test requires few steps to run, minimal pre-analytical handling, small sample volume, and a simple to interpret numerical cut-off makes for a simple and reliable identification of patients with a primary hemostatic disorder or to measure the efficacy of any anti-platelet therapeutic in ten minutes or less from assay start. The T-TAS® 01 is for the global evaluation of overall hemostatic ability using physiologic flow conditions, and is sensitive to both aspirin and P2Y12 inhibition, as well as the various vWD subtypes and Glanzmann Thrombasthenia. Separate reagent kit or addition of exogenous agonists aren’t necessary.
DiaPharma delivers solutions by providing strong personal support with technical competence and experience to ensure customer expectations will be met or exceeded. Our strength is grounded in both science and staff. For more than 20 years, DiaPharma has been proud to give each of our customers a truly personalized experience—a focused, dedicated resource that understands our customers’ needs, and has the scientific and technical expertise to help customers make the best product choices. It’s Not Just Support. It’s Solutions.
ML-00-00837Rev01
SARS-CoV-2 Antibody ELISAs for Hemostasis Research
It’s Not Just Support. It’s Solutions.
SARS-CoV-2 Antibody ELISA Kits and Mechanistic Biomarker Assays for COVID-19 Related Research
DiaPharma is your trusted supplier of high quality assays for your COVID-19 related research
Is there anything COVID-19 doesn’t touch? We know SARS CoV-2 impacts various hemostasis parameters. Research is ongoing to gain a better understanding of the mechanisms and pathways involved in COVID-19.
Beyond specialty hemostasis assays, DiaPharma supplies ELISA kits to test for SARS CoV-2 IgG and IgM Antibodies. These assays can be used to help differentiate the possible causes of antibodies against SAR-CoV-2 in test samples, whether from prior infection, vaccination, or both.
With quantitative and qualitative ELISAs to detect antibodies to Nucleocapsid or Spike protein, DiaPharma has many options to fit your assay needs.
Explore assays for SARS-CoV-2 Antibodies, Thromboinflammation, Coagulation, Fibrinolysis, Complement, Platelet Function, and Organ Injury (apoptosis and necrosis).
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00836Rev02
Learn the Latest from DiaPharma at ISTH 2021
It’s Not Just Support. It’s Solutions.
Virtual Conference, Real Swag
Visit DiaPharma’s Virtual Booth at ISTH 2021
Get your FREE DiaPharma T-shirt or water bottle!
Choose from four designs in our “It’s Not A…” line of t-shirts, or DiaPharma logo sport bottle.
The ISTH 2021 Congress promises the latest science in thrombosis and hemostasis, with plenary sessions, state-of-the-art sessions, master classes, oral communications, poster sessions, supported symposia, and presentation theatres.
Visit us at the ISTH 2021 Congress to learn about our full line of hemostasis clinical and research products.
DiaPharma is your resource for all things bleeding and clotting.
![]() |
COAGULATION & FIBRINOLYSIS MARKERSChromogenic FVIII, FIX*, tPA*, PAI-1* and more |
|
COVID-RELATED COAGULOPATHYThrombin Generation*, vWF, ADAMTS-13*, Antiphospholipid Antibodies, Complement* |
![]() |
HEMOSTASIS ANALYZERSFDA cleared T-TAS® 01 whole blood platelet function analyzer From our partner, Technoclone: Ceveron® s100* All-in-one coagulation research analyzer for automated measurements, including ADAMTS-13, TGA and FXIII |
![]() |
ANTICOAGULATION MEASUREMENTHeparin, Warfarin, DOACs*, DOAC-Stop™* |
*For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00825Rev01
Platelet Party? Let T-TAS® 01 be your designated driver.
Platelet Party? Let T-TAS® 01 be your designated driver. Use the leading edge in impaired primary hemostasis assessment and get results quickly with whole blood. The DiaPharma Group is excited to provide Fujimori Kogyo/Zacros’s T-TAS® 01 system – an automated microchip flow chamber system developed for the quantitative assessment of the thrombus formation process under physiologic flow conditions. The test requires few steps to run, whole-blood collection followed by transfer of 320 μL to a blood reservoir and attachment to test chip. Minimal pre-analytical handling and a simple to interpret numerical cut-off makes for a simple and reliable identification of patients with a primary hemostatic disorder or to measure the efficacy of any anti-platelet therapeutic in ten minutes or less from assay start.
The T-TAS® 01 is for the global evaluation of overall hemostatic ability using physiologic flow conditions, and is FDA-cleared for the analysis of platelet thrombus formation in those with impaired primary hemostatic function and for those on anti-platelet therapy. The T-TAS® 01 is sensitive to both aspirin and P2Y12 inhibition, as well as the various vWD subtypes and Glanzmann Thrombasthenia. Separate reagent kit or addition of exogenous agonists aren’t necessary.
It’s not just support. It’s solutions. Our scientific experts and customer support teams are just a call or click away. Explore our wide portfolio of hemostasis assays from DiaPharma. 1.800.447.3846 / techsupport@diapharma.com.
ML-08-00029Rev01
The Cost Savings of APC Resistance Screening
It’s Not Just Support. It’s Solutions.
Save with every screening.
By screening for Factor V Leiden with the Coatest® APC™ Resistance V kit from DiaPharma, your lab could save thousands of dollars.
Each kit was designed to be easy to use for in-house screening, offering fast results and low costs for both large and small volume labs.
The most common FV Leiden screening test performed, Coatest® APC Resistance V offers close to 100% specificity, and is applicable to patients on anticoagulant therapy like heparin or warfarin.
Ideal for:
- Ordering physicians looking for a sensitive assay with rapid turnaround
- Labs looking to bring testing in-house
- Labs looking for cost savings
Functional APC Resistance screening with Coatest® APC Resistance V offers an economical alternative to individual genetic testing, and significantly decreases the need for PCR analyses.
Save money without sacrificing reliability.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00828Rev01
Thrombodynamics – The Next Dimension in Blood Clot Analysis
It’s not just support. It’s solutions.
Thrombodynamics®
The Next Dimension in Blood Clot Analysis
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Visit diapharma.com to learn about our hemostasis analyzers, including Thrombodynamics®, Ceveron 100 series®, and T-TAS® 01.
Copyright 2021 DiaPharma.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
ML-09-00019Rev01
Count on DiaPharma for your vWD Research Products
It’s Not Just Support. It’s Solutions.
Full portfolio of von Willebrand Disease Research Products
vWF Activity, Antigen, Collagen Binding, Propeptide, and more.
From DiaPharma.
Product Spotlight: vWFpp
- New! Convenient ELISA for research related to vWF clearance mechanisms
- Rapid double monoclonal ELISA: < 90 min assay time
- Pre-coated strips make the assay easy to perform
- No interference by heterophilic antibodies
Additional products for your vWF research:
REAADS vWF Activity ELISA
Mouse monoclonal anti-human vWF antibody recognizes the functional A1 domain of vWF
REAADS vWF Antigen ELISA
- Easily quantify vWF Antigen
Technozym® vWF:CBA ELISA*
- For research related to Type 2 vWD
- Human collagen III, I or VI coated plates available
*For research use only. Not for use in diagnostic procedures.
Platelet Function Testing
T-TAS® 01
- The leading edge in primary hemostasis assessment
- Global evaluation of overall hemostatic ability using physiological flow conditions
- Whole blood testing with results within 10 minutes
Explore our wide portfolio of hemostasis assays from DiaPharma.
It’s Not Just Support. It’s Solutions.
Our scientific experts and customer support teams are just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
ML-00-00820Rev01
Measure Only ACTIVE Neutrophil Elastase with ProAxsis ELISA
It’s Not Just Support. It’s Solutions.
DiaPharma is Your Exclusive Source
For ProAxsis ProteaseTag™ Active Neutrophil Elastase Assay
The Problem
Assessing active protease levels in complex biological samples such as sputum or bronchoalveolar lavage samples are problematic due to a lack of reliable and robust methodologies, which result in data with high variability and limited reproducibility. Most commercially available antibody based assays measure total protease levels that are composites of the amounts of latent, active, and inhibitor-enzyme complexes, which may have limited value in correlations with disease severity. Fluorogenic or chromogenic substrates can be hydrolysed by multiple substances within a biological sample and therefore are not suitable for biomarker analysis utilizing complex fluids.
The Solution
ProteaseTag™ Active NE Immunoassay meets the need for a robust assay to measure the active biomarker. Using the patented NE-Tag™, an activity-dependent assay has been developed which is the only one that can detect active proteases with a standard microplate reader, without utilizing chromogenic or fluorogenic substrates.
ProteaseTag™ Active NE is available in 2 formats – standard and lateral flow, providing NE detection limits ranging from 7.2 – 1000 ng/ml.
Why measure only active NE?
- Neutrophil Serine Proteases (including neutrophil elastase) are important for immune responses to bacterial infections.
- Bacterial infections are a major hurdle for exacerbations in lung diseases like COPD, CF, and Bronchiectasis.
- Higher levels of active NE enzyme vs. total NE in a sample has been shown to correlate with severity of chronic lung diseases and occurrence of bacterial exacerbations.
- Development of NE inhibitors is an attractive therapeutic target for pharmaceutical companies, but requires excess active NE enzyme to be effective.
- This makes measurement of active NE critical during drug development stages.
Learn more details about ProAxsis ProteaseTag® Active NE Immunoassay and ProAxsis NEATstik® Rapid NE Activity Test
For research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00818Rev01
Clot Club: Hypercoagulation During Sickle Cell Disease
It’s Not Just Support. It’s Solutions.
Clot Club: Hypercoagulation During Sickle Cell Disease
Sickle cell disease (SCD) is an inherited hemoglobin disease that disrupts the ability of red blood cells (RBCs) to deliver oxygen throughout the body. RBCs are normally round and flexible, which allows them to flow easily through the vasculature. However, in SCD, RBCs are crescent-shaped due to the expression of an atypical sickle hemoglobin variant (HbS). The abnormal shape of sickle RBCs can cause them to clump together and block blood flow and promote thrombosis. Due to the hypercoagulable state of SCD, thrombotic complications can drive ischemic stroke, venous thromboembolism, severe pain episodes, and organ damage.
Coagulation factors are key initiators in the pathogenesis of SCD. Interestingly, the coagulation system can be activated and elevated in individuals with SCD, even in the absence of vascular occlusions.
Coagulation Markers in Research
It is suggested that aberrant coagulation and platelet overactivation contribute to the pathogenesis of SCD. Further research and clinical trials are needed to explore the mechanisms driving abnormal coagulation in SCD and to identify effective therapies to treat it.
Coagulation Factors | Components | Function | Biomarkers and Methods of Evaluation | Activity in Sickle Cell Disease |
Extrinsic Pathway | Tissue factor (TF) FVII | Primary pathway to initiate coagulation following vascular endothelial injury | Prothrombin time (PT) | Increased TF expression |
Intrinsic Pathway | Prekallikrein HMWK, FXII, FXI |
Activated by exposed collagen in the subendothelium and functions to initiate clot formation | Activated partial thromboplastin time (aPTT) | Decreased Prekallikrein, FXII, and HMWK plasma levels Increased levels of procoagulant microparticles |
Common Pathway | FV, FVIII, FIX, FX thrombin FXIII fibrin |
Catalysts in the final steps of coagulation to cleave fibrinogen and form blood clots | Thrombin Generation Assays (TGA), TAT, PAP, F1.2, D-dimers, Fibrinogen | Increased thrombin levels |
Fibrinolysis | Plasmin | Enzymatic degradation of fibrin in blood clots | uPA, tPA, PAI-1, D-dimers | Increased fibrinolytic activity |
Platelet Activation | Collagen Fibrinogen, vWF ADAMTS-13 |
Platelets activate and aggregate to form a platelet plug | vWF, ADAMTS-13 | Increased platelet numbers, platelet activation, and platelet aggregation |
Complement System | C3a C5a |
Activated by the coagulation system and contributes to thrombus formation | C3a and C5a | Increased C3a and C5a expression |
Anticoagulant Proteins | Protein C Protein S |
Negative feedback to regulate coagulation and inflammation | Protein C Protein S |
Decreased Protein C and Protein S levels |
Automated Measurement of Primary and Secondary Hemostasis Markers
Instrument | Fully Automated Coagulation Analyzer | Clot Growth & Fibrinolysis Dynamics | Primary Hemostasis and Platelet Function Testing | |
Ceveron® 100 Series | Thrombodynamics | T-TAS® 01 | Atlas PST |
Ceveron® series, Thrombodynamics®, and Atlas® PST are for research use only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00819Rev01
What’s New at DiaPharma? Meet our Pandemic Pets and People
It’s Not Just Support. It’s Solutions.
Meet the Team
We welcomed several new members, 2-legged and 4-legged, to the DiaPharma family during the pandemic!
Mary Alice Our Senior Support Scientist, Abi, welcomed daughter Mary Alice into their family last spring, shortly after the start of the pandemic! Mary Alice joins Abi, her husband, their three oldest children, and their dog, Sammy. |
Kit Kat Our Executive Vice President, Mike, is thrilled to welcome Kit Kat – his youngest got to pick the name. Kit Kat joins Mike, his wife, and their three human kids. Mike says, “She always steals my seat ‘at work'”! |
Rachel + Patches Our Scientific Product Manager, Matt, welcomed two new additions! Daughter Rachel and puppy Patches join Matt, his wife, their two oldest daughters, and three cats…talk about a full house! |
Breslin Our Scientific Director, Jen, welcomed Golden Retriever Breslin over the summer. Breslin is a “service dog flunkie” who is loving her career change. She joins Jen, DiaPharma office dog Ozone, and two cats who scare her. |
|
Louie Simon Our Business Development Manager, Olivia, just welcomed son Louie Simon just last week! He joins Olivia, her husband, their two daughters, and their dog. Congrats to everyone on the new additions! |
Product Focus
COVID-19 Markers
Is there anything COVID-19 doesn’t touch? DiaPharma has biomarker assays for your COVID-19 related research. Thromboinflammation, Complement, Organ Injury, Cell Death, Platelet Function Assays: DiaPharma is your trusted supplier of high quality research products to investigate COVID-19.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00817Rev01
Complement Biomarkers for Alcoholic Liver Disease Research
It’s Not Just Support. It’s Solutions.
DiaPharma has the tools for your alcoholic liver disease research
Complement Biomarkers for Alcoholic Hepatitis
The complement system is a critical component of the immune system that aids in the body’s defense against bacterial and/or viral infections. However, excessive activation of the complement system can result in uncontrolled inflammatory responses leading to organ damage, e.g. liver injury.
It was previously believed that in Alcoholic Hepatitis (AH), hepatocellular injury is the result of the direct deleterious effects of ethanol on liver cells by inducing oxidative stress and mitochondrial dysfunction.
Recent studies have shown that complement activation may also play a role in the pathogenesis AH. Complement factors are therefore attractive candidates for biomarkers in research studies that may indicate severity of disease and predict response to therapies for the treatment of AH.
Moreover, components of the complement pathway could also be potential targets for therapeutic intervention themselves.
Complement Biomarker Assays Available from DiaPharma:
- DiaPharma C3a ELISA
- DiaPharma C5a ELISA
- DiaPharma sC5b-9 ELISA
Measure apoptosis and total cell death with our cytokeratin 18/Keratin 18 (CK18/K18) biomarkers:
- M30 Apoptosense® ccK18 ELISA
- M65® ELISA K18 ELISA
- M65® EpiDeath® ELISA
Additional Biomarkers of Interest:
- Osteopontin (OPN)
- Soluble CD163 (sCD163)
Visit diapharma.com for our comprehensive portfolio.
All products are for research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00814Rev01
Now available, Anti-Human HbS (Clone 57-8) for flow cytometry
It’s Not Just Support. It’s Solutions.
Distribution Matters: Measure Using Flow Cytometry
Anti-Hemoglobin S antibody now available!
IQ Products, of the Netherlands, just released a new monoclonal antibody for detection of HbS in flow cytometry applications. Now, researchers can accurately measure HbS distribution within a sample with no overlapping HPLC peaks to allow for variant discrimination. This unique antibody offering can be used in conjunction with additional flow cytometry antibodies that target HbA, HbF and pan Hb.
Request a trial sample to test with your new or ongoing sickle cell research projects or therapy applications via DiaPharma, the preferred distribution partner of IQ Products for the US and Canada.
Flow cytometry analysis of whole blood stained with anti-HbS. Histograms: uninterrupted line represents HbS high sample, interrupted line represents blank sample.
Plus, a full panel of antibodies allows for detection of various types of hemoglobin. This is especially useful for measuring the distribution of hemoglobin types within the total number of cells in a sample.
Ordering information:
Regulatory Status: Analyte Specific Reagent (ASR). Analytical and performance characteristics are not established. Package size: 1.0mL (50µg/mL)
Item | Clone | Description | Product Code |
Anti-HbS FITC | 57-8 | Anti-Hemoglobin S antibody conjugated with fluorochrome FITC | IQP-574F |
Anti-HbF1 Dy-410 | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome Dy-140 | IQP-567D |
Anti-HbF1 FITC | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome FITC | IQP-567F |
Anti-HbF1 R-PE | WBAC HbF1 | Anti-Hemoglobin F antibody conjugated with fluorochrome R-PE | IQP-567R |
Anti-panHb APC | PHB1 | Anti-pan Hemoglobin antibody conjugated with fluorochrome APC | IQP-585A |
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00809Rev01
INRoads to researching liver disease and coagulation
It’s Not Just Support. It’s Solutions.
DiaPharma has the tools for your Liver Disease Coagulopathy Research
Markers of Hemostasis
Liver diseases such as acute fatty liver or cirrhosis can be associated with imbalances in coagulation, whether due to defects of platelet count/function, decrease in synthesis of coagulation factors, decrease in clearance of activated coagulation factors, or overactive fibrinolysis.
Research may focus on answering questions such as which subjects are bleeding risks? Which may have thrombotic complications? What is the severity of the liver disease? Do you need more information than the INR can give?
If you’re studying intrahepatic thrombosis, liver fibrogenesis, or developing new hemostasis-focused liver disease therapies, DiaPharma can help you select the assays that best suit your needs.
DiaPharma’s long-time expertise in the Hemostasis and Liver Disease fields means we’re uniquely positioned to deliver solutions.
Technothrombin® TGA*
- Give thrombotic potential a number. Research thrombin generation when studying disease and progression
- Automatable on the Ceveron® s100 or t100
Fibrinolytic Markers*
- PAI-1 Activity and Antigen, Plamsin-Antiplasmin (P-AP) ELISAs
Bleeding Disorder Markers
- vWF activity, vWFantigen, vWF propeptide, collagen binding* ELISAs
T-TAS01® Platelet Function Analyzer
- Discover the leading edge in primary hemostasis assessment
- Global evaluation of overall hemostatic ability in whole blood, using physiologic, flow conditions
- Easy interpretation, reduced costs, simple pre-analytics
Non-Invasive Biomarkers for Fatty Liver Disease*
- CK18 and ccCK18 cell death biomarkers for liver disease
- Measure apoptosis (M30®) or total cell death (M65®)
Visit diapharma.com for our portfolio of biomarker assays for Complement, Bleeding Disorders, and Fibrinolysis
*Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
COVID-19 and Coagulation Research
Studying coagulation in COVID-19? Explore assays from DiaPharma to answer your COVID-19 research questions.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00804Rev01
Clot Club #22
LUPUS ANTICOAGULANTS/ANTIPHOSPHOLIPID ANTIBODIES/ANTIPHOSPHOLIPID ANTIBODY SYNDROME – Part 2
Contact System Cross-Talk: Tools for Investigating Contact Activation Pathway
It’s Not Just Support. It’s Solutions.
DiaPharma has the tools for your Contact Activation Research
Contact Activation and its role in coagulation, anticoagulation, and inflammation
The contact activation pathway has been investigated as a target for potential pharmaceutical drugs. Its interactions in coagulation, anticoagulation, fibrinolysis, complement and inflammation make it complex but attractive for therapeutic interventions.
If you’re doing pre-clinical work or performing clinical trials, you need reliable, relevant tests. DiaPharma can help you select the right assays for suitable end points.
Assays to gain a better understanding of the contact system and its potential benefits:
Technothrombin® TGA*
- Give thrombotic potential a number. Research thrombin generation when studying disease and progression.
Technochrom® C1-INH*
- C1-Esterase Inhibitor Activity
ROX FXIa*
- Chromogenic Assay for Factor XIa
Prekallikrein and Kallikrein Measurement*
- Highest quality chromogenic substrates, including S-2302, from the leaders in chromogenic substrate technology
- Assays for Prekallikrein Activator Activity, Factor XII, Kallikrein Activity
- PKA Standard, calibrated against the 3rd International Standard for PKA
Assays are automatable on the Ceveron® 100 series
Coatest® and Coamatic® Heparin
- Reliable anticoagulation measurement using anti-Xa method
Plus our portfolio of biomarker assays for Complement, Bleeding Disorders, and Fibrinolysis
*Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
COVID-19 and Coagulation Research
Studying coagulation in COVID-19? Explore assays from DiaPharma to answer your COVID-19 research questions.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
Diapharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
Technical Support: 1.800.447.3846
ML-00-00801Rev01
Finally – A New Option to Measure Human Wnt3A Protein
It’s Not Just Support. It’s Solutions.
Detect the Undetectable
Light up your Wnt3A
Lack of commercial and high-throughput options to measure Human Wnt proteins in serum has hampered Wnt-signaling research for too long. A new immunoassay technology, FluoBolt™, now offers the Wnt-signaling community an easier and more robust measurement of Wnt3A. This expands research options for studying mechanisms of disease and use of Wnt3A as a biomarker in clinical research.
FluoBolt™ Wnt3A kit benefits:
- Super simple and fast protocol
- Robust fluorescent signal output
- Open platform technology (most standard plate readers)
- 96 well format
- Ready-made standards and controls
- Serum-based matrix
- Multiple fluorophore label options available
- Focus on quality from Austrian-based manufacturer, Fianostics
Kits are available for purchase via DiaPharma in the US and Canada OR send your samples to Fianostics for FluoBolt™ analysis services.
FluoBolt™ Methodology:
Nano-structured metal enhances signal from fluorophores conjugated to detection antibodies close to bottom of the plate. This produces a more robust signal than standard ELISA methods and reduces background signal.
Available FluoBolt™ kits:
- FluoBolt™ Noggin
- FluoBolt™ Asporin
- FluoBolt™ Periostin
- FluoBolt™ Wnt3a
- FluoBolt™ alpha-Klotho
Amino Acid Sequence Identity with Human | |||||||
Source | https://www.uniprot.org | ||||||
Mouse | Rat | NHP | Pig | Canine | Zebra Fish | Hamster | |
Periostin | 90% | 87% | 92-93% | 95% | 96% | 54% | 89% |
Asporin | 89% | 89% | 96-99% | 89% | 89% | 54% | 89% |
Noggin | 99% | 99% | 99-100% | 99% | 96% | 55% | 99% |
Wnt3a | 96% | 89% | 99-100% | 96% | 71% | 82% | 96% |
Klotho | 86% | 84% | 93-99% | 88% | n.a. | 50% | 85% |
Research Use Only in U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00797Rev01
Non-Invasive Biomarkers For NASH Drug Development
It’s Not Just Support. It’s Solutions.
Biomarker Assays for Fatty Liver Disease Clinical Trials
Cytokeratin 18 (CK18/ccCK18/K18)
Include M30 Apoptosense® (ccCK18) and M65® ELISA (CK18) as part of your mechanistic biomarker panel to get a fuller picture of effects of your drug candidate.
The Problem
|
The Solution
|
|
|
The Advantages
- Determine ongoing disease activity
- Early indication of drug efficacy
- Reduce biopsies in clinical trials
- Simpler and quantitative assays
- Provide supplementary information to traditional biomarkers
Specializing in Mechanistic Biomarkers |
|||
![]() |
![]() |
![]() |
![]() |
NAFLD/NASH | ALD/AH | DILI Research | K18: M30®/M65® |
Explore our full portfolio of assays.
Help your drug candidate move forward.
DiaPharma offers:
Collagen IV • L-FABP • FGF-19 • FGF-21 • Fibronectin • hsCRP • Mac-2-BP • Noggin • NGAL • Osteopontin • PAI-1 • sCD163 • and more
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.If you’d like to speak with an expert about which biomarker would be most useful for your project, our scientific and customer support teams are just a call or click away. |
Copyright © 2021 DiaPharma Group, Inc. All rights reserved. Our mailing address is: ML-00-00786Rev01 |
Count on DiaPharma for your vWD Research Products
It’s Not Just Support. It’s Solutions.
Full portfolio of von Willebrand Disease Research Products
From vWF Activity, Antigen, Collagen Binding, Propeptide, and more. From DiaPharma.
vWF Activity Measurement
REAADS vWF Activity ELISA
- Mouse monoclonal anti-human vWF antibody recognizes the functional A1 domain of vWF
Senova vWF propeptide ELISA*
- For research related to Type 1C vWD
Technozym® vWF:CBA ELISA*
- For research related to Type 2 vWD
- Human collagen III, I or VI coated plates available
vWF Antigen Measurement
REAADS vWF Antigen ELISA
- Easily quantify vWF Antigen
FVIII Chromogenic Activity Measurement
Chromogenix Coamatic® Factor VIII
Chromogenix Coatest® SP Factor VIII
Chromogenix Coatest® SP4 Factor VIII
- Featuring bovine factor reagents
Platelet Function Testing
T-TAS® 01
- The leading edge in primary hemostasis assessment
- Global evaluation of overall hemostatic ability using physiologic, flow conditions.
Learn More |
* Research Use Only. Not for use in diagnostic procedures.
Explore our wide portfolio of hemostasis assays from DiaPharma.
It’s Not Just Support. It’s Solutions.
Our scientific experts and customer support teams are just a call or click away.
Contact Us |
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
ML-00-00789Rev01
Clot Club #21
LUPUS ANTICOAGULANTS/ANTIPHOSPHOLIPID ANTIBODIES/ANTIPHOSPHOLIPID ANTIBODY SYNDROME – Part 1
T-TAS®01 – The Leading Edge in Primary Hemostasis Assessment
It’s Not Just Support. It’s Solutions.
Discover the Leading Edge in Primary Hemostasis Assessment
Global evaluation of overall hemostatic ability using physiologic, flow conditions. Exclusively from DiaPharma.
Advantages of T-TAS® 01
Ease of Interpretation
A numeric cut-off easily identifies those with primary hemostasis disorders, assisting with more timely determination of appropriate treatment strategy
Reduced Costs
May need fewer blood draws, as extra tests may be eliminated, improving the patient’s experience as well as eliminating the associated costs
Simple Pre-Analytics
Fewer blood draws without required fasting improves the patient’s (and phlebotomist’s) experience
Direct use of whole blood minimizes pre-analytical errors
Rapid
Results in 10 minutes makes T-TAS® 01 a valid POC platelet function test
Physiologically Relevant
T-TAS® 01 reconstructs in vivo blood flow conditions
Learn More |
For in vitro diagnostic use.
Explore our wide portfolio of hemostasis assays from DiaPharma.
It’s Not Just Support. It’s Solutions.
Our scientific experts and customer support teams are just a call or click away.
Contact Us |
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
ML-00-00785Rev01
Clot Club #20
DETECTING HEMOGLOBIN VARIANTS DURING SICKLE CELL DISEASE RESEARCH: WHICH METHOD IS BEST?
Is there anything COVID-19 doesn’t touch? Assays for your COVID-19 research
It’s Not Just Support. It’s Solutions.
Biomarker Assays for your COVID-19 Related Research
Thromboinflammation, Complement, Organ Injury, Platelet Function Assays
DiaPharma is your trusted supplier of high quality research products to investigate COVID-19. Explore some of our favorite assays to use to detect biomarkers of coagulation, fibrinolysis, inflammation, apoptosis, necrosis, and more.
Research use only. Not for diagnostic procedures.
It’s Not Just Support. It’s Solutions.Our scientific experts and customer support teams are just a call or click away. |
Copyright © 2021 DiaPharma Group, Inc. All rights reserved. Our mailing address is: ML-00-00776Rev01 |
FluoBolt™ KLOTHO Super Sensitive and Easy Assay
It’s Not Just Support. It’s Solutions.

Figure 1 Klotho can exist in a membrane-bound or soluble state. The membrane bound Klotho is mainly expressed on cells of the kidney and acts locally on kidney biology via signaling interactions with FGF-23. Soluble Klotho can be produced by protease cleavage sites within the membrane bound isoform, or a proposed directly secreted isoform. As a soluble form, Klotho can enter the blood stream and act distally, similar to a hormone or cytokine.
FluoBolt™-KLOTHO:
LIGHT UP YOUR ASSAY
- EASIER, MORE SENSITIVE THAN ELISA
- Single step assay – no wash step, no enzyme substrate
- Stable signal over time
- Alternative fluorophores available
Get it from the leader in the field – testing services also available from FIANOSTICS
Improve your data consistency
96-well format, complete kit with a standard and controls in a pooled serum matrix
FluoBolt™-Technology provides a high sensitivity Klotho protein assay for basic and clinical research.
Measure α-KLOTHO in just 10 uL of undiluted serum or plasma samples.
This assay is similar to a standard ELISA in the fact that this assay is a sandwich immunoassay comprised of a monoclonal capture antibody and a polyclonal detection antibody, but different from a standard ELISA in the fact that it utilizes Metal Enhanced Fluorescence (MEF) to dramatically increase the sensitivity with the same antibodies.
Although there are assays for measuring Klotho protein levels available in the market, they are reported to have inconsistent quality records, or are semi-quantitative in nature (eg. immunoprecipitation-immunblot). FluoBolt™-Technology provides a high sensitivity Klotho protein assay for basic and clinical research, which increases detection and may improve data consistency in literature.
The kit offers individual lyophilized standard/calibrator vials, so no dilution series or calculations are needed. The calibrator is a recombinant protein with a c-terminal His-tag and an MW of approx. 120kD representing the whole extracellular domain (isoform 1) containing KL1 and KL2. Additionally, the kit also includes 2 lyophilized controls in a serum matrix.
Learn more here.
Research use only in the U.S. and Canada. Not for diagnostic procedures.
It’s Not Just Support. It’s Solutions.Our scientific experts and customer support teams are just a call or click away. |
Copyright © 2021 DiaPharma Group, Inc. All rights reserved. Our mailing address is: ML-00-00775Rev01 |
Measure Only ACTIVE Neutrophil Elastase With ProAxsis ELISA
It’s Not Just Support. It’s Solutions.
DiaPharma is Your Exclusive Source
For ProAxsis ProteaseTag™ NE Assay
Why measure only active NE?
- Neutrophil Serine Proteases (including neutrophil elastase) are important for immune responses to bacterial infections.
- Bacterical infections are a major hurdle for exacerbations in lung diseases like COPD, CF and Bronchiectasis.
- NE is an enzyme that exists in latent, active and inhibitor bound states.
- Higher levels of active NE enzyme vs. total NE in a sample has been shown to correlate with severity of chronic lung diseases and occurrence of bacterial exacerbations.
- Development of NE inhibitors is an attractive therapeutic target for pharmaceutical companies, but requires excess active NE enzyme to be effective.
- This makes measurement of active NE critical during drug development stages.

(Respiratory Research Thulborn, 2019)
ProAxsis tackles the need to measure only active NE
ELISA with ProteaseTag™ technology
ProAxsis (Belfast, Ireland) has tackled this need to specifically measure only active NE by developing an ELISA formatted assay with their ProteaseTag™ technology. In this kit, a NE-specific protease inhibitor acts as a “capture Ab” to immobilize only NE in the active form and free of native biological inhibitors.
The technology is suitable for complex biological samples (ie sputum or BAL) and is not dependent on kinetic readouts for precise, sensitive and reproducible data. This assay is able to distinguish between active and latent NE enzyme and quantitative between 7.2 -1000 ng/mL.
Learn more details about ProAxsis ProteaseTag® Active NE Immunoassay here.
Visit diapharma.com for more.
It’s Not Just Support. It’s Solutions.Our scientific experts and customer support teams are just a call or click away. |
Copyright © 2021 DiaPharma Group, Inc. All rights reserved. Our mailing address is: ML-00-00773Rev01 |
What’s New at DiaPharma?
It’s Not Just Support. It’s Solutions.
Meet the Team
Tinu Adewole
East Territory Manager
Tinu has been with DiaPharma since July 2013. She enjoys staying healthy and active, these days by working with a virtual Personal Trainer, taking walks in the neighborhood, and doing online YouTube pilates & yoga videos. She says, “It took me about 3 months into the pandemic to get my act together. I didn’t want to put on any more ”Pandemic Pounds”!
She looks forward to traveling once things are safer and would love to go to Portugal. Home improvement projects give her a creative outlet, and she spends time binge watching Netflix as we all do!
Tinu has used this time to increase product knowledge and disease state knowledge through reading more publications, listening to webinars, and watching speakers during virtual conferences. Staying connected to customers via Zoom has been a good way to see each other “face to face”.
But there is no substitute for in person interaction and we all look forward to seeing our customers soon!!
Clot Club
Insights into an Imbalanced vWF Antigen to ADAMTS13 Activity Ratio in COVID-19.
Contributed by Abi Kasberg, Ph.D.
One of the many complicated outcomes associated with severe cases of COVID-19 is the high occurrence of thrombotic and microthrombotic events. SARS-CoV-2-induced endothelial injury drives elevated inflammatory responses that promote dysregulated coagulation systems, in a condition named COVID-19-associated coagulopathy (CAC). The severity of CAC is associated with the onset of thromboembolisms and thrombotic microangiopathies (TMAs). Additional clinical findings have highlighted the occurrences of microvascular thrombi and hypercoagulability in COVID-19 patients. This suggests that vascular endothelia and microvasculature may be experiencing dysregulated hemostasis following SARS-CoV-2 infection. Given the recent emergence and worldwide impact of COVID-19, it is of great importance to identify and understand the mechanisms that are driving microthrombotic complications in COVID-19 patients.
Visit diapharma.com for ADAMTS13, vWF, Thrombin Generation Assays, and more.
Explore assays from DiaPharma to answer your COVID-19 research questions.
It’s Not Just Support. It’s Solutions.
Our scientific experts and customer support teams are just a call or click away.
Copyright © 2021 DiaPharma Group, Inc. All rights reserved.
DiaPharma Group, Inc. 8948 Beckett Rd 45069 West Chester US
ML-00-00767Rev01
Insights into an Imbalanced vWF antigen to ADAMTS-13 activity ratio in COVID-19
– Contributed by Abi Kasberg, PhD
One of the many complicated outcomes associated with severe cases of COVID-19 is the high occurrence of thrombotic and microthrombotic events. SARS-CoV-2-induced endothelial injury drives elevated inflammatory responses that promote dysregulated coagulation systems, in a condition named COVID-19-associated coagulopathy (CAC). The severity of CAC is associated with the onset of thromboembolisms and thrombotic microangiopathies (TMAs). Additional clinical findings have highlighted the occurrences of microvascular thrombi and hypercoagulability in COVID-19 patients. This suggests that vascular endothelia and microvasculature may be experiencing dysregulated hemostasis following SARS-CoV-2 infection. Given the recent emergence and worldwide impact of COVID-19, it is of great importance to identify and understand the mechanisms that are driving microthrombotic complications in COVID-19 patients.
Two components that are critical for the maintenance of microvascular hemostasis are von Willebrand factor (vWF) and the vWF protease ADAMTS-13 (a disintegrin-like and metalloproteinase with thrombospondin type 1 motif 13). Inflammatory conditions trigger changes to the relative levels of vWF antigen and ADAMTS-13 activity, such that imbalanced vWF to ADAMTS-13 ratios are associated with organ failure and death (Katneni et al. 2020). Recent COVID-19 clinical studies suggest that altered ratios of vWF antigen levels to ADAMTS-13 activity (vWF/ADAMTS-13) are associated with and predictive of acute kidney injury and COVID-19 disease severity (Henry et al. 2020 and Mancini et al. 2020). This post discusses recent clinical research findings and the proposed roles that the vWFADAMTS-13 axis may have during SARS-CoV-2 pathogenesis in COVID-19.
The functional relationship between vWF and ADAMTS-13
vWF is an acute phase protein, meaning that vWF plasma concentrations fluctuate in response to systemic inflammation. Increased inflammation promotes the release of vWF from vascular endothelial cells and platelets, which result in elevated plasma vWF levels found in the form of ultra large multimers (ULVWF). Under normal shear flow conditions, vWF multimers and platelets coexist without contributing to thrombus formation. However, high shear stress conditions following vascular injury enable vWF multimers to accumulate in the blood which in turn activate platelet adhesion and platelet aggregation.
To prevent ULVWF accumulation in the blood, the protease ADAMTS-13 specifically cleaves vWF multimers to the extent that circulating ULVWF multimers are marginally detectable in healthy individuals. ADAMTS-13 deficiency, whether hereditary or acquired, can result in the onset of thrombotic thrombocytopenic purpura (TTP), which is caused by the accumulation of ULVWF multimers that promote platelet aggregation and uncontrolled microthrombi formation.
During systemic inflammation, vWF plasma levels are elevated accompanied by a decrease in ADAMTS-13 activity. This suggests that the ratio of ADAMTS-13 activity to vWF antigen levels are sensitive to inflammation and are important for maintaining healthy hemostasis and vascular integrity. Variation to the high molecular weight vWF/ADAMTS-13 ratio can drive a prothrombotic state, as seen with disseminated intravascular coagulation (DIC).
The vWF to ADAMTS-13 axis is imbalanced during COVID-19
Clinical studies of COVID-19 patients have reported that vWF antigen levels are elevated accompanied by a decrease in ADAMTS-13 activity levels (Mancini et al. 2020). Increased vWF levels are likely due to their release as acute phase reactants in response to endothelial injury caused by SARS-CoV-2 infection. It is suggested that decreased ADAMTS-13 activity is due to substrate consumption and inflammationmediated degradation (Henry et al. 2020). Together, these changes create a dramatic increase in the vWF antigen to ADAMTS-13 activity ratios in severe COVID-19 patients, at levels three to seven times higher than normal (Mancini et al. 2020). These described alterations to the vWF/ADAMTS-13 ratio enables vWF to accumulate in the blood at levels that ADAMTS-13 is unable to overcome, creating an environment receptive to microthrombosis formation and hypercoagulability.
An interesting difference to highlight is between TTP and COVID-19 microangiopathy. TTP is the result of decreased ADAMTS13 enzymatic activity and is characterized by the accumulation of ULVWF multimers. In contrast, there have been no reports of ULVWF multimers in the plasma of COVID-19 patients despite changes to the vWF/ADAMTS-13 ratio (Mancini et al, 2020). Instead, COVID-19 microangiopathy more closely resembles sepsis-induced thrombotic microangiopathy, a condition where ADAMTS-13 levels are depleted as a secondary effect to cytokines produced during sepsis.
An additional clinical study also describes the association of the vWF/ADAMTS-13 ratio to the severity of clinical outcomes of COVID-19, including acute kidney injury (Henry et al. 2020). Together with elevated LDH levels and low hemoglobin, authors conclude that these results indicate a TMA-like phenomenon instead of infection-driven coagulopathy (Henry et al. 2020). Changes to the vWF/ADAMTS-13 ratio correlate with patient age, which is interesting to consider given that age may contribute to prothrombic states, and thus higher COVID-19 mortality rates among the elderly. Due to the important roles and dynamics of vWF and ADAMTS-13 in COVID-19 and thrombosis, research is critically needed to further investigate the vWF/ADAMTS-13 ratio and its contribution to COVID-19 progression and outcomes.
Proposed mechanisms of the vWF to ADAMTS-13 axis during COVID-19
Pulmonary endothelial cells are believed to function as initial sites of severe COVID-19 complications. Local injury and inflammation in the lungs drive endothelial activation and the substantial release of vWF into the blood. This causes the relative levels of vWF, platelets, and ADAMTS-13 activity to be altered, which gives rise to thrombosis. The vWF/ADAMTS-13 ratio imbalance contributes to a state of hypercoagulability and increases risk of microthrombosis, acute kidney injury, and microangiopathy (Henry et al. 2020 and Mancini et al. 2020). This is supported by evidence of TMAs in the small vasculature of the lungs of COVID-19 patients (Mancini et al. 2020).
Systemic inflammation can extend these complications throughout the body, promoting microthrombosis in other organs (Mancini et al. 2020). The observed COVID-19 microangiopathy does not appear to be TTP, likely due to ADAMTS-13 activity being reduced due to consumption instead of being deficient (Mancini et al. 2020). These clinical studies suggest that the vWF-ADAMTS-13 axis is a potential novel research biomarker to predict COVID-19 severity and shed light on the pathways that promote inflammatory microthrombosis formation (Mancini et al. 2020). Further research studies are needed to provide insight into the mechanisms of the vWF-ADAMTS-13 axis during COVID-19 to guide research efforts and improve therapeutic outcomes.
Future Research Directions to Consider
The function is vWF is regulated by multiple factors, including vWF concentration, vWF multimer size, the amount of circulating platelets, and blood flow rate (shear stress). How do these factors impact the vWF-ADAMTS-13 axis during COVID-19?
vWF is proteolytically cleaved by other enzymes in addition to ADAMTS-13, such as plasmin, neutrophil released proteases, and possibly ADAM10 and ADAM17. Are the ratios of these enzymes to vWF impacted during COVID-19?
Could therapeutics aimed at restoring the vWF/ADAMTS-13 ratio be strategies for treating microthrombi in COVID-19 and preventing acute kidney injury? Potential treatments to consider would be anti-vWF caplacizumab, antiplatelet agents, ADAMTS-13 therapies, and plasma exchange (Henry et al. 2020).
ADAMTS-13 is expressed in the hepatic stellate cells of the liver. Liver function abnormalities have been reported in COVID-19 patients. Are expression levels of ADAMTS-13 antigen in the liver impacted by SARS-CoV-2 infection? If so, could downregulated ADAMTS-13 liver expression contribute to the reported decrease of ADAMTS-13 activity in the blood during COVID-19?
Further Reading
Henry BM, Benoit SW, Santos de Oliveira MH, Lippi G, Favaloro EJ, Benoit JL. 2020 ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV- 2 induced secondary thrombotic microangiopathy. Int J Lab Hematol. 2020 Dec 3;10.1111/ijlh.13415. doi: 10.1111/ijlh.13415.
Katneni UK, Aikaterini A, Hunt RC, Schiller T, DiCuccio M, Buehler PW, Ibla JC, Kimchi-Sarfaty, C. Coagulopathy and
Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. Thromb Haemost. 2020 Dec;120(12):1668-1679. doi: 10.1055/s-0040-1715841.
Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, Novembrino C, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2020 Nov 23;10.1111/jth.15191. doi: 10.1111/jth.15191.
ML-00-00764 Rev01
PKA Products for Reliable, Convenient IVIG and Albumin Safety Testing
Immunoglobulin Testing Assays
Reliable, convenient testing for procoagulant contaminants
Diapharma offers a variety of products for sensitive quality control and safety testing to ensure removal of thrombogenic agents in IVIG and Albumin preparations.
Prekallikrein Activity Assays
Specialty Range of PKA Assay Kits, Reagents & Controls
Fractionation of Human plasma to produce Human Albumin and Immunoglobulin preparations can result in concentration of PKA. Diapharma offers the highest quality PKA assay kits and reagents from Pathway Diagnostics.
Benefits:
- Complete kits of matched reagents that are EP compliant
- Standard & control calibrated against the PKA international Standard
- Minimal batch-to-batch variation
- Unique Immunoglobulin high-blank blocking reagent
- Human Prekallikrein Pool: Save time and repeat runs with this ready to use, convenient, reproducible Human Prekallikrein Pool.
Featured Product: Prekallikrein Activator Assay Standard
- For use in the determination of PKA. Ideal to use with in-house developed PKA assays to increase convenience and streamline workflow.
Ordering Info:
- PW30100 Prekallikrein Activator (PKA) Assay Kit
- PW30200 Prekallikrein Activator (PKA) Assay Ig Kit
- PW301EP Prekallikrein Activator (PKA) Assay Kit – EP method
- PW302EP Prekallikrein Activator (PKA) Assay Ig Kit – EP method
- PW30304 Human Prekallikrein Pool
- PW51005 Just Positive PKA Control
- PW52005 High Positive PKA Control
- PW30305 Prekallikrein Activator Assay Standard – NEW!
- S820340 Chromogenix S-2302™
ROX FXIa
Chromogenic kit for determination of low levels of FXIa in enriched or highly purified protein
- The most sensitive kit on the market
- Low interference – ideal for in-process and final testing of immunoglobulin preparations
- Reagents comprise highly purified components
Technothrombin TGA
Fluorogenic assay for determination of thrombin generation
- Give thrombotic potential a number
- Ceveron® s100 for automated TGA or 96-well plate applications
Chromogenic substrates
S-2302™
S-2366™
|
S-2238™
S-2288™
|
All products are for research use only in the U.S. and Canada.
It’s Not Just Support. It’s Solutions.
Questions about any product in our lineup? We’re just a click or phone call away.
800.526.5224 | info@diapharma.com | diapharma.com
8948 Beckett Rd, West Chester, OH 45069
ML-00-00759Rev01
Thank you for Visiting DiaPharma Virtually while attending TLMdX®!
Biomarker Assays for NASH Clinical Trials
Thank you for “stopping by” at The Liver Meeting® Digital Experience!
Non-invasive biomarkers are becoming more and more prominent in research and clinical trials of potential new drugs for Non-alcoholic fatty liver disease (NAFLD)/Nonalcoholic steatohepatitis (NASH) and Alcoholic Liver Disease (ALD)/Alcoholic Hepatitis (AH).
Key changes in these plasma biomarkers could reduce the frequency of biopsies in clinical trials, give an early indication of the efficacy of potential new therapies in development, and provide mechanistic information about a drug’s action in NASH and AH subjects.
These biomarkers mean simpler assays using easily obtainable samples, and they can provide supplementary information to ALT and AST data, where there can be significant overlap in levels among subjects with or without disease.
One of the most prominent biomarkers is Keratin 18 (K18/CK18). Circulating CK18 levels are reflective of hepatocyte cell death. The M30® Apoptosense and M65® ELISAs detect caspase-cleaved CK18 and total CK18, respectively, and allow for discrimination between apoptotic and necrotic cell death modes.
DiaPharma offers additional non-invasive biomarker assays for NAFLD/NASH, AH, and DILI research. Incorporating these biomarkers into your research adds valuable information about changes in disease activity, which could decrease time and costs of studies. M30® and M65® Cytokeratin 18 (CK18) ELISAs, Osteopontin, Mac-2 Binding Protein, sCD163, and L-FABP are just a few of the biomarker assays offered by DiaPharma to help your drug candidate move forward.
If you’d like to speak with an expert about which biomarker would be most useful for your project, call 800.447.3846 or email us today.
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, just a call or click away.
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00754Rev01
Notice of discontinued GSD SARS-CoV-2 IgA ELISA test kits
The Gold Standard Diagnostic SARS-CoV-2 (COVID-19) IgA ELISA assay (#GSD01-1029) has been
discontinued and will no longer be available for purchase through DiaPharma.
Our current portfolio of COVID-19 serology kits can be found here.
Complement Your TMA Research
COUNT ON DIAPHARMA
for a Complete Portfolio of Thrombotic Microangiopathy (TMA) Research Products
ADAMTS13 Measurement
- Technozym ADAMTS13 Activity
- ELISA for determination of ADAMTS13 activity
- Calibrators & Controls traceable to WHO 1st International Standard ADAMTS13 plasma
- No interference by bilirubin, hemolytic, or lipemic samples
- Use for ADAMTS13 inhibitor determination in Bethesda Assay
- Technozym ADAMTS13 Inhibitor
- ELISA for determination of antibodies directed against ADAMTS13
- Differentiation between TTP and non-TTP autoantibodies
- Technofluor ADAMTS13 Activity on Ceveron s100
- Fully automated FRET assay with results in < 30 minutes
- Stable lot calibration curve with a high linearity
Research use only in the U.S. and Canada. Not for diagnostic procedures.
Complement ELISA Assays
- Diapharma C3a
- Easily detect complement component 3a
- Diapharma C5a
- Easily detect complement component 5a
- Diapharma sC5b-9
- Easily detect the membrane attack complex (MAC)
- GA Anti-Factor H
- Detect antibodies to complement Factor H
Research use only in the U.S. and Canada. Not for diagnostic procedures.
Serologic E. Coli Assay
- Hycult EchECK ELISA
- Detect antibodies against Enterohemorrhagic Escherichia coli (EHEC)
O157:H7 LPS for several weeks
- Detect antibodies against Enterohemorrhagic Escherichia coli (EHEC)
Research use only in the U.S. and Canada. Not for diagnostic procedures.
Antiphospholipid Antibody ELISAs
- Complete ELISA kits for aPS testing
- Anti-Beta2 Glycoprotein I (Aβ2GPI)
- Anti-Cardiolipin (aCL)
- Anti-Phosphatidylserine (aPS)
- Anti-Prothrombin
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise,
with support just a call or click away.
diapharma.com 800.447.3846
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00756Rev01
Thank you for “visiting” us at SETAC SciCon2
Thank You for Visiting DiaPharma
at SETAC SciCon2!
PERFORM ENDOCRINE DISRUPTOR
|
Non-invasive, easy to use, accurate ecotoxicology assays
Environmental impact matters.
Use TECOmedical Mucus Collection Swabs and ELISA kits to test fish:
- Follow individuals and populations over time
- Measure endocrine disruption with our vitellogenin ELISAs
- Measure liver damage with our hyaluronic acid ELISA
- Are your fish stressed? Detect with our cortisol ELISA.
Benefits:
- Non-invasive, easy to use, accurate ecotoxicology assays
- Applicable to over 35 species of fish
- Saves cost and time
- Standards and controls included
Learn more at diapharma.com. Feel free to contact us or your Territory Manager.
Research use only in the U.S. and Canada
It’s Not Just Support. It’s Solutions.Over 20 years of scientific expertise, with support just a call or click away. diapharma.com 1.800.447.3846 |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00757Rev01
Full portfolio of SARS-CoV-2 Antibody ELISAs to suit your needs for stage of immune response, sensitivity needs, and price point.
The quality you trust from DiaPharma
Full portfolio of SARS-CoV-2 Antibody ELISAs to suit your needs for stage of immune response, sensitivity needs, and price point. • Ideal for COVID-19 research, epidemiological studies, vaccine development, long-term efficacy or sustainability of immune response |
![]() |
QUANTITATIVE SARS-CoV-2 ELISAs for detection of IgG antibodies
Brought to you by our partner, Technoclone. Kits manufactured in Austria in collaboration with Florian Krammer, PhD (Icahn School of Medicine at Mount Sinai, New York) *Research use only in the U.S. and Canada |
TECHNOZYM anti SARS-CoV-2 NP IgG ELISA kit
TECHNOZYM anti SARS-CoV-2 RBD IgG test kit
|
SARS-CoV-2 ELISAs
Product | Part Number | RUO or Clinical | Antibody Target | Antigenic Target | Top Sensitivity (time-dependent) | Top Specificity (time-dependent) | Features |
RAPIT COVID-19 lgM/ lgG Test Kit | RUOCL0100NS0 | RUO | one line for IgM and IgG | N and S in same test | 91.10% | 95.40% | Rapid, Whole Blood or Serum |
COVID19N-REAAD™ Anti-SARS-CoV-2 Nucleocapsid lgG ELISA | RUOCE0100NP1 | RUO | IgG | N protein | 98.20% | 100% | |
COVID19-REAAD™ Anti-SARS-CoV-2 lgG ELISA | RUOCE0200NS2 | RUO | IgG | Both N + S1RBD | Not Reported | Not Reported | |
SARS-CoV-2 IgG ELISA Test Kit | GSD01-1028 | EUA Submitted | IgG | N protein | 100% | 100% | FDA EUA Submitted |
TECHNOZYM anti SARSCoV-2 NP IgG ELISA | 5600200 | RUO | IgG | N protein | 100% >15d |
99.80% | Quantitative, using a standard curve |
TECHNOZYM anti SARSCoV-2 RBD IgG ELISA | 5600100 | RUO | IgG | RBD | 100% >15d |
99.30% | Quantitative, using a standard curve |
Generic Assays SARS-CoV-2 IgG+ |
3940 | RUO | IgG | Separate S1, S2, N | > 98% | > 98% | More samples per plate than with Calibrators |
Generic Assays SARS-CoV-2 IgG |
3920 | RUO | IgG | S1 and N | > 98% | > 98% | More samples per plate than with Calibrators |
Generic Assays SARS-CoV-2 IgM |
3930 | RUO | IgM | S1 and N | > 98% | > 98% | More samples per plate than with Calibrators |
Generic Assays SARS-CoV-2 NP IgG ELISA Kit | 41A222R | RUO | IgG | N protein | 93.30% | 93.89% | Use with plasma or serum |
Generic Assays SARS-CoV-2 S1RBD IgG ELISA | 41A223R | RUO | IgG | S1 RBD | Not Reported | Not Reported | Use with plasma or serum |
SARS-CoV-2 NP IgM ELISA Kit | 41A224R | RUO | IgM | N protein | 88.64% | 96.31% | Use with plasma or serum |
SARS-CoV-2 NP Ab ELISA Kit | 41A225R | RUO | Total Antibodies | N protein | 93.30% | 95% | Use with plasma or serum High-sensitive |
SARS-CoV-2 S1RBD IgG ELISA Kit | 41A240R | RUO | IgG | S1 | >96% | >96% | Use with plasma or serum |
SARS-CoV-2 S1 IgA ELISA Kit | 41A247R | RUO | IgA | S1 | >96% | >95% | Use with plasma or serum |
SARS-CoV-2 NP IgA ELISA Kit | 41A248R | RUO | IgA | N protein | N/A | N/A | Use with plasma or serum |
Questions about any product in our lineup? We’re just a click or phone call away. 800.526. 5224 | info@diapharma.com | diapharma.com
*Research use only in the U.S. and Canada |
ML-00-00753Rev01 |
Don’t Miss the Award Winning AACC Poster on the new T-TAS 01 Platelet Function Analyzer!
Poster Alert!
AACC Virtual Event’s “2020 Hematology and Coagulation Division’s Best Abstract Award”
Jump straight to the good stuff and check out “Comparison of the T-TAS® 01 PL Assay with PFA-100 for Assessment of Primary Hemostatic Function” (B136), presented by Jeffrey Dahlen.
Live poster Q&A chat session on Wednesday, December 16 from 12:30 – 1:30 PM, CST.
T-TAS® 01: The world’s first FDA cleared ex vivo flow chamber system for the quantification of global thrombus forming ability of whole blood under physiologic conditions.
Available exclusively from DiaPharma in the U.S. and Canada!
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, just a call or click away.
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-08-00028Rev01
Complement Your TMA Research
COUNT ON DIAPHARMA
for a Complete Portfolio of Thrombotic Microangiopathy (TMA) Research Products
ADAMTS13 Measurement
- Technozym ADAMTS13 Activity
- ELISA for determination of ADAMTS13 activity
- Calibrators & Controls traceable to WHO 1st International Standard ADAMTS13 plasma
- No interference by bilirubin, hemolytic, or lipemic samples
- Use for ADAMTS13 inhibitor determination in Bethesda Assay
- Technozym ADAMTS13 Inhibitor
- ELISA for determination of antibodies directed against ADAMTS13
- Differentiation between TTP and non-TTP autoantibodies
- Technofluor ADAMTS13 Activity on Ceveron s100
- Fully automated FRET assay with results in < 30 minutes
- Stable lot calibration curve with a high linearity
Complement ELISA Assays
- Diapharma C3a
- Easily detect complement component 3a
- Diapharma C5a
- Easily detect complement component 5a
- Diapharma sC5b-9
- Easily detect the membrane attack complex (MAC)
- GA Anti-Factor H
- Detect antibodies to complement Factor H
Serologic E. Coli Assay
- Hycult EchECK ELISA
- Detect antibodies against Enterohemorrhagic Escherichia coli (EHEC) O157:H7 LPS for several weeks
Research use only in the U.S. and Canada. Not for diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise,
with support just a call or click away.
diapharma.com 800.447.3846
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00739Rev01
Large Portfolio of SARS-CoV-2 Antibody ELISAs from DiaPharma
The quality you trust from DiaPharma
Full portfolio of SARS-CoV-2 Antibody ELISAs to suit your needs for stage of immune response, sensitivity needs, and price point
- Ideal for COVID-19 research, epidemiological studies, vaccine development, long-term efficacy or sustainability of immune response
- Open-system, standard ELISAs that require no special readers and can be automated for higher throughput
New! QUANTITATIVE SARS-CoV-2 ELISAs for detection of IgG antibodies
TECHNOZYM anti SARS-CoV-2 NP IgG ELISA kit
- Reacts sensitively in the early stages of the immune response
- Includes 96 test wells + calibrator and control material
- Cut- off: 5 U/mL
- Negative Agreement: 99.8%
- Positive Agreement (days post symptom onset):
- <5 d: 14.7 %
- 5-10 d: 45.7 %
- 11-15 d: 76.5 %
- > 15 d: 100%
TECHNOZYM anti SARS-CoV-2 RBD IgG test kit
- Reacts sensitively in the later stages of the immune response
- Includes 96 test wells + calibrator and control material
- Cut- off: 5 U/mL
- Negative Agreement: 99.3%
- Positive Agreement (days post symptom onset):
- <5 d: 5.9 %
- 5-10 d: 34.3 %
- 11-15 64.7 %
- >15 d: 100%
Brought to you by our partner, Technoclone. Kits manufactured in Austria in collaboration with Florian Krammer, PhD (Icahn School of Medicine at Mount Sinai, New York)
Research Use Only in the U.S. and Canada. Not for diagnostic procedures.
Also available:
- SARS-CoV-2 ELISAs for detection of IgG or IgA antibodies
- Nucleocapsid-based (N-Protein) target – tested at ~100% specificity
- With this broad range of options, increase sensitivity and improve your serologic testing power at both early and late stages
See our full line of SARS-CoV-2 antibody tests at diapharma.com!
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, with support just a call or click away.
1.800.447.3846 | techsupport@diapharma.com
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00735Rev01
Diapharma Announces Partnership with Proaxsis
ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that it has appointed Diapharma Group Inc. as the exclusive distributor of its portfolio of respiratory research assays for the North America region.
Based in Ohio, Diapharma has specialised in the commercialisation of products within the research and diagnostic fields in the United States and Canada since it was founded in 1997. This partnership agreement provides them with exclusive access to ProAxsis’ activity-based immunoassay kits for the quantification of the active forms of neutrophil elastase, proteinase 3 and cathepsin G.
Speaking about the agreement, Dr David Ribeiro, CEO of ProAxsis, said: “We’re delighted to have reached this agreement with Diapharma. Finding a suitable commercial partner for our portfolio in North America was a key short-term objective for the company and we are very excited about partnering with a company that has such experience in the commercialisation of research-focused products in this region of substantial commercialisation potential.”
With over 20 years of expertise in proteolytic enzyme activity assays, DiaPharma sees a natural fit with ProAxsis. Olivia Stricker, PhD, Business Development Manager at Diapharma, added: “We’re pleased to have gained access to the innovative ProteaseTag® technology of ProAxsis and look forward to providing our customers with solutions for protease-focused research at the bench and clinical trials.”
Any enquiries concerning ProAxsis’ work with proteases and other inflammatory biomarkers can be directed to info@proaxsis.com.
ABOUT PROAXSIS
ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has developed activity-based immunoassays for the specific quantification of the active form of Neutrophil Elastase, Proteinase 3 and Cathepsin G.
In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.
Aside from the provision of assays, ProAxsis is able to offer a sample analysis service at its purpose-built laboratory facility in Belfast, and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.
ProAxsis became a fully owned subsidiary of Netscientific plc in October 2020.
ABOUT DIAPHARMA
DiaPharma Group, Inc. in West Chester, Ohio is a privately held distributor of superior biotechnology products throughout the US and Canada. For over 20 years, DiaPharma has been the exclusive distributor of Chromogenix, a gold standard in chromogenic substrate technology, and have grown to represent assays for hemostasis and thrombosis, as well as unique biomarkers for organ damage, oncology, autoimmunity, infectious diseases, metabolic syndrome, and ecotoxicology. The product menu ranges from chromogenic substrates, activity assays, ELISA kits and antibodies to instrumentation. Diapharma’s team provides strong technical competence and experience to clinical and research scientists to ensure customer expectations will be met or exceeded.
Collagen IV for Liver Fibrosis Research: Not just a kidney collagen
DiaPharma Serum Collagen IV ELISA
Biomarker of Liver Fibrosis
Easy To Use ELISA Now Available from DiaPharma
- Clinical research quality ELISA with an established publication record now available from DiaPharma
- Simple-to-use, well-characterized mAb sandwich ELISA
- Non-invasive fibrosis serum biomarker for liver research (NASH, AH, Hepatitis)
Diapharma offers an established, well-published Human Collagen IV ELISA for use with serum samples.
Various domains of Collagen IV have been used as biomarkers for basement membrane formation or degradation and an overall indicator of fibrosis.
For liver research, Collagen IV is the first collagen to be synthesized during in vitro liver injury models and has used as a biomarker for disease states like NASH/NAFLD, AH, and hepatitis.
Additionally, serum levels of collagen IV fall in response to drug candidates in clinical research. The Diapharma Collagen IV ELISA kit recognizes the 7S domain and the triple helix domains of Collagen IV.
References:
- Dingleman, R.F. et al.(1983). Collagen formation by the hepatocyte in primary monolayer culture and in vivo. Science, 219, 1343-1345.
- Mak, R.F. et al. (2017). Basement Membrane Type IV Collagen and Laminin: An Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease. The Anatomical Record, 300:1371-1390.
- Obata, K. et al. (1989). One step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin. Chim. Acta, 181, 293- 304.*
- Yokoya, Y. et al. (1992). Concentration of serum laminin and type IV collagen in liver diseases assayed by a sandwich enzyme-immunoassay using monoclonal antibodies. Clin. Chim. Acta, 210, 109- 118,
*Original historic reference for this ELISA kit
Collagen IV is well-suited for biomarker research panels, and can be used alone or combined with these next generation biomarkers available from DiaPharma: CK18 (M30®/M65®), α-GST, Noggin, Mac-2 Binding Protein, L-FABP, Hyaluronic Acid, and more
These products are for research use only in the U.S. and Canada. Not for diagnostic purposes.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise just a call or click away.
diapharma.com 800.447.3846
8948 Beckett Rd 45069 West Chester, OH 45069 US
ML-00-00686Rev01
Visit us Virtually at SETAC SciCon2
Virtual Conference, Real Swag!
Get Your Free T-shirt* at the SETAC North America 41st Annual Meeting!
PERFORM ENDOCRINE DISRUPTOR
|
||
|
*While supplies last
We look forward to talking with you about our for Non-invasive, easy to use, accurate ecotoxicology assays.
Environmental impact matters.
Use TECOmedical Mucus Collection Swabs and ELISA kits to test fish:
- Follow individuals and populations over time
- Measure endocrine disruption with our vitellogenin ELISAs
- Measure liver damage with our hyaluronic acid ELISA
- Are your fish stressed? Detect with our cortisol ELISA.
Our TECOmedical products features:
- Applicable to over 35 species of fish
- Saves cost and time
- Standards and controls included
Learn more at diapharma.com. Feel free to contact us or your Territory Manager.
Research use only in the U.S. and Canada
It’s Not Just Support. It’s Solutions.Over 20 years of scientific expertise, with support just a call or click away. |
||
|
diapharma.com 1.800.447.3846 |
|
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00689Rev01
Visit DiaPharma while attending The Liver Meeting® Digital Experience
Biomarker Assays for
NASH Clinical Trials
Virtual Conference, Real Swag!
Visit us virtually while attending The Liver Meeting® Digital Experience, and get a voucher for a FREE 2020 T-SHIRT!
|
|
Learn about Mechanistic Liver Biomarkers
DiaPharma offers non-invasive biomarker assays for NAFLD/NASH, AH, and DILI research. Gain valuable information, save time and costs, by incorporating these early indicators of changes in disease activity into your research. Visit diapharma.com for our full portfolio of assays, including M30® and M65® Cytokeratin 18 (CK18) ELISAs, Mac-2 Binding Protein, and more. We look forward to meeting virtually at TLMdX®!
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, just a call or click away.
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00732Rev01
Unique C1-INH Activity Assay for Gene Therapy Research
Technochrom C1-INH
Easy, Automatable Assay for Measuring C1 Esterase Inhibitor (C1-INH) Activity
- Simple and fast assay for chromogenic determination of C1-INH activity in plasma or concentrates
- Useful for gene therapy studies in Hereditary Angioedema (HAE)
Ref: Qiu T, Chiuchiolo MJ, Whaley AS, et al. Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema. Allergy. 2019;74(6):1081-1089. doi:10.1111/all.13582
Research use only in the U.S. and Canada.
Not for use in diagnostic procedures.
Visit diapharma.com for our full portfolio of products for the latest coagulation and fibrinolysis research.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise,
with support just a call or click away.
diapharma.com 800.447.3846
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00714Rev01
What’s New at Diapharma?
Staff Spotlight
Tom Boulden
Western Territory Manager
Tom Boulden joined the Diapharma team as the Western Territory Manager in February of 2017 fresh out of his military service. Tom’s background includes his experience as a Chemical, Biological, Radiological, and Nuclear NCO in the Army, and a MS degree in Biomedical Diagnostics from Arizona State University. While Tom enjoyed laboratory work, he revels in meeting new people and loves being one of the faces of Diapharma. Since the start of our difficult 2020, Tom has filled his off time with a number of new hobbies, such as tending to his vegetable and fruit gardens, and making homebrew meads and various wines. He uses these hobbies as an opportunity to connect with his community as he shares the fruits of his labor with his neighbors and those in need. The rest of Tom’s time is spent finding new and creative ways to educate and entertain his 3 year old boy.
Introducing the T-TAS® 01
The first FDA cleared microfluidic flow chamber based analyzer to measure platelet clotting functionality.
- Global assay allows for easy and cost-effective quantitative determination of platelet function, and easy screening of bleeding patients with an unknown etiology or for surgery prep.
- System makes use of no exogenous agonist activation
- Leads to a clearer picture of true platelet activation and dysfunction without masking platelet release disorders.
- Allows for quantitative monitoring of platelet antagonists alone and in combination.
- Platelet activation is driven solely by physiologically relevant shear rates seen in large arteries and exposed collagen coated on the micro-capillary surface.
Visit diapharma.com or call 1.800.447.3846 to learn more.
Visit diapharma.com for our complete portfolio of hemostasis, liver disease, oncology, and ecotoxicology assays.
It’s not just support. It’s solutions.
Over 20 years of scientific expertise,
just a call or click away.
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00727Rev01
M65 EpiRat™ ELISA – Assess liver safety signals in drug development
M65 EpiRat™ ELISA
New Tool for Preclinical Drug Safety Studies
Why Use the M65 EpiRat™ ELISA?
- Increased sensitivity and liver specificity compared to traditional biomarkers (ALT, AST) – complementary biomarker for your DILI toolbox
- Detect liver toxicity signals at an early stage in drug development by directly measuring hepatocyte cell death caused by the drug candidate
- Gain mechanistic information on the livery injury signal (apoptosis and/or necrosis)
- Save time and money – make educated decisions regarding future clinicial studies and stop wasting time on the wrong drug candidate
- Translational use with M65® EpiDeath® and M30® Apoptosense®, established biomarker assays for K18 in human samples
How does it work?
The M65 EpiRat™ ELISA measures the amount of hepatocyte cell death, both apoptosis and necrosis. It is based on the M5 and M6 antibodies, which bind to the biomarker Keratin 18 (K18). Circulating levels of K18 are commonly elevated when the liver endures damage, through disease or toxicological effects.
M65 EpiRat™ ELISA’s unique characteristics:
- Rat-specific measurement of total cell death in K18 positive cells – quantifies hepatocyte cell death to assess liver toxicity
- Sensitive serum biomarker for quantification of K18 in rat serum and plasma samples
- Convenient ready to use ELISA format and can be split up for use at several occasions.
The M65 EpiRat™ ELISA is optimized as a rat-specific assay and represents the final piece of the puzzle for the complete K18 portfolio. Diapharma offers a full line of valuable products for all stages of drug development. Visit diapharma.com for more.
Research use only in the U.S. and Canada. Not for diagnostic procedures.
It’s Not Just Support. It’s Solutions.Scientific expertise just a call or click away. |
Visit diapharma.com 1.800.447.3846 |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00701Rev01
Visit DiaPharma at THSNA 2020 Virtual Conference
VIRTUAL CONFERENCE, REAL SWAG
Visit the DiaPharma virtual booth at THSNA 2020 to learn about our COVID-19 related thrombosis research products, explore our full portfolio of coagulation, fibrinolysis, and inflammation markers, and get a free DiaPharma 2020 t-shirt!
![]() |
COAGULATION & FIBRINOLYSIS MARKERS: Chromogenic FVIII, FIX*, vWF, PAP*, TGA*, ADAMTS-13* and more |
![]() |
ANTICOAGULATION MEASUREMENT: Heparin, DOACs* |
![]() |
HEMOSTASIS ANALYERS: New, FDA cleared T-TAS 01 global whole blood platelet function analyzer |
![]() |
New Ceveron s100* all-in-one analyzer means easy TGA and ADAMTS13 measurement |
*Research Use Only. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise,
with support just a call or click away.
diapharma.com 800.447.3846
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00703Rev01
Non-Invasive Biomarkers for NASH Clinical Research Studies
Biomarker Assays for
NASH Clinical Trials
Cytokeratin 18 (CK18 and ccK18):
Non-invasive biomarkers for assessing hepatocyte apoptosis and necrosis
Biomarker | Utility in NASH Clinical Trials | Available Assays | Catalog # |
Total CK18 (M65®) | Biomarker for hepatocyte cell death (apoptosis and necrosis) | M65® ELISA | P10020 |
M65® EpiDeath ELISA | P10040 | ||
caspase-cleaved CK18 (ccK18/M30®) |
Biomarker for hepatocyte apoptosis | M30® Apoptosense ELISA | P10011 |
The Problem:
- In early phase NASH trials, performing liver biopsies to evaluate the effect of a potential drug candidate is not always practical or feasible.
- These relatively short-duration early trials may not result in significant changes in liver histology.
- Traditional non-invasive biomarkers for NASH, such as serum ALT and AST levels, are notoriously insensitive and non-specific, and do not always accurately reflect the extent of liver injury.
The Solution: Non-Invasive, mechanistic biomarkers that are reflective and predictive of changes in liver histology
- Serum CK18 (M65®) and ccK18 (M30®) measure hepatocyte apoptosis and necrosis.
- Apoptosis and necrosis are underlying mechanisms that are directly involved in the pathogenesis of NAFLD
- Changes in CK18 and ccK18 levels may therefore be early indicators for changes in disease activity in response to drug treatment.
- Changes in serum CK18 and ccK18 levels have been shown to correlate with histological changes in the liver.
Additional NASH Biomarker ELISAs from Diapharma
Use M30® Apoptosense® and M65® ELISA as part of your mechanistic biomarker panel to get a fuller picture of effects of your drug candidate.
Visit diapharma.com for our full portfolio of assays, including:
Collagen IV • L-FABP • FGF-19 • FGF-21 • Fibronectin • hsCRP • Mac-2-BP • Noggin • NGAL • Osteopontin • PAI-1 • sCD163
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise, just a call or click away.
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00685Rev01
Your Resource for COVID-19 Related Thrombosis and Fibrinolysis Products
Your Resource for COVID-19 Related Thrombosis and Fibrinolysis Products
COAGULATION, FIBRINOLYSIS, ANTICOAGULATION, and IVIG Safety Testing/QC
Fibrinolytic Markers*: PAI-1, tPA, PAP
Bleeding Disorder Markers: vWF
DOAC Research* and Heparin Measurement Reagents
IQ HITAlert™*
Ceveron® s100*: Automated Thrombin Generation Testing (TGA), ADAMTS-13, and FXIII*
Inflammation Marker and Complement ELISAs*
Testing for Immunoglobulin (IVIG) preparations*: PKA, FXIa, TGA
*Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Announcing the First Quantitative SARS-COV-2 ELISAs for Detection of IgG Antibodies!
- Ideal for COVID-19 research, epidemiological studies, and vaccine development
- TECHNOZYM anti SARS-CoV-2 NP IgG test kit (cat. no.: 5600200)*
- TECHNOZYM anti SARS-CoV-2 RBD IgG test kit (cat. no.: 5600100)*
- Calibrators & Controls included; open-system, standard ELISAs that require no special readers and can be automated for higher throughput
*Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Contact us Today to Learn More. diapharma.com 800.447.3846
ML-00-00687Rev01
Quality Products for Anticoagulation Research
COUNT ON DIAPHARMAAnticoagulation Measurement |
Full Portfolio of Products for the Latest
Coagulation & Inflammation Research
DOAC Calibrators & Controls
High quality calibrators and controls for the reliable measurement of Apixaban ● Rivaroxaban ● Edoxaban ● Arixtra ● Dabigatran
Technochrom anti-Xa
Chromogenic anti-Xa kit for accurate DOAC measurement
Technoclot DTI
Modified Thrombin Time for Direct Thrombin Inhibitor (DTI) studies
Ceveron s100
Walk-away Thrombin Generation Assay (TGA) for studying potential new anticoagulants
DOAC-STOP™ Tablets
Simplify your testing and get accurate results with the first product to effectively remove DOACs from plasma. Perform clotting assays on plasma containing DOACs in anticoagulant research
Research use only in the U.S. and Canada. Not for diagnostic procedures.
ADAMTS13
FXIII activity
Thrombin Generation
Chromogenic FVIII & FIX
DOAC Measurement
C1-Inhibitor |
![]() |
|
Plus, reliable tools for heparin & warfarin measurement
Coamatic® Heparin
Coatest® Heparin
- The leaders in chromogenic substrate technology
- Chromogenic anti-Xa kit for accurate heparin measurement
- Well published, well established kits for clinical or industrial use
- Measure Low Molecular Weight Heparin (LMWH) and Unfractionated Heparin (UFH)
DiaPharma Factor X
- Chromogenic Factor X for warfarin measurement in patients with unreliable INRs
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise,
with support just a call or click away.
diapharma.com 800.447.3846
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00684Rev01
Perform endocrine disruptor studies without killing the fish
NON-INVASIVE, EASY TO USE, ACCURATE
|
|
Environmental impact matters. Use TECO® Mucus Collection Swabs and test kits to test fish for: | |
+ follow individuals and populations over time + endocrine disruption – vitellogenin ELISA + liver damage – hyaluraonic acid ELISA + stress – cortisol ELISA |
+ applicable to over 35 different fish species + save cost and time + standards and controls included |
It’s not just support. It’s solutions. |
|
|
|
800.526.5224 | diapharma.comRESEARCH USE ONLY IN THE US AND CANADA • ML-00-00683Rev01 |
NEW! First Quantitative SARS-CoV-2 Antibody ELISA Kits from Diapharma
The quality you trust from Diapharma
New! First Quantitative SARS-CoV-2 ELISAs* for detection of IgG antibodies
*For Research Use Only in the US & Canada
- Ideal for COVID-19 research, epidemiological studies, and vaccine development
TECHNOZYM anti SARS-CoV-2 NP IgG test kit (cat. no.: 5600200)
- Reacts sensitively in the early stages of the immune response
- Includes 96 test wells + calibrator and control material
- Cut- off: 5 U/mL
- Negative Agreement: 99.8%
- Positive Agreement (days post symptom onset):
- <5 d: 14.7 %
- 5-10 d: 45.7 %
- 11-15 d: 76.5 %
- > 15 d: 100%
TECHNOZYM anti SARS-CoV-2 RBD IgG test kit (cat. no.: 5600100)
- Reacts sensitively in the later stages of the immune response
- Includes 96 test wells + calibrator and control material
- Cut- off: 5 U/mL
- Negative Agreement: 99.3%
- Positive Agreement (days post symptom onset):
- <5 d: 5.9 %
- 5-10 d: 34.3 %
- 11-15 64.7 %
- >15 d: 100%
- Kits manufactured in Austria in collaboration with Florian Krammer, PhD (Icahn School of Medicine at Mount Sinai, New York)
Questions? Our scientific support staff is happy to discuss any product in our lineup.
1.800.447.3846 / techsupport@diapharma.com
Over 20 years of scientific expertise,
with support just a call or click away.
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00681Rev01
Clot Club #16
Activated Protein C Resistance (APCR), Factor V Leiden (FVL), and a Case Report of a Family with the presence of FVL over 5 generations.
David L. McGlasson, MS, MLS(ASCP)
PRESS RELEASE: FIRST QUANTITATIVE SARS-CoV-2 ANTIBODY TEST
|
For Research Use Only in US and Canada
Subtitle: A contribution to contain the global pandemic
With more than thirty years of experience, Technoclone has developed a precise, research use only, SARS-CoV-2 antibody test together with a recognized team of experts from the University of Natural Resources and Life Sciences Vienna, the Medical University of Vienna and the University of Veterinary Medicine, Vienna.
The development
“Our aim was to develop the best quality test possible – quantitative test with an accuracy of almost 100 percent. In the course of development, different viral proteins and detection systems were investigated using COVID-19-positive sera, ”said Dr. Nikolaus Binder, PhD – CSO at Technoclone
One of our main goals was to develop a test with a specificity and sensitivity of over 99 percent. On the one hand, we have succeeded in ensuring that false negative and false positive results are below one percent and also determined a cut off value. The cut off value indicates how high the antibody count in infected people should be in order for immunity to exist.
After nine weeks of intense development and internal testing of over 200 samples, our two SARS-CoV-2 antibody tests were tested in several studies.
Since the formation of antibodies takes time after a viral infection, the development of two different ELISA tests has proven to be advantageous in order to achieve the desired precision and accuracy of the test results.
The TECHNOZYM anti SARS-CoV-2 NP IgG test kit shows more sensitivity in the early stage of the immune response. The TECHNOZYM anti SARS-CoV-2 RBD IgG test kit only responds in the main and late phase due to the antibodies to the receptor binding domain (RBD) correlating with immunity.
The analysis of over 2000 samples confirmed our internally determined results.
Now available and offered worldwide
A unique feature of our tests is that antibodies are determined quantitatively, not only to confirm an immune response to SARS-CoV-2, but also to measure the actual concentration of these antibodies. Therefore, not only can the immune response in an individual be assessed, but it can also be monitored over time.
Moreover, with respect to the effect of possible vaccines or the long-term immunity of individuals, a direct determination of the antibody levels is necessary, which should help to contain the pandemic.
The cooperation with our partners has proven the professionalism and know-how in the field of biotechnology in Austria in order to solve complex challenges quickly and efficiently.
We at Technoclone would like to thank everyone involved in this project and are pleased to be able to offer COVID-19 assays “Made in Austria” worldwide.
Founded by the Vienna Business Agency. A fund of the City of Vienna.
Vienna, September 9th 2020 | Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH Brunner Str. 67 | 1230 Wien | Austria Contact: Dr. Nikolaus Binder CSO Phone: +43 1 86373 – 0 For Research Use Only in US and Canada ML-00-00678Rev01 |
Clot Club – Current Ideas & Conundrums in Coagulation & COVID-19
Coagulation & COVID-19: Current Ideas & Questions
At this point in the pandemic, SARS-CoV-2 research has introduced more questions than answers. Since so much of the outstanding questions swirl around clotting and coagulation, DiaPharma’s own, Dr. Abi Kasberg, explored current ideas and continuing unknowns of disease caused by SARS-CoV-2. Check out Diapharma’s latest Clot Club blog that covers Abi’s thoughts on some FAQs on COVID-19 that cover questions about abnormal clotting, immune response complications, complement interactions, etc.
It’s Not Just Support. It’s Solutions.
Our scientists are happy to discuss any product in our lineup.
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00671Rev01
50% Off TK1 ELISA: Measure What Matters in Cancer Research
Measure What Matters
Cell proliferation ELISA for all stages of drug discovery and development
TK 210 ELISA
- Translational biomarker of cell proliferation
- Easy to use sandwich ELISA
- The better way to measure TK1
Research use only in the U.S. and Canada. Not for diagnostic procedures.
Visit diapharma.com for our complete lineup of cell proliferation and apoptosis assays
It’s Not Just Support. It’s Solutions.
800.526.5224 | info@diapharma.com | diapharma.com
Diapharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
ML-00-00673Rev01
UNIQUE OFFER!
![]() |
Take this opportunity to try the unique AroCell TK 210 ELISA:
- based on proprietary monoclonal antibodies
- a sensitive and specific immunoassay for accurate measurement of human TK1 in serum
- offers new possibilities for studying tumor growth and response to potential new anti-cancer drugs
Research Use Only in the U.S. and Canada. Not for diagnostic procedures.
It’s Not Just Support. It’s Solutions.
diapharma.com info@diapharma.com |
ML-00-00672Rev01 |
Proposed Mechanisms of Platelet Dynamics during COVID-19
The novel coronavirus worldwide pandemic of 2020 is infecting and claiming lives at a rapid rate. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to severe acute respiratory distress and multiple system organ failure in a disease called COVID-19. SARS-CoV-2 enters cells by endocytosis through binding of the viral spike protein to the cell membrane enzyme ACE2. It is predicted that the main entry point of SARS-CoV-2 into the body is through the respiratory system due to the expression of ACE2 on airway epithelium and lung tissue. Following initial respiratory damage, clinical reports suggest that in a subgroup of severe COVID-19 patients the immune system responds with high levels of cytokine expression, termed a cytokine storm. Cytokine storms drive hyper- inflammation that can be toxic to organs, and could ultimately lead to multiple organ failure in severe cases of COVID-19. Critically ill COVID-19 patients also display abnormal thrombosis and low platelet counts, suggesting that coagulation processes are critical components in the final stages of COVID-19. In the majority of COVID-19-related deaths, disseminated intravascular coagulation (DIC) occurs. DIC is a condition in which small blood vessels throughout the body are blocked by blood clots.
Platelets are small anucleated megakaryocyte cell fragments generated in bone marrow and the lung, and are essential during thrombus formation. Under normal wound healing events, platelet receptors bind immobilized Von Willebrand factor (VWF) and collagen located in exposed subendothelial matrix, resulting in platelet adhesion. Platelets are then activated to induce conformational changes that lead to the exposure of integrin binding sites necessary for platelet-to-platelet aggregation and platelet plug formation. Additional platelets are attracted through the release of dense platelet granules. Platelet plugs are stabilized through binding fibrinogen.Occurring concomitantly with platelet aggregation, the extrinsic pathway is initiated by tissue factor (TF) to activate the generation of thrombin that is required to form a fibrin mesh. Thrombin is then responsible for activating the intrinsic pathway to facilitate repeating coagulation events to form clots in a positive feedback loop. To prevent thrombosis, fibrinolysis occurs to dissolve blood clots during wound healing, facilitated by plasmin and serpins.
Clinical manifestations of COVID-19 can include thrombocytopenia (low platelet count), accompanied by microvascular thrombosis and increased pathological clotting. Due to the association of abnormal clotting with lethality in severe COVID-19 patients, it is important to understand the underlying mechanisms driving these thrombotic events. To explore this further, we have compiled a list of potential mechanisms and future research directions that could explain how abnormal clotting occurs while platelet count is low during COVID-19 pathogenesis. These ideas are originally published in Xu et al. 2020 and Zaid et al. 2020, with the latter being released prior to peer-review.
1. SARS-CoV-2 could be directly reducing platelet production
To explore this hypothesis, mechanisms of activity used by other coronaviruses are considered. It is reported that infection with coronaviruses SARS-CoV and HCoV-229E cause thrombocytopenia, similar to the thrombocytopenia seen in COVID-19. HCoV-229E functions through the CD13 cell surface receptor. CD13 is expressed on the surface of epithelial cells in the lung and respiratory tract, as well as on activated endothelial cells, lymphocytes, and platelets. After entering bone marrow cells and platelets through CD13, HCoV-229E induces apoptosis and reduces hematopoiesis, resulting in thrombocytopenia.
Due to similarities in antigen characteristics between the SARS-CoV-2, SARS-CoV, and HCoV-229E coronaviruses, along with the comparable presentation of thrombocytopenia, it is speculated that SARS-CoV-2 may be directly inhibiting hematopoiesis in bone marrow. After entering bone marrow and platelet cells through a cell surface receptor, it is speculated that SARS-CoV-2 could be inhibiting cell growth and promoting apoptosis, ultimately leading to decreased platelet production and thrombocytopenia during COVID-19.
Future Directions to Consider:
- Does SARS-CoV-2 directly enter bone marrow cells and platelets through a cell surface receptor? If so, is this through ACE2 or another receptor?
- Do hematopoietic cells and platelets undergo apoptosis following SARS-CoV-2 infection?
- Could a cytokine storm destroy or skew differentiation of hematopoietic progenitor cells in the bone marrow, resulting in decreased platelet production? This could be an indirect effect of SARS-CoV-2
- What happens to COVID-19 outcomes when patients have preexisting low platelet counts due to underlying conditions like cancer and treatment with chemotherapy?
- How is the hematopoietic potential of the lungs impacted in COVID-19? Are the platelets released from megakaryocytes in the lung, rather than in the blood marrow, undergoing the same changes as the bone marrow-released platelets?
2. SARS-CoV-2 could be promoting platelet destruction
Increased levels of immune complexes and autoantibodies are observed in COVID-19, which could be leading to immune-mediated thrombocytopenia. Immune-mediated thrombocytopenia occurs when the immune system specifically targets and destroys platelets. This happens when auto- antibodies and immune complexes are deposited on the surface of platelets. These platelets then become targets for immune-mediated damage and destruction. COVID-19 associated immune thrombocytopenic purpura is caused by platelet autoantibodies and can lead to life-threatening bleeding (Lévesque et al, 2020). Molecular mimicry may also be occurring, where antibodies are produced in response to viral infection that specifically target antigens on platelets, ultimately tagging them for destruction.
Future Directions to Consider:
- Are immune complexes, autoantibodies, or other antibodies binding to platelets in COVID-19? If so, does this lead to platelet destruction?
- If this is immune-mediated, do immune TTP therapies improve outcomes for COVID- 19 patients?
- Is there a correlation of immune-mediated reactions and the level of immune responsiveness to decreased platelet numbers?
3. Platelets may be consumed during COVID-19 thrombus formation
Viral infection in the lungs causes damage in the lung and perhaps other organs. The damaged tissue in turn activates platelets to aggregate and form microthrombi. The increasing number of microthrombi may be consuming circulating platelets.
Future Directions to Consider:
- Does therapeutic treatment for thrombocytopenia in COVID-19 patients result in improved outcomes?
- Does SARS-CoV-2 infection alter the activation and aggregation of platelets such that platelets are more prone to accumulate into microthombi?
- Does the level of viral load or immune responsiveness correlate with damage and thus platelet consumption?
4. Platelets could be hyper-activated in COVID-19
As platelets are critical for hemostasis, they are also important components of inflammation. To promote inflammation, platelets express inflammatory cytokines, which attract neutrophils into inflamed tissues. A recent study (Zaid et al, 2020) examined blood samples collected from severe COVID-19 patients. These blood samples exhibit low platelet counts and high levels of the inflammation marker lactate dehydrogenase (LDH). Viral RNA was also identified in platelets collected from COVID-19 patients. These platelets, although low in number, were more likely to produce inflammatory cytokines when stimulated by thrombin compared to platelets from non- severe COVID-19 individuals. The study therefore suggests that platelets are primed to produce inflammatory cytokines following SARS-CoV-2 infection, and are more likely to release extracellular vesicles, which are part of the coagulation and inflammation processes. PKCδ phosphorylation, which is necessary for platelet aggregation and activation, was significantly increased on the platelets from COVID-19 patients following stimulation with thrombin. Under flow conditions, severe COVID-19 platelets adhered to collagen-coated surfaces more efficiently than non-severe and healthy controls (Zaid et al, 2020). The study concludes that platelets, although less in number, are hyper-active and may be contributing to increased inflammation and thrombosis following SARS- CoV-2 infection.
Future Directions to Consider:
- Are platelets from COVID-19 patients better able to activate neutrophils than non- COVID-19 samples? Does this correlate with disease severity?
- How are thrombosis, inflammation, and COVID-19 outcomes affected after blocking platelet activation pathways? Is there a decrease in disease severity or thrombi formation following anti-platelet therapies or in individuals with underlying defects in platelet activation? Does this correlate with disease severity?
- How long does platelet priming last? Is platelet hyper-activity contributing to the spontaneous clotting issues that have been observed in the weeks following mild cases of COVID-19?
- Would the risk for severe COVID-19 complications be higher in people who are already at high risk for thrombosis?
- Are platelets directly infected by SARS-CoV-2, or is viral RNA being transferred to platelets from megakaryocytes, or from some other source?
Referenced Papers
Lévesque V, Millaire E, Corsilli D, Rioux-Massé B, Carrier F. Severe immune thrombocytopenic purpura in critical COVID-19. Int J Hematol. 2020 Jul 1;1-5.
Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. 500 Ann Hematol. 2020;99(6):1205-1208.
Zaid, Y. et al. (2020). Platelets Can Contain SARS-Cov-2 RNA And Are Hyperactivated in COVID-19. medRxiv preprint. doi: https://doi.org/10.1101/2020.06.23.20137596.
New NAFLD serum biomarkers for translational research
Detect the Undetectable
NOGGIN, ASPORIN, PERIOSTIN, WNT3A in Liver Disease Research
Liver regeneration and fibrosis involve regulation by Bone Morphogenetic Proteins (BMPs) and TGF-beta 1 (Figure 1)
Proteins in these pathways are highly conserved; therefore these assays have potential to be used for translational pre-clinical studies in mice, rats, pigs, etc., shown in the cross-reactivity chart below
Progression of Liver Disease
Figure 1 Liver injuries triggered by acute and chronic damage activate dormant signals responsible for initiating liver repair. The TGFβ-1, Hedgehog (Hh), and Wnt signaling pathways are key and cooperative orchestrators of liver repair. Changes in each of these pathways pushes the liver toward fibrosis or tissue regeneration. Proteins of these pathways, as well as proteins regulated by these pathways are useful biomarkers (yellow boxes) to study the various stages of liver diseases in pre-clinical and clinical research.
Need for non-invasive biomarkers to study NAFLD/NASH
Until now, the ability to study these processes was problematic due to the limited sensitivity of available assays for associated signalling pathways.
The FluoBolt™ line of highly sensitivity assays mean researchers can measure these markers in NAFLD subjects…finally making these measurements possible.
New Data to support studies with NOGGIN, ASPORIN:
Serum NOGGIN and ASPORIN levels differ in human NAFLD (Simple Steatosis and NASH) subjects compared to controls.
Serum levels of NOGGIN and ASPORIN levels change in subjects receiving potential NAFLD therapies
Amino Acid Sequence Identity with Human | |||||||
Source | https://www.uniprot.org | ||||||
Mouse | Rat | NHP | Pig | Canine | Zebra Fish | Hamster | |
Periostin | 90% | 87% | 92-93% | 95% | 96% | 54% | 89% |
Asporin | 89% | 89% | 96-99% | 89% | 89% | 54% | 89% |
Noggin | 99% | 99% | 99-100% | 99% | 96% | 55% | 99% |
Wnt3a | 96% | 89% | 99-100% | 96% | 71% | 82% | 96% |
Klotho | 86% | 84% | 93-99% | 88% | n.a. | 50% | 85% |
Available FluoBolt™ kits:
- FluoBolt™ Noggin
- FluoBolt™ Asporin
- FluoBolt™ Periostin
- FluoBolt™ Wnt3a
- FluoBolt™ a-Klotho
Visit diapharma.com for our complete line of NASH/NAFLD biomarkers.
Research Use Only in U.S. and Canada. Not for diagnostic procedures.
It’s Not Just Support. It’s Solutions.
Over 20 years of scientific expertise,
with support just a call or click away.
Visit diapharma.com
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00665Rev02
DOAC-Stop
![]() |
DOAC-StopResearch Use Only. Not for use in diagnostic procedures. |
|
Jennifer J. Kiblinger Scientific Director |
What is DOAC-Stop?
- It’s a sample pre-treatment
- DOAC-Stop is the first general agent to remove DOACs (Direct Oral Anticoagulants) from plasma, for simplified testing
- DOAC-Stop efficiently removes all types of DOACs (Direct Oral Anticoagulants) including dabigatran, apixaban, rivaroxaban and edoxaban, from test plasmas with minimal effect on currently-known clotting variables
How does it work?
- Adsorbent product (proprietary composition based on activated charcoal) that extracts DOACs from plasmas
- Simple procedure: add one mini-tablet per 1ml test plasma (volume is not critical)
- Mix for 5 minutes and centrifuge down the adsorbent.
- The resulting plasma is then depleted of DOACs
- Yields similar APTT, dRVVT, PT(INR) and other results as if DOACs had not been present.
Tips
- Mix with test plasmas for 5 minutes after the mini-tablet has fully dispersed, NOT from the time of its addition
- A longer incubation time could be used if not fully dispersed within 5 minutes, although studies show still effective.
DOAC-Stop Applications
- Plasmas treated with DOAC-Stop can be used for reliable routine assessment of known blood coagulation parameters.
- The degree of shortening induced by DOAC-Stop in a clotting time test depends on the concentration and type of DOAC as well as the on the underlying plasma itself.
- Clotting time results with DOAC sensitive tests such as dRVVT and APTT tests, may be expressed as ratios of test result before to that obtained after DOAC Stop treatment. This ratio ranges upward from 1.0 and correlates positively with DOAC concentration depending on which DOAC and test is used.
- This “Correction Ratio” where the clotting test result before sample treatment by DOAC-Stop is divided by the clotting test results after treatment by DOAC-Stop, may be useful with high phospholipid dRVVT reagents
How much does it remove?
- DOAC-Stop absorbs up to an estimated 2,000ng/ml of any DOAC in less than 5 minutes.
- Leaves no residual effect
What About Heparin and Warfarin?
- There is negligible interference with vitamin K antagonist or heparinoid anticoagulants.
Works On | May Work | Doesn’t Work |
Dabigatran | Hirudin* | Heparin |
Apixaban | Bivalirudin* | Warfarin |
Rivaroxaban | Lepirudin* | |
Edoxaban | Argatroban* |
*Bivalirudin is similar to hirudin and lepirudin, and probably would be extracted by DOAC-Stop from plasmas, although more slowly than DOACs, being of higher MW. DOAC-Stop may also bind argatroban and hirudin-type anticoagulants, but studies need done
What about other proteins?
- Specificity for removing DOACs is at least partly due to molecular size.
- Practically all proteins, clotting factors and inhibitors of physiological origin affecting coagulation tests have molecular size above approximately 30,000.
- The adsorbing agent in DOAC Stop has a pore capacity of approximately 5000
- Therefore, activated charcoal-based product extracts DOACs efficiently with no effect on heparin-type anticoagulants.
- Each lab must validate the assay to ensure no DOAC-Stop binding of other proteins that could affect other assays
Packaging
- Each tablet or tube contains enough DOAC-Stop agent for processing 1ml of citrated test plasma (0.5-1.5ml is acceptable).
- Products are stable at ambient temperature for over 5 years if kept dry.
X9904-50 | 50 mini-tabs |
X9904-100 | 100 mini-tabs |
“Inhibitor Dots”
- Inhibitor “Dots” provide a pre-determined quantity of a coagulation inhibitor such as a DOAC or heparin on a plastic dipstick. They allow laboratories to prepare inhibitor samples at any concentration in any biological fluid for use in research, teaching or other purposes.
- DOAC-like substances are provided in 500ng quantities; heparin as 0.3Iu, dried in a stabilizing and rapidly soluble film on a narrow dispenser strip.
- Each inhibitor dot is colored for simple identification.
- The binding agents in the dots total 200ug and have insignificant effect on clotting or other tests when dispersed in 1ml of plasma or blood.
- Each Dot dissolves within 2 minutes after being immersed in a fluid.
In Conclusion
- Removal by extraction of DOACs by DOAC-Stop allows labs to perform clotting assays that are affected by the presence of DOACs
- It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results.
- Plasmas treated with DOAC-Stop can be used for valid factor assays.
- It can prevent false LAC positive results due to DOACs in testing for lupus anticoagulants in a plasma sample
- Research use only in the U.S. and Canada
Questions?
What’s New at Diapharma?
Staff Spotlight
Meet some of our Working From Home co-workers!
Much of the Diapharma staff has been working from home since March, and that means lots of Zoom meetings…sometimes featuring our “new co-workers!”
*Note from Office Dog, Ozone: he’s upset he wasn’t featured, and doesn’t buy his human’s excuse that 90 pounds is not a lapdog. | ![]() |
We deliver solutions.
Diapharma is your partner who can support your work at every stage, and help you find solutions from the start.
Doing COVID-19 related studies? We have products to meet your needs in these hot topic areas:
- HEMOSTASIS: bleeding and clotting disorders, hemostasis analyzers
- MULTI-ORGAN DAMAGE: Assess cell death associated with multi-organ failure due to COVID-19 related sepsis and tissue damage
It’s easy to get lost in an endless list of available products or default to past testing protocols. But like you, we truly care about your results. We appreciate and value the outcome of any trial. Our team excels at helping you explore every option, leaving only product choices that are smart, straightforward, and on-track for success.
Visit diapharma.com for a complete list of mechanistic biomarkers, including our SARS-CoV-2 ELISAs, ideal for COVID-19 research, epidemiological studies, and vaccine development.
It’s not just support. It’s solutions.Over 20 years of scientific expertise, just a call or click away. |
||
|
Visit diapharma.com |
|
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00656Rev01
Diapharma Announces Partnership with Zacros
August 7, 2020 – Diapharma Group is pleased to announce that it has entered into an exclusive partnership with ZACROS.
Fujimori Kogyo Co., Ltd (ZACROS), headquartered in Tokyo, Japan, and Diapharma Group (Diapharma), headquartered in West Chester, Ohio, have entered into an exclusive agreement for the distribution of the T-TAS®01 (Total Thrombus-formation Analysis System) products in the United States and Canada.
The T-TAS 01 system is the world’s first instrument for the quantification of thrombus forming ability of the blood under physiological flow conditions. The T-TAS 01 with PL chip has been cleared by the US Food and Drug Administration (FDA) for the analysis and evaluation of platelet thrombus formation in patients receiving antiplatelet therapy—including aspirin, clopidogrel, prasugrel and ticagrelor—and in patients with primary hemostasis abnormalities such as Glanzmann’s thrombasthenia or von Willebrand’s Disease.
Diapharma is a distributor of hemostasis and coagulation products in the US and Canada. Diapharma delivers an established customer base performing diagnostic as well as basic and clinical research in thrombosis, hemostasis, bleeding, and clotting disorders. Diapharma has expertise with instrument sales for the hemostasis market and expects to support the launch of the T-TAS 01 instrument and consumables for sales to clinical laboratories performing testing related to coagulation and bleeding.
Diapharma offers a robust technical support staff and technically savvy outside salesforce that can educate users about the features of the T-TAS 01 products.
Together, Diapharma and ZACROS plan to provide solutions to researchers and clinicians in the fields of thrombosis and hemostasis.
ML-08-00017Rev01
Keratin 18: A Non-Invasive Biomarker for Organ Damage
The quality you trust from Diapharma for SARS-CoV-2 Research
Keratin 18 (K18/CK18)
A non-invasive biomarker for multi-organ damage
- Assess cell death associated with multi-organ failure due to COVID-19 related sepsis and tissue damage
- Measure circulating K18: K18 is expressed in cells of epithelial origin, including lung, GI, kidney, and liver
- M65® ELISA: Measures total cell death (necrosis + apoptosis)
- M30® Apoptosense: Specific for apoptosis
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Visit diapharma.com for a complete list of mechanistic biomarkers for COVID-19 research, including our SARS-CoV-2 ELISAs, ideal for COVID-19 research, epidemiological studies, and vaccine development.
Beware of Imposters!
Not all K18 kits are created equal.
- The M30® Antibody is a unique antibody that detects a caspase-cleaved epitope of K18
- Look for the trademark on the M30® & M65® kits
- Only available through Diapharma in the U.S. and Canada
- The M30 Apoptosense® kit was optimized to allow for better discrimination between normal and abnormal samples (Bantel H et al 2014).
It’s not just support. It’s solutions.
Our scientific support staff is happy to discuss any product in our lineup.
1.800.447.3846 / techsupport@diapharma.com
Over 20 years of scientific expertise,
with support just a call or click away.
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00642Rev01
Clot Club #14
COVID-19 AND CLOTTING
David L. McGlasson, MS, MLS(ASCP)
THE COVID-19 PANDEMIC AND THE ISSUE(S) OF ANTICOAGULATION-Part II
NEW! PKA Standard for IVIG and Albumin Safety Testing
IMMUNOGLOBULIN TESTING ASSAYS |
Reliable testing for procoagulant contaminants |
Diapharma offers a variety of products for sensitive quality control and safety testing to ensure removal of thrombogenic agents in IVIG and Albumin preparations.
Prekallikrein Activity Assays
Specialty Range of PKA Assay Kits, Reagents & Controls
Fractionation of Human plasma to produce Human Albumin and Immunoglobulin preparations can result in concentration of PKA. Diapharma offers the highest quality PKA assay kits and reagents from Pathway Diagnostics.
Benefits:
- Complete kits of matched reagents that are EP compliant
- Standard & control calibrated against the PKA international Standard
- Minimal batch-to-batch variation
- Unique Immunoglobulin high-blank blocking reagent
- Human Prekallikrein Pool: Save time and repeat runs with this ready to use, convenient, reproducible Human Prekallikrein Pool.
Featured Product: Prekallikrein Activator Assay Standard
- For use in the determination of PKA. Ideal to use with in-house developed PKA assays to increase convenience and streamline workflow.
Ordering Info: |
|
Prekallikrein Activator (PKA) Assay Kit Prekallikrein Activator (PKA) Assay Ig Kit Prekallikrein Activator (PKA) Assay Kit – EP method Prekallikrein Activator (PKA) Assay Ig Kit – EP method Human Prekallikrein Pool Just Positive PKA Control High Positive PKA Control Prekallikrein Activator Assay Standard – NEW! Chromogenix S-2302™ |
ROX FXIa
(110050)
Chromogenic kit for determination of low levels of FXIa in enriched or highly purified protein
- The most sensitive kit on the market
- Low interference – ideal for in-process and final testing of immunoglobulin preparations
- Reagents comprise highly purified components
Technothrombin TGA
(5006010)
Fluorogenic assay for determination of thrombin generation
- Give thrombotic potential a number
- Ceveron® s100 for automated TGA or 96-well plate applications
Chromogenic substrates |
|
S-2302 (S820340)
S-2366 (S821090)
|
S-2238 (S820324)
S-2288 (S820852)
|
All products are for research use only in the U.S. and Canada.
The Diapharma team brings a deep knowledge base and strong technical expertise to every customer interaction. Questions about any product in our lineup? We’re just a click or phone call away.
800.526.5224 | info@diapharma.com | diapharma.com
ML-00-00650Rev01
8948 Beckett Rd, West Chester, OH 45069
No biopsy required? TK1 will inform on active tumor proliferation.
For Research Use Only in the United States and Canada
(800) 526-5224 info@diapharma.com |
RelevantProliferation informs whether or not the tumor is growing or potential drug shows promise TimelyStudy efficacy as frequently as desired from the same subject SafeLiquid biopsy means surgery is not required for molecular data SpecificNo interferences from either homologs or paralogs StandardSimple ELISA format means no complex, complicated, or proprietary equipment is needed TranslatableFrom cell culture to xenografts to human clinical studies, use the same marker at all stages of discovery |
8948 Beckett Rd, West Chester, OH 45069
ML-00-00648Rev01
Interact LIVE with our partner Technoclone during the ISTH 2020 Congress!
Interact LIVE with Technoclone at the ISTH 2020 Virtual Congress
Virtual Congress, Virtual T-shirt? Never!
Diapharma and Technoclone have you covered! Redeem your voucher for a special edition ISTH 2020 Technoclone t-shirt!
Visit the Technoclone virtual booth for:
- LIVE support chat
- TechnoNews updates
- Special virtual coffee break
- T-shirt voucher: A special edition Technoclone t-shirt with a mask covering the coagulation scheme! Be sure to get your ISTH 2020 Virtual Delegate Bag
You’re invited to the LIVE Product Theater: Ceveron s100 – A Solution for Challenging Times in Haemostasis!
- Tuesday, July 14, 13:15-14:00 EDT
- Product Theater Virtual Meeting Room 7
Diapharma is your trusted resource for all things bleeding and clotting. Our scientific experts will be engaged in the virtual meeting and ready to address any of your hemostasis product needs. Reach out to us at techsupport@diapharma.com or 1.800.447.3846 to discuss our complete offering of thrombosis and hemostasis reagents, assays and analyzers. We look forward to connecting with you soon!
Technoclone products are for research use only in the U.S. and Canada.
Contact us today to learn more.Our scientific support staff is happy to discuss any product in our lineup. |
![]() |
Over 20 years of scientific expertise,
with support just a call or click away.
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00644Rev01
Biomarker Assays for NASH Clinical Trials
Biomarker Assays for NASH Clinical Trials
Cytokeratin 18 (CK18 and ccK18):
Non-invasive biomarkers and assessing hepatocyte apoptosis and necrosis
Biomarker | Utility in NASH Clinical Trials | Available Assay | Catalog # |
Total CK18 (M65®) | Biomarker for hepatocyte cell death (apoptosis and necrosis) |
M65® ELISA | P10020 |
M65® EpiDeath ELISA | P10040 | ||
Caspase-cleaved CK18 (ccK18/M30®) |
Biomarker for hepatocyte apoptosis | M30® Apoptosense ELISA | P10011 |
- CK18 and ccK18 have been used as secondary endpoints in over 60 NAFLD/NASH clinical trials to assess efficacy of new therapeutics
- Mechanistic biomarkers: Hepatocyte apoptosis and necrosis are underlying mechanisms involved in the pathogenesis of NAFLD. Changes in CK18 and ccK18 may reflect changes in disease activity in study subjects in response to drug therapy
- More specific for liver than ALT & AST
- Sensitive: Depending on mechanism of action of the drug, changes can be observed within weeks, or even hours
- Non-invasive: Changes in serum CK18 and ccK18 have been shown to correlate with changes in liver histology (ballooning, inflammation, and fibrosis)
- CK18 can be used as a prescreening tool to reduce screen failure rates by helping to identify study subjects with a NAS ≥ 4
Additional NASH Biomarker ELISAs from Diapharma
Collagen IV • L-FABP • FGF-19 • FGF-21 • Fibronectin • hsCRP • Mac-2-BP • Noggin • NGAL • Osteopontin • PAI-1 • sCD163
And more! Visit diapharma.com for our full panel of assays.
Research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Over 20 years of scientific expertise,
with support just a call or click away.
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00637Rev01
Highest Quality Assays for IVIG and Albumin Safety Testing
IMMUNOGLOBULIN TESTING ASSAYS |
Reliable testing for procoagulant contaminants |
In order to reduce the risk of thromboembolic events, manufacturers need reliable assays to test procoagulant contaminants in IVIG and Albumin preparations.
Diapharma offers a variety of products for sensitive quality control and safety testing to ensure removal of thrombogenic agents.
Prekallikrein Activity Assays
Specialty Range of PKA Assay Kits, Reagents & Controls
Fractionation of Human plasma to produce Human Albumin and Immunoglobulin preparations can result in concentration of PKA. Diapharma is excited to offer the highest quality PKA assay kits and reagents from Pathway Diagnostics.
Benefits:
- Complete kits of matched reagents that are EP compliant
- Standard & control calibrated against the 2nd PKA international Standard
- Minimal batch-to-batch variation
- Unique Immunoglobulin high-blank blocking reagent
Featured Product: Human Prekallikrein Pool
- Save time and repeat runs with this ready to use, convenient, reproducible Human Prekallikrein Pool.
Ordering Info:
Prekallikrein Activator (PKA) Assay Kit | |
Prekallikrein Activator (PKA) Assay Ig Kit | |
Prekallikrein Activator (PKA) Assay Kit – EP method | |
Prekallikrein Activator (PKA) Assay Ig Kit – EP method | |
Human Prekallikrein Pool | |
Just Positive™ PKA Control | |
High Positive™ PKA Control | |
Chromogenix S-2302™ | |
|
ROX FXIa
(110050)
Chromogenic kit for determination of low levels of FXIa in enriched or highly purified protein
- The most sensitive kit on the market
- Low interference – ideal for in-process and final testing of immunoglobulin preparations
- Reagents comprise highly purified components
Technothrombin® TGA
(5006010)
Fluorogenic assay for determination of thrombin generation
-
-
- Give thrombotic potential a number
- Ceveron® s100 for automated TGA or 96-well plate applications
-
Chromogenic substrates
S-2302™ (S820340)
S-2366™ (S821090)
|
S-2238™ (S820324)
S-2288™ (S820852)
|
All products are for research use only in the U.S. and Canada.
The Diapharma team brings a deep knowledge base and strong technical expertise to every customer interaction. Questions about any product in our lineup? We’re just a click or phone call away.
800.526. 5224 | info@diapharma.com | diapharma.com
ML-00-00630Rev01
8948 Beckett Road, West Chester, OH 45069
Keratin 18 News! An update on its use in hepatology research
An update on K18 as a Liver Injury Biomarker
The Scoop:
Keratin 18 (also known as cytokeratin 18), measured by the M30 Apoptosense® and M65 EpiDeath® ELISA, is used extensively in NASH clinical trials and others for:
- Secondary efficacy endpoint
- Pre-screening tool to reduce screen failures
In addition, K18 was explored by multiple groups for further research on use in DILI to:
- Increase early prediction
- Increase tissue specificity
Read more here.
K18 is among the most abundant proteins in the liver, but absent in muscle cells and non-epithelial cells. This plus its minimal day-to-day fluctuations in healthy subjects, means increased specificity for researching liver injury events.
Beware of Imposters!
Not all K18 kits are created equal.
- The M30 Antibody is a unique antibody that detects a caspase-cleaved epitope of K18
- Look for the Peviva trademark, on the M30 & M65 kits
- Only available through Diapharma in the U.S. and Canada
- The M30 Apoptosense® kit was optimized to allow for better discrimination between normal and abnormal samples (Bantel H et al 2014).
VLV Bio products are for research use only in the U.S. and Canada
Over 20 years of scientific expertise, with support just a call or click away. |
Visit diapharma.com |
Diapharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069 ML-00-00412Rev01 |
Next Generation Assays for Hemophilia A & B Gene Therapy Research
Diapharma is your source for Chromogenic Assays and Thrombin Generation Testing in Hemophilia Gene Therapy Studies
Easily and Accurately Measure FVIII activity in gene therapy studies
-
COAMATIC® FVIII (K822585)
-
COATEST® SP FVIII (K824086)
-
COATEST® SP4 FVIII (K824094)
Contains bovine factor reagents
Assay FIX in hemophilia B gene therapy studies:
ROX Factor IX (900020)
Bringing Chromogenic Factor IX determination into the next era
Research use only in the U.S. and Canada.
CEVERON® TGA RB Kit (5006011)
Thrombin Generation Assay for Hemophilia Studies
- With low concentration of phospholipid micelles and rhTF for researching global response to gene therapy preparations
Automated on Ceveron® t100 / Ceveron® s100
- Optimized for the fully automated measurement of Thrombin Generation on Ceveron® t100 and Ceveron® s100
- Easy as a routine assay
- Precise
- Fast
- Up to 36 samples in a single run
Research use only in the U.S. and Canada.
More Information:
FACTOR VIII
For chromogenic determination of FVIII levels in plasma and concentrates
COAMATIC® FVIII (K822585)
- Sensitive and reproducible – measure FVIII in moderate to severe hemophilia A patients
- Suitable to measure b-domain deleted FVIII and extended half-life recombinant replacement products
- Suitable for monitoring new, longer acting agents
- No need for factor deficient plasma
- Instrument applications available
- FDA cleared for diagnostic us
COATEST® SP FVIII (K824086)
- Ideal for measuring FVIII concentrates
- 1% BSA in accordance with recommendation for dilution of highly purified FVIII concentrates
- Conforms to EP FVIII potency test requirements
- FDA cleared for diagnostic use
COATEST® SP4 FVIII (K824094)
- Coatest SP FVIII factor reagent divided into 4 vials, for smaller volume testing
- FDA cleared for diagnostic use
TECHNOCHROM® FVIII:C* (5344101)
TECHNOCHROM® FVIII:C FOR CEVERON ALPHA* (5344103)
- Excellent reagent stability, accuracy and precision
- Four reference standards (cal. against WHO)
- Assay range 0-200%
FVIII INHIBITOR REAGENT KIT* (5152005)
FVIII INHIBITOR REAGENT KIT HCV NEG.* (5152009)
Reagent kit for the determination of Factor VIII Inhibitor according to Bethesda
- Improved specificity in the lower range of antibody detection due to to dilution with buffered normal FVIII plasma (1 IU.FVIII/ml)
- Contains FVIII INH plasma as positive control and FVIII INH free plasma as negative control
FVIII INHIBITOR PLASMA* (5159008)
FVIII INHIBITOR PLASMA HCV NEG.* (5159010)
FVIII DEFICIENT PLASMA, IMMUND.* (5154002)
FVIII DEFICIENT PLASMA, NATIVE* (5154007)
FACTOR IX (FIX)
Bringing chromogenic Factor IX determination into the next era
ROX FIX* (900020)
- Highly sensitive chromogenic assay for Factor IX activity in plasma or concentrates
- Study of new FIX variants and Hemophilia B gene therapy
– Does not overestimate FIX activity compared to certain aPTT reagents in qualifying FIX variants - Reliable potency assignments of recombinant and plasma-derived FIX
- FIX deficient plasma not required
* Research Use Only in the U.S. and Canada. Not for diagnostic procedures.
Visit diapharma.com for our complete line of chromogenic substrates, inhibitors, assay kits, proteins, enzymes, and more.
Questions? Over 20 years of scientific expertise and customer support just a click or phone call away.
8948 Beckett Rd, West Chester, OH 45069
ML-00-00614Rev01
FluoBolt™ α-KLOTHO – NEW and COMPLETE Immunoassay Kit
Detect the Undetectable
Introducing a COMPLETE immunoassay kit for detecting soluble Klotho protein from Diapharma
FluoBolt™ α-KLOTHO
This complete kit for the measurement of human α-Klotho in plasma or serum is in a convenient 96-well format, and includes calibrator set and control samples in a pooled serum matrix.
The FluoBolt™ α-Klotho is similar to a standard ELISA in the fact that it’s a sandwich immunoassay comprised of a monoclonal capture antibody and a polyclonal detection antibody. But it differs in that it utilizes Metal Enhanced Fluorescence (MEF) to dramatically increase the sensitivity of the antibody pair.
This state of the art FluoBolt™ technology allows scientists to detect the undetectable.
FluoBolt™ α-KLOTHO provides a high sensitivity soluble Klotho protein assay for basic and clinical research.
Kit features include:
- Uses 10 µL of undiluted sample volume
- 6 x individual lyophilized calibrators (range of 0-25 ng/mL)
- 2 x lyophilized controls
- No cross-reactivity with human β-KLOTHO or FGF-23 interference (Figures 1 and 2)
Use FluoBolt™ α-KLOTHO as a biomarker for research in:
- Kidney diseases
- Fibrosis
- Cancer research
- Neuro diseases
- Bone diseases
- Cardiovascular diseases
- Diabetes
Fianostics is adding to the toolbox for Klotho researchers with FluoBolt™ α-Klotho. The hope is to increase the options available to researchers so that they can produce accurate results and reliable conclusions.
Other FluoBolt™ kits available:
- FluoBolt™ Noggin
- FluoBolt™ Asporin
- FluoBolt™ Periostin
- FluoBolt™ Wnt3a
Research Use Only in U.S. and Canada. Not for diagnostic procedures.
Over 20 years of scientific expertise,
with support just a call or click away.
Visit diapharma.com
Diapharma Group, Inc., 8948 Beckett Rd, West Chester, OH 45069
ML-00-00605Rev01
Count on Diapharma for COVID-19 Related Thrombosis Research Products
Your trusted source for COVID-19 related thrombosis research products
EXPLORE OUR FULL LINE OF COAGULATION, FIBRINOLYSIS, AND INFLAMMATION MARKERS
As research on COVID-19 continues, it is becoming clearer that the virus has a massive impact on hemostasis. More and more publications point to thrombosis, clotting issues, increased inflammation, changes in fibrinolysis, and the use of anticoagulants (heparins and DOACs) as key issues to investigate in COVID-19 studies. Diapharma is a trusted provider for the highest quality research products related to all things bleeding and clotting.
We welcome an opportunity to chat with you about the COVID thrombosis puzzle and more.
Technothrombin® TGA
- Give thrombotic potential a number. Research thrombin generation when studying disease and progression.
- Ask us about automated TGA on the Ceveron® 100 series.
Thrombodynamics® T2F and Thrombodynamics-4D® T2T
- Observe the full spatiotemporal dynamic clotting potential from just 120 uL.
- Thrombodynamics 4D additionally allows the dynamic analysis of thrombin generation.
- Fibrinolysis is highlighted by decreasing clot intensity.
Fibrinolytic Markers
- PAI-1 Activity and Antigen, Plamsin-Antiplasmin (P-AP) ELISAs.
Bleeding Disorder Markers
- vWF activity, antigen, propeptide, collagen binding ELISAs.
Complement ELISAs
- Study effects of infection and complement activation on outcomes.
Anti-Xa Assay Kits & DOAC Research Reagents
- Measure UFH and LMWH in heparin anticoagulation with reliable chromogenic anti-Xa tests.
- Research DOAC concentrations with our line of calibrators and controls.
- Clean up your research by removing confounding DOACs from your plasma sample.
IQ HITAlert™
- Study Heparin Induced Thrombocytopenia (HIT) in test plasma.
Technoscreen® ADAMTS-13
- Studying viral infections leading to thrombotic microangiopathies (TMAs)? Rapidly screen potential research subjects for ADAMTS13 activity.
Inflammation Markers ELISAs
- Osteopontin, IQ Macro163® for soluble CD163, L-FABP, C-Reactive Protein.
Autoimmune Disorder ELISAs
- Anti-Phospholipid IgG, IgM, IgA, Anti-CCP, anti-IA2, Anti-GAD
Testing for Immunoglobulin (IVIG) preparations
- Highest quality chromogenic assays for Prekallikrein Activator and FXIa Thrombin Generation Testing for global coagulation measurement.
Contact ustoday to learn more about our lineup. All products are for research use only in the U.S. and Canada. Not for diagnostic purposes. |
![]() |
|
Over 20 years of scientific expertise, with support just a call or click away. |
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00606Rev01
Exclusive partnership with Stasys Medical
May 1, 2020- Diapharma Group is pleased to announce an exclusive partnership with Stasys Medical.
Stasys Medical is a Seattle based start-up, developing new technology to rapidly measure primary hemostasis and platelet function. The Stasys instrument measures the contractile forces and clot aggregation size generated by platelets to classify hemostasis in a small volume whole blood sample, under physiologic flow conditions. This data can then be used to assess the risk of uncontrolled bleeding, platelet dysfunction, or coagulation problems in each subject. Stasys continues to refine the features of the instrument, but is releasing the current instrument in a beta or prototype format to address timely research needs concerning thrombosis dysfunction and COVID-19. The Stasys instrument is not approved for diagnostic use by the FDA and is intended for research uses only.
Diapharma Group is a West Chester, Ohio based distributor of hemostasis and coagulation products in the US and Canada. Diapharma provides an established customer base performing diagnostics as well as basic and clinical research in thrombosis, hemostasis, bleeding and clotting disorders. Diapharma has a strong background in instrument sales for the hemostasis market and expects to help Stasys connect with researchers quickly. Diapharma offers a robust technical support staff and technically savvy outside sales force that can educate researchers about the features of the Stasys instrument through on-site demonstrations and training.
Together, Diapharma and Stasys Medical plan to provide solutions to researchers hoping to better understand platelet force, aggregation, and function in relation to the risk of hypercoagulation and excessive bleeding.
Perform Endocrine Disruptor Studies While Preserving the Fish
|
||
PERFORM ENDOCRINE DISRUPTOR
|
||
|
||
NON-INVASIVE, EASY TO USE, ACCURATE ECOTOXICOLOGY ASSAYS ELISA |
||
Environmental impact matters. Use TECO® Mucus Collection Swabs and test kits to test fish for: + follow individuals and populations over time + applicable to over 35 different fish species |
Contact us today to learn more. 800.526.5224 | diapharma.com |
|
|
||
Research use only in the U.S. and Canada. Not for use in diagnostic procedures. | ||
|
||
Over 20 years of scientific expertise,
|
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00603Rev01
What’s New at Diapharma?
STAFF SPOTLIGHT
Meet Dionna Benick
Accounting, Operations and Customer Service Support
If you’ve called our customer service line, you may have spoken with Dionna. Helping people is in her nature! She writes, “I was born and raised in Cincinnati, Ohio. I have 3 brothers and 4 sisters. I am a huge family person; it literally makes me so happy just to hang out with my
entire family.
I am drawn to helping people when they have an issue/problem. My husband calls me Mother Teresa. He says everyone knows exactly who to call when they have a problem. He swears I should have been a Psychologist.
I enjoy having the opportunity to build relationships with our customers who are all over the country. You get to learn so much about people, other states and just the world in general by simply carrying a conversation with customers. Working at Diapharma and being a part of that family makes me just very lucky.”
Dionna just celebrated her one-year anniversary on April 16. We’re glad to have Dionna on our team!
PRODUCT SPOTLIGHT
Measure What Matters in Cancer Research
Unique cell proliferation and apoptosis ELISAs
Oncology markers for all stages of drug discovery
In cancer research, time is everything.
TK 210 ELISA
- Translational biomarker of cell proliferation
- The better way to measure Thymidine Kinase 1 (TK1)
M30® Apoptosense®
- Translational biomarker of apoptotic cell death
- Can be used in combination with M65® ELISA for necrosis measurement
Detect the Undetectable
Expand your cancer research toolbox with us and explore our ultra high sensitive, no wash, no substrate ELISA series from Fianostics, featuring FluoBolt™ Technology.
- Single-step procedure
- Long-term stable signals
- No special instrumentation required
Ordering Info
Arocell TK210 ELISA
1001-15
Peviva M30® Apoptosense®
P10011
Peviva M65® Epideath
P10040
Peviva M65® ELISA
P10020
Fianostics FluoBolt™ Noggin
FIA-1701
Fianostics FluoBolt™ Asporin
FIA-1702
Fianostics FluoBolt™ Periostin
FIA-1703
Fianostics FluoBolt™ α-Klotho
FIA-1704
Mac-2 Binding Protein
DPG27362
M65® EpiRat
P10060
IQ Macro163™ ELISA
IQP-383
Chromogenic Substrate CS PSA (KLK3)
DPG586-25
All products are for research use only in the U.S. and Canada.
Not for diagnostic purposes.
Over 20 years of scientific expertise, with support just a call or click away.
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00599Rev01
Supporting the Clinical Hemostasis Lab
|
COUNT ON DIAPHARMA |
Your Resource for Specialty Coagulation Products and Scientific Support |
Valuable tools for anticoagulation measurement: |
Diapharma Factor X KitChromogenic Factor X for measuring warfarin when INRs are unreliable |
Coamatic® Heparin ● Coatest® Heparin
|
![]() |
Antiphospholipid Antibody ELISAs |
Complete ELISA kits for aPS testing
|
![]() |
Over 20 years of scientific expertise, with support just a call or click away. |
Visit diapharma.com |
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069 ML-00-00596Rev01 |
Reliable Assays for IVIG Testing
|
IMMUNOGLOBULIN TESTING ASSAYS |
Reliable testing for procoagulant contaminants |
In order to reduce the risk of thromboembolic events, IVIG manufacturers need reliable assays to test procoagulant contaminants in IVIG preparations.
Diapharma offers a variety of products for sensitive safety testing to ensure of thrombogenic agents.
Prekallikrein Activity Assays
Specialty Range of PKA Assay Kits, Reagents & Controls
Fractionation of Human plasma to produce Human Albumin and Immunoglobulin preparations can result in concentration of PKA. Diapharma is excited to offer the highest quality PKA assay kits and reagents from Pathway Diagnostics!
Benefits:
- Complete kits of matched reagents that are EP compliant
- Standard & kit control calibrated against the 2nd PKA international Standard
- Minimal batch-to-batch variation
- Unique Immunoglobulin high-blank blocking reagent
Ordering Info:
PW30100 | Prekallikrein Activator (PKA) Assay Kit |
PW30200 | Prekallikrein Activator (PKA) Assay Ig Kit |
PW301EP | Prekallikrein Activator (PKA) Assay Kit – EP method |
PW302EP | Prekallikrein Activator (PKA) Assay Ig Kit – EP method |
PW30304 | Human Prekallikrein Pool |
PW51005 | Just Positive™ PKA Control |
PW52005 | High Positive™ PKA Control |
S820340 | Chromogenix S-2302™ |
ROX FXIa
(110050)
Chromogenic kit for determination of low levels of FXIa in enriched or highly purified protein
- The most sensitive kit on the market
- Low interference – ideal for in-process and final testing of immunoglobulin preparations
- Reagents comprise highly purified components
Technothrombin® TGA
(5006010)
Fluorogenic assay for determination of thrombin generation
- Give thrombotic potential a number
- Ceveron® s100 for automated TGA or 96-well plate applications
Chromogenic substrates
S-2302™ (S820340)
S-2366™ (S821090)
|
S-2238™ (S820324)
S-2288™ (S820852)
|
All products are for research use only in the U.S. and Canada.
The Diapharma team brings a deep knowledge base and strong technical expertise to every customer interaction. Questions about any product in our lineup? We’re just a click or phone call away.
800.526. 5224 | info@diapharma.com | diapharma.com
ML-00-00587Rev01
8948 Beckett Road, West Chester, OH 45069
Emerging Exploratory Biomarkers for Drug Safety Studies
|
|||
Improve Early DILI/DIKI Prediction Increased Tissue Specificity |
|||
|
|
||
|
ELISAs for Drug-Induced Liver Injury (DILI) |
||||
Biomarker | Sample Type | Description | Available Assay | Product # |
Keratin 18 (K18) | Serum or plasma | Highly specific biomarker for hepatocyte cell death (necrosis and apoptosis) |
Peviva M65® ELISA Peviva M65 EpiDeath® ELISA |
|
Caspase-cleaved Keratin 18 (ccK18) | Serum or plasma | Highly specific specific biomarker for hepatocyte apoptosis | Peviva M30 Apoptosense® | P10011 |
Osteopontin (OPN) | Serum or plasma | Biomarker for hepatic inflammation and necrosis |
Osteopontin Osteopontin N-Half |
|
Alpha Glutathione S-Transferase (a-GST) | Serum or plasma | Short half-life; sensitive to rapid changes in liver damage | TECO® Alpha GST | TE1056 |
Liver Fatty Acid Binding Protein (L-FABP, FABP1) | Serum or plasma | Sensitive marker for hepatic injury (leakage) | Diapharma L-FABP | DPGLFABP |
ELISAs for Drug-Induced Kidney Injury (DIKI) |
||||
Biomarker | Sample Type | Description | Available Assay | Product # |
Alpha Glutathione S-Transferase (α-GST) | Urine | Biomarker for proximal tubule damage | TECO® Alpha GST | TE1056 |
Osteopontin (OPN) | Urine | Biomarker for damage to loop of Henle and distal tubule |
Osteopontin Osteopontin N-Half |
|
Liver Fatty Acid Binding Protein (L-FABP, FABP1) | Urine | Marker of acute kidney injury; useful for early detection of renal damage accompanying tubular dysfunction | Urinary L-FABP (FABP1) | 006 |
Cystatin C (Cys C) | Serum, plasma or, urine | Assay for estimation of the glomerular filtration rate (GFR); more sensitive than serum creatinine tests | IMD Rapid Cystatin C | 31241 |
Neutrophil Gelatinese-Associated Lipocalin (NGAL) | Urine | Biomarker for distal tubular |
Diapharma NGAL (96) Diapharma NGAL (2 x 96) IMD Lipocalin-2 |
|
Alpha Klotho (α-Klotho) | Plasma | Biomarker of impaired renal function, cytoprotective | FluoBolt™ α-KLOTHO (MEF-FIA) | FIA-1704 |
Questions about any product in our lineup?We’re just a click or phone call away.800.526.5224 | info@diapharma.com | diapharma.com |
![]() |
*Research use only in the U.S. and Canada. Not for diagnostic procedures. | ML-00-00518Rev01 |
World Hemophilia Day
In recognition of World Hemophilia Day (April 17th), Diapharma would like to shine a spotlight on all of the innovation taking place surrounding bleeding disorders, like hemophilia. In order to do this, we are calling attention to a new documentary film that exemplifies the extraordinary feats that can be tackled with ever improving therapies, called Bombardier Blood.
BOMBARDIER BLOOD- Bombardier Blood follows mountaineer Chris Bombardier on a historic mission to become the first person with hemophilia to climb the Seven Summits, the highest mountain on each continent, including the world’s tallest peak, Mount Everest. The intimate, unflinching film also chronicles Chris’s quest to bring aid and fundraise for people with hemophilia where access to life-saving treatment is scarce, and the disease is often deadly. This film is produced by Alex Borstein, the two-time Emmy-Award winning actress best known for her work on “The Marvelous Mrs. Maisel” and “Family Guy”. She has joined the producing team to raise funds for the charity Save One Life.
More details at https://www.bombardierblood.com/ and www.swohf.org.
ML-00-00595Rev01
New! Human WNT3A protein detection kit – FluoBolt™ WNT3A
Announcing FluoBolt™ WNT3A from Fianostics
Light Up Your Research!
MEF-FIA for human WNT3A
Detect the Undetectable
Diapharma added a critical kit to our product line up: FluoBolt™ WNT3A.
With the limited options currently available for WNT3A protein detection, this kit is a welcome addition to researchers for the Wnt/β-catenin pathway toolbox.
No need to keep measuring transcript levels because the new FluoBolt™ technology allows scientists to detect the undetectable.
FluoBolt™ WNT3A Features:
- Reliable new option for Human WNT3A protein detection
- Serum and cell culture samples
- Familiar 96-well immunoassay format
- Rapid ELISA-like protocol
- MEF technology and fluorescent readout enhance sensitivity
- Overcomes the hurdles of low signal with previous standard Human WNT3A ELISAs
- No expensive instrument system required
- Kit includes 6 standards and 2 controls in serum matrix
Kit Characteristics:
- Method: Metal Enhanced Direct Sandwich Fluorescence Immunoassay in 96-well format
- Sample Type: Serum and Plasma
- Standard Range: 0 to 2,800 pmol/L (0-112 ng/mL). 6 standards and 2 controls in a serum based matrix
- Conversion Factor: 1 ng/mL = 25 pmol/L
- Sample Volume: 20 uL (undiluted sample)/well
- Incubation/time/temperature: Single-step assay / Overnight / Room Temperature
- Sensitivity: LOD (0 pmol/L+3 SD); 50 pmol/L (2 ng/mL); LLOQ 175 pmol/L (7 ng/mL)
- Specificity: Tested for human WNT3A, but human shares 100-95% aa sequence identity with primates, mice, rats and pigs.
Other FluoBolt™ kits available:
- FluoBolt™ Noggin
- FluoBolt™ Asporin
- FluoBolt™ Periostin
- FluoBolt™ αKlotho
Over 20 years of scientific expertise, with support just a call or click away.
Visit diapharma.com
Diapharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069
ML-00-00584Rev01